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Chapter 1 Introduction
1General introduction
Chronic fatigue syndrome
Chronic fatigue syndrome (CFS) is a complex condition that is characterized by severe 
fatigue present for at least six months leading to disability (1). In addition to fatigue, 
a patient has to report at least four out of eight accompanying symptoms in order to fulfill 
the US Center for Disease Control (CDC) criteria for CFS (table 1) (1, 2). These symptoms 
include: memory/concentration problems, post-exertional malaise, non-refreshing sleep, 
muscle pain, joint pain, headache, sore throat, and tender lymph nodes in the neck or 
armpit. In both Europe and the USA, the estimated prevalence of CFS ranges between 200 
and 1400 per 100000 persons (3-6), with an estimated prevalence of 1% of the population in 
the Netherlands (7). Approximately 75% of CFS patients is of female gender, and symptoms 
start at a mean age between 29 and 35 years old (8). The majority of patients reports an acute 
onset of symptoms, for example after an infectious episode or a stressful event (8).
A model used to understand this complex illness is that of the four P’s (8). This model 
discerns predisposing factors (e.g. childhood trauma), precipitating factors (infection, 
surgery, etc.) and perpetuating factors (e.g. focus on bodily symptoms, poor sense of 
control). The fourth P stands for prognostic factors, as it is known that those patients that 
attribute their symptoms to a physical cause and patients with psychiatric comorbidity 
show lower recovery rates (9).
Table 1 Diagnostic criteria for the chronic fatigue syndrome
Diagnostic criteria CFS (1, 2):
1.  The individual has had severe chronic fatigue for 6 or more consecutive months that is not due 
to ongoing exertion or other medical conditions associated with fatigue (these other conditions 
need to be ruled out by a doctor after diagnostic tests have been conducted).
2. The fatigue significantly interferes with daily activities and work.
3. The individual concurrently has 4 or more of the following 8 symptoms: 
 • post-exertional malaise lasting more than 24 hours
 • unrefreshing sleep
 • significant impairment of short-term memory or concentration
 • muscle pain
 • pain in the joints without swelling or redness
 • headaches of a new type, pattern, or severity
 • tender lymph nodes in the neck or armpit
 • a sore throat that is frequent or recurring
With respect to the causes of CFS and optimal methods for its diagnosis and treatment, 
there are a lot of questions that remain unanswered. For example, the diagnosis of CFS 
can only be made when other fatigue-causing illnesses (e.g. hypothyroidism, anemia) are 
ruled out. There is no specific (blood) test that can be used to prove the presence of CFS. 
This is one of the causes of the often long period between the start of symptoms, and the 
eventual diagnosis which may take up to five years (3). Another difficulty is the optimal 
treatment for CFS patients. Both cognitive behavioral therapy (CBT) and graded exercise 
therapy (GET) are effective treatment modalities (10-14). These behavioral interventions 
aim at gradual increase of activity levels with CBT also aiming at a change in cognitive 
processes thought to maintain fatigue and disability, such as a lack of control over fatigue, 
and the tendency to focus on symptoms (15). Despite the fact that these therapies can be 
highly effective, a substantial proportion of patients does not improve after completion of 
these time-consuming therapies (14). Therefore, there is an ongoing search for an effective 
treatment for those patients not responding to CBT and GET.
This thesis focuses on (biological) aspects of CFS that could be used to diagnose and 
treat CFS more effectively. Although there is an emphasis on the immune system and 
the proinflammatory cytokine interleukin-1 (IL-1), we also widened our perspective 
by investigating the role of the hypothalamic-pituitary-adrenal axis (HPA axis) and the 
cardiovascular system in CFS. These regulating systems will now be introduced.
The immune system & proinflammatory cytokines
The immune system is the host’s defense mechanism against external pathogens (bacteria, 
viruses, fungi, etc.) and potential harmful internal cells (e.g. tumors, necrotic tissue). It can 
be divided into the ‘innate immune system’, and the acquired ‘adaptive immune system’. 
Successful functioning and interaction of these systems is necessary to maintain proper 
functioning of an organism and prevent the occurrence of illness. Where the innate immune 
system is important for the first line defense, the adaptive immune system (consisting of 
B- and T-cells) is involved in immune memory and specific targeting of pathogens (16). 
Cytokines are proteins that predominantly belong to the innate immune system. Cytokines 
are produced by a wide range of immunological and non-immunological cells, and have an 
important role in coordinating the immune response. Most cytokines will be produced when 
the cells are exposed to an endogenous (damage associated molecular patterns, DAMP’s) 
or exogenous (pathogen associated molecular patterns, PAMP’s) stimulus. An example is 
activation of monocytes by lipopolysaccharide (LPS) from Gramm-negative bacteria, one 
of the most potent activators of the immune system (17). An important source of cytokine 
production in the human body are monocytes and macrophages, which predominantly 
produce interleukin-6 (IL-6), interleukin-1 (IL-1) and tumor necrosis factor (TNF). In 
addition to regulating mechanisms, pro-inflammatory cytokines such as interleukin-1β 
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1(IL-1β) and IL-6, are able to cause symptoms that often accompany an inflammatory 
response, such as fever (18) and lethargic behavior (19). This specific effect, which resembles 
the symptoms of CFS, has contributed to the idea that proinflammatory cytokines could 
play an important role in CFS.
Measurement of circulating cytokines is difficult. First, since the proinflammatory 
cytokines are potentially deleterious to the host, their concentrations in the circulation 
are generally low. Second, a number of factors are known to influence cytokine 
concentrations. For example, processing protocols, storage time and number of freeze-
thaw cycles are known to have a substantial influence on cytokine concentrations (20, 21), 
which is important knowledge for interpretation of the studies that have been 
performed. More details on cytokine regulation and action, especially regarding IL-1 
will be presented in chapter 2.
The hypothalamic-pituitary-adrenal axis and cortisol
The HPA axis is an important component of the endocrine system. It controls the reaction 
to stress, and plays a role in regulation of different homeostatic processes (22). The end 
product of the HPA axis is cortisol, which is produced by the adrenal gland (figure 1). 
The adrenal gland is under control of adrenocorticotropic hormone (ACTH) released by 
the anterior lobe of the pituitary, which in turn is stimulated by corticotropin-releasing 
hormone (CRH) production of the hypothalamus. Cortisol acts on mineralocorticoid 
and glucocorticoid receptors in the body to influence several processes. It also gives a 
negative feedback signal to the hypothalamus, decreasing the release of CRH. In healthy 
individuals, cortisol increases upon awakening and declines during the day (22). In addition, 
cortisol is released in case of physical or emotional stress, and by its regulation of different 
functions (homeostasis, cardiovascular, etc.), cortisol promotes survival (23). The HPA axis 
and the immune system interact in a bidirectional way. For example, high concentrations 
of glucocorticoids released upon a stressor, are able to suppress the immune system by 
inhibition of pro-inflammatory cytokines and stimulation of anti-inflammatory cytokines 
(e.g. interleukin 10) (24). Deregulation of the HPA axis results in disease with Addison’s 
and Cushing’s disease as its most extreme forms, respectively representing hypo- and 
hyperfunctioning. As will be discussed in more detail below, more subtle derangements 
of the HPA axis have been described in CFS and in related disorders as fibromyalgia (25, 26). 
The cardiovascular system & orthostatic intolerance
Blood pressure is tightly controlled in order to maintain adequate cerebral perfusion 
(figure 2). Especially the autonomous nervous system (ANS) plays an important role. The 
ANS influences the heart rate and vascular resistance of peripheral blood vessels, which 
together with blood volume and cardiac output are important for the maintenance of an 
Figure 1 Schematic overview of the HPA axis
Figure 1 Schematic overview of the hypothalamic-pituitary-adrenal axis (HPA axis). Corticotropin-
releasing hormone (CRH) is released by the paraventricular nucleus of the hypothalamus and has a 
stimulating effect on the anterior lobe of the pituitary, which in turn secretes adrenocorticotropic hormone 
(ACTH). ACTH stimulates the adrenal cortex leading to cortisol production. Cortisol has an inhibiting 
effect on both the pituitary and hypothalamus.
Figure 2 Blood pressure regulation
Hypothalamus Pituitary Adrenal cortex
CortisolACTHCRH
Blood pressure ↓ Baroreceptor
activation
Increased
cardiac output
Vasoconstriction
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1adequate blood pressure. When a person changes position, from horizontal to vertical, these 
mechanisms have to respond quickly in order to maintain the blood pressure and warrant 
cerebral circulation. For example, as a consequence of a drop of blood pressure upon 
standing (pooling of blood in the lower extremities) the baroreceptors, which are located at 
the carotid sinus, sense decreased pressure and cause an increased heart rate and peripheral 
vasoconstriction (27). This response and other mechanisms prevent cerebral hypoperfusion, 
which can result in dizziness, headache, and even syncope. Dysfunction of these regulatory 
mechanisms can cause orthostatic intolerance, which is a cluster of conditions (orthostatic 
hypotension, postural orthostatic tachycardia syndrome, etc.) causing the patients to have 
symptoms in the upright position. As will be discussed in more detail below, orthostatic 
intolerance has been connected with CFS (3, 28).
Outline of the thesis
The immune system (29-31), HPA axis (25, 32), and cardiovascular system (28, 33, 34) have all 
been extensively studied in CFS. Despite these previous studies, there is still no proper 
understanding of pathophysiological mechanisms involved in CFS. In this thesis, I have tried 
to investigate the role of the aforementioned systems in CFS, with the aim of gaining more 
insight into mechanisms involved in a complex illness such as CFS.
The role of the immune system in CFS patients has predominantly been investigated by 
measuring circulating cytokines (31). This interest in the role of proinflammatory cytokines 
in CFS comes from studies that show typical CFS-like behavior after the administration 
of cytokines to healthy individuals (35-38). Especially IL-1 (α and β) appears to be related 
to fatigue and has been measured in fatigue-causing illnesses. We reviewed in chapter 2 
the relation between circulating IL-1α, IL-1β or the IL-1 receptor antagonist (IL-1Ra) and 
fatigue in different (inflammatory and non-inflammatory) diseases. In addition, to obtain 
insight in causality, studies evaluating the effect of lowering IL-1 on fatigue severity were 
reviewed.
A difficulty with studies inhibiting proinflammatory cytokines, is that most of these drugs 
are not able to cross the blood-brain barrier because of their large molecular weight. This is 
no problem when there is a peripheral inflammatory response, but could become a problem 
when the target is the central nervous system. While evaluating the most effective strategy to 
inhibit IL-1 in CFS, we came upon studies from Dr Tobinick (39, 40). In these animal and human 
studies (39, 41, 42), it is claimed that rapid central delivery of drugs can be accomplished through 
injection in the perispinal region. In this region there is a valveless venous plexus, also called 
the Baton’s plexus. Tobinick claims that injection of a drug in the soft tissue surrounding 
this plexus and placing the patient/animal in an upside-down position, the retrograde flow 
delivers drugs into the central nervous system (CNS). In chapter 3 we repeated such animal 
experiments, and investigated if this indeed is a proper method to bypass more harmful 
methods of administering drugs into the CNS.
Given the data in the literature pointing to IL-1 as an important mediator of fatigue, the next 
step was to perform a randomized controlled trial (RCT) in CFS patients, to evaluate the 
effect of the IL-1Ra anakinra on fatigue severity and disabilities. In chapter 4 we described 
the study protocol used to perform this study and in chapter 5 the outcome of the RCT.
With the RCT, we had the opportunity to study cytokine disturbances in a group of well-
defined CFS patients. In addition, all patients were asked to bring a healthy, age-matched, 
neighborhood control at their first study which served as a proper control group. Methods 
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1to measure a large group of cytokines simultaneously with high specificity and sensitivity 
have been improved over the past years. In chapter 6 we investigated if one of these new 
methods ‘proximity extension assay’ can help us to identify different cytokine profiles in 
CFS patients compared to controls or identify individually altered cytokines.
In a recent systematic review on circulating cytokines in CFS, TGF-β was the only cytokine 
that was elevated in CFS in the majority of studies performed (31). In chapter 7 we aimed at 
replicating this finding in two separate CFS cohorts.
Altered functioning of the HPA axis has been investigated frequently in CFS. In a review 
on this subject, it was concluded that there is substantial evidence for hypocortisolism in 
CFS patients (25). In chapter 8 we asked ourselves the question if we could replicate and 
extend these findings in a large case-control study. To that end, we not only measured 
cortisol in saliva, as was done in most previous studies, but also used hair cortisol which 
reflects long-term cortisol output. In addition, we investigated if lowering IL-1 had an 
effect on salivary and hair cortisol.
While conducting these studies, the Institute of Medicine (IOM), published a new case-
definition for CFS based on an extensive literature search. The IOM proposed a new 
name for CFS, i.e., Systemic Exertion Intolerance Disease (SEID) (3). The aim of this new 
definition was to accelerate the diagnostic procedure in CFS, and providing objective 
measurements to diagnose patients. One of the criteria of the SEID diagnosis is the 
presence of orthostatic intolerance, with postural orthostatic tachycardia syndrome (POTS) 
as its most frequent form. In chapter 9 we investigated the prevalence of POTS in a large 
cohort of CFS patients, and investigated whether these patients are clinically different from 
CFS patients without POTS. In addition, to investigate the diagnostic value of POTS, we 
compared the prevalence of POTS in CFS patients to the prevalence of POTS in fatigued 
patients who did not fulfill the CFS criteria.
Chapter 10 summarizes the results of the studies and implications of the findings for future 
research are discussed.
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Abstract
Fatigue is commonly reported in a variety of illnesses, and it has major impact on quality 
of life. Previously it was thought that fatigue originates in the skeletal muscles, leading to 
cessation of activity. However, more recently it has become clear that the brain is the central 
regulator of fatigue perception. It has been suggested that pro-inflammatory cytokines, 
especially interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β), play a prominent role 
in the development of central fatigue, and several studies have been performed to elucidate 
the connection between inflammation and these central processes. 
In this narrative review, mechanisms of action of IL-1 are described, with special attention 
to its effect on the central nervous system. In addition, we present a summary of studies 
that i) investigated the relationship between circulating IL-1α and IL-1β and fatigue 
severity, and/or ii) evaluated the effect of inhibiting IL-1 on fatigue. We aim to improve 
the understanding of fatigue in both inflammatory and non-inflammatory illnesses, which 
could help develop strategies to treat fatigue more effectively.
Reviewing the studies that have been performed, it appears that there is a limited value of 
measuring circulating IL-1. However, inhibiting IL-1 has a positive effect on severe fatigue 
in most studies that have been conducted.
Background
General introduction and aims
There is growing evidence supporting the theory that the central nervous system plays 
an important role in the perception of fatigue. The central nervous system processes and 
values sensory information, as well as guides motivational behavior involving decisions 
to discontinue activity or to invest effort. Cytokines have been suggested as prominent 
mediators in the induction of this central fatigue.
In this narrative review, we explored the evidence for the connection between pro-
inflammatory cytokines, especially interleukin-1 (IL-1), and the perception of fatigue. 
Next to investigations that have examined whether there is a relation between circulating 
IL-1 and severity of fatigue (table 1), the effect of blocking IL-1 on fatigue severity has 
also been reported (table 2). For example, trials have been performed in rheumatoid 
arthritis (1, 2), Sjögren’s syndrome (3), and diabetes (4). In this review, the different mechanisms 
of action of IL-1 will be discussed, especially considering its action in the CNS. We also 
review studies performed up to this writing that searched for a relation between IL-1 and 
fatigue in a variety of inflammatory and non-inflammatory illnesses.
Interleukin-1
To elucidate the contribution of IL-1 to the experience of fatigue, it is important to have 
a view of the pleiotropic action this cytokine. Because of the important role of IL-1 
in the innate immune system and other physiological systems, it has become a field of 
great interest. Of the 11 members of the IL-1 family, two prominent members, IL-1alpha 
(IL-1α) and IL-1beta (IL-1b), have been described most frequently in the literature on 
fatigue. IL-1a, IL-1b and the IL-1 receptor antagonist (IL-1Ra) bind to the type 1 IL-1 
receptor (IL-1R1). Whereas IL-1α and IL-1b activate an inflammatory signal upon binding 
to the IL-1R1, IL-1Ra binds to the same receptor but does not activate a signal. 
Chapter 2 Interleukin-1 as a mediator of fatigue
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IL-1a is constitutively present as a bioactive precursor inside a wide range of cells. It 
is present, for example, in epithelial cells of the lungs, keratinocytes of the skin, and in 
vascular endothelial cells (5). During necrosis resulting in cell death, the bioactive IL-1α 
precursor is released. Furthermore, IL-1a is present on the surface of monocytes and B 
lymphocytes (6). IL-1b is produced by more specific subsets of cells; it is a product of 
monocytes, tissue macrophages and dendritic cells (5). In order to become biologically 
active the IL-1b precursor is first cleaved by caspase-1, an intracellular enzyme that is 
activated by a complex of intracellular proteins termed “the inflammasome” (7). There is 
also an alternative mechanism by which the inactive IL-1β precursor is converted into 
an active cytokine. In presence of a high numbers of neutrophils, enzymes released by 
these cells, such as elastase and proteinase-3, will cleave the IL-1b precursor and yield the 
bioactive moiety (8). After binding of IL-1α or IL-1b to the IL-1R1, a complex signaling 
cascade is activated, eventually leading to ‘nuclear factor kappa-light-chain-enhancer of 
activated B cells’ (NFκB) production and subsequent gene transcription (9). In this manner, 
IL-1 action leads to a variety of biological events, ranging from activation of the acquired 
immune system to the induction of fever and slow-wave sleep (10). For the scope of this 
review, we will focus on the ability of IL-1 to induce fatigue.
Important when investigating the involvement of IL-1 in disease, is to note that circulating 
concentrations of IL-1b often are at best only slightly elevated (picograms/mL) even under 
conditions of severe pathology (11). A large part of IL-1b remains inside the cell, and in 
the circulation it is bound to other proteins, such as the type 2 IL-1 receptor (IL-1R2), 
which serves as a decoy receptor, leading to a decrease in bioactivity (12). Therefore IL-1Ra, 
which is secreted by various cells in an inflammatory environment, has been proposed as a 
surrogate marker for IL-1b activity (12, 13). 
Effect of Interleukin-1 on the central nervous system
The central nervous system (CNS) plays an important role in cytokine-induced fatigue. 
As stated earlier, IL-1α and IL-1b are produced by a broad range of immunocompetent 
and non-immunological cells. Elevation of IL-1 in the brain contributes to behavioral 
alterations described as ‘sickness behavior’, which includes increased feelings of fatigue 
and depressed mood, loss of interest in social interactions and reduction of physical activity 
both in animals and in humans treated for different malignancies (14-19). The observed 
behavioral alterations in response to the intrathecal administration of pro-inflammatory 
cytokines indicate that, in addition to its peripheral effect on the immune response, IL-1 
also signals to the brain via several immune-to-brain communication pathways. 
Before peripherally produced cytokines can have an effect on the brain, they have to find 
a way to reach the CNS. In most diseases described in this review, there is no disruption 
of the blood-brain barrier (BBB) to allow proteins to gain access to the CNS. However, 
there are several mechanisms by which this barrier can be bypassed (figure 1). Some 
parts of the BBB are more permeable, especially those surrounding the circumventricular 
organs (CVOs), and cytokines like IL-1 can cross the BBB in this area by diffusion through 
the fenestrated endothelium (1) (20-22). For IL-1α, IL-1b and IL-1Ra, there is a saturable 
transport system from blood to the CNS (2) (20), and production of cytokines by locally 
activated perivascular endothelial cell and macrophages has also been described (3) (23). 
These three routes combined are often described as the humoral pathway. There is also a 
neuronal pathway, which uses the vagal nerve and sometimes also other peripheral afferent 
nerve fibers (4), directly transmitting the cytokine signal to relevant brain regions (24). 
The fifth route, activated by both the humoral and neuronal pathways, is activation of 
the immunocompetent cells of the brain, being the microglia (5). These cells are able to 
produce IL-1b locally once they have become activated (25, 26). In chronic fatigue syndrome 
(CFS), a syndrome characterized by severe fatigue, evidence for microglial activation has 
already been reported in a small group of patients (27). 
The IL-1R1 is distributed throughout the brain, although human studies on this topic are 
scarce (28). The intracellular pathways after IL-1R1 activation in the brain are similar to 
those in the periphery, eventually leading to NFκB activation and subsequent gene 
transcription (28). In an animal experiment, an increase of IL-1b mRNA was found in 
the hypothalamus directly after peripheral injection of IL-1b, where it is able to induce 
fever (15). While the concentration in the hypothalamus decreased within 24 hours, 
upregulation of IL-1b mRNA persisted in the cerebral cortex, and this was accompanied by 
a decrease in spontaneous activity lasting several days. Hypothetically, such persistence of 
IL-1b transcription might be due to epigenetic changes in microglial cells, a process that is 
thought to play a role in several neuroinflammatory disorders (29, 30). 
Once cytokines have reached the brain, there are changes in behavior through dopamine 
and serotonin neurotransmitter systems. Cytokines can influence dopamine synthesis 
via oxidative stress and disruption of the enzyme tetrahydrobiopterin (BH4), which is 
important for conversion of phenylanine to the dopamine precursors tyrosine and L-3,4-
dihydroxyphenylalanine (L-dopa). In addition, cytokines can enhance dopamine transporter 
activity and dopamine receptor functioning. Alternatively, cytokines can affect serotonin 
functioning through the activation of indoleamine 2,3dioxygenase (IDO) in peripheral 
immune cells or microglia and kynurenine pathways (31-36). Immunotherapy models 
have identified a dissociation between the role of dopamine and serotonin in symptom 
expression, with mood and cognitive symptoms being more responsive to treatment with 
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serotonin reuptake inhibitors (SSRIs) and fatigue and psychomotor functioning being 
more responsive to treatment with dopaminergic medications (37-39). This suggests that 
fatigue symptoms may involve alterations in dopamine functioning. Indeed, animal studies 
show that dopamine depletion alters motivational behaviour in a way similar to cytokine 
administrations (40-43), and it has been demonstrated that immune-induced reductions in 
physical activity and effort expenditure can be reversed with dopamine treatment (14, 44). In 
addition, fatigue is a common symptom in many psychiatric and neurological conditions that 
have been associated with alterations of the dopamine system including Parkinson’s disease 
and depression (37, 45-47). Besides their effects on brain neurotransmitter systems, IL-1 can 
also influence brain functioning through their effect on hippocampal neuroplasticity, 
neurogenesis (48) or via neuro-endocrine mechanisms involving the hypothalamic pituitary-
adrenal axis (HPA) functioning (49). These effects have been associated with the development 
of mental problems that often concur with fatigue-symptoms, such as impairments in learning 
and memory and depressive-like behaviour.
To give a clear view of the possible role of IL-1 in the development of fatigue in different 
diseases, we will discuss the studies that have been performed. 
Figure 1 Overview of routes by which peripherally produced IL-1 is able to influence IL-1 levels 
in the brain
Figure 1 gives an overview of the five different routes that can be used by peripherally produced 
IL-1α and IL-1β to access the CNS. The first route (1) is diffusion of IL-1 trough the fenestrated 
endothelium surrounding blood vessels in the circumventricular organs (CVO’s). The rest of the 
brain microvasculature is surrounded by the blood-brain barrier (BBB), where diffusion is not 
possible due to tight junctions between cells. In these areas IL-1 can be transported across the 
BBB by a saturable transport system (2), or it can activate perivascular macrophages at the brain 
side of blood vessels, stimulating them to produce IL-1 (3). These three routes combined are 
frequently described as the humoral pathway, which is able to activate microglial cells in the brain 
parenchyma (5). Another important system is the neuronal pathway, where peripherally produced 
IL-1 stimulates afferent nerves, especially the vagal nerve, causing local IL-1 production in the 
CNS by microglial cells (4). Increased concentrations of IL-1 in different areas of the brain are 
suspected to influence neurotransmitter systems (e.g. dopamine and serotonin), thereby exerting 
its effect on behavior and the development of fatigue.
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2
Overview of studies investigating the role of Interleukin-1 
in disease
Inflammatory illnesses
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic disease characterized by recurrent, often symmetrical 
destructive arthritis. In addition to local joint inflammation, RA is known for systemic 
symptoms such as fatigue. The prevalence of fatigue in the RA population varies between 
40% and 88%, depending on criteria and questionnaires used (50-52). Although the exact causal 
mechanism of fatigue is unknown (53), it can be predicted by pain, sleep disturbances and 
depression, rather than by disease activity (54). The contribution of cytokine disturbances to 
the development of fatigue remains to be elucidated, but could be prominent as treatment 
with tumor necrosis factor alpha (TNF-α) inhibitors has a positive effect on fatigue compared 
to treatment with methotrexate alone (55).
Cytokine disturbances in RA are well known, and are predominantly driven by increased 
TNF-α and IL-1, although TNF-α is measured more frequently. Both concentrations of IL-1b 
and IL-1Ra are slightly elevated in RA, and both correlate with disease severity, reflected by 
elevated pain scores and an increased erythrocyte sedimentation rate (ESR) (56, 57). Several 
findings suggest a central activation of the immune system in RA patients. A study evaluating 
IL-1 concentrations in cerebrospinal fluid (CSF) in 14 female RA patients with moderate disease 
activity and 12 healthy subjects found IL-1b concentrations in CSF are increased in patients, 
and positively correlated to fatigue severity (R=0.55, p<0.05) (26). Such a correlation was not 
present for pain or tender joint count. IL-1Ra in CSF was lower in RA patients compared to 
healthy subjects. Furthermore, IL-1b concentrations in CSF were significantly higher than in 
plasma, which suggests a central proinflammatory state in RA patients. 
The next step is to assess the effect of IL-1 blockade on fatigue severity in RA, which has 
been investigated by using monoclonal antibodies against IL-1b (canakinumab, Ilaris) and 
recombinant IL-1Ra (anakinra, Kineret) in patients with current disease activity (1, 2). In 
both studies there was a significant decrease of fatigue severity. The double blind study 
performed by Alten et al. (1) measured fatigue using the ‘Functional Assessment of Chronic 
Illness Fatigue’ (FACIT-F) questionnaire in patients on different canakinumab dosing 
regimens next to methotrexate, compared to patients who used placebo. At 12 weeks, two out 
of three canakinumab groups reported a small but significant decrease in fatigue compared 
to placebo. With respect to disease response rate, measured by joint inflammation and other 
disease specific characteristics, there was only a significant response in one of the groups 
(150mg canakinumab s.c. once every four weeks). An inherent problem with canakinimab, 
being a monoclonal antibody, is its failure to reach the CNS, and hence only fatigue driven    D
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syndrome (FCAS), Muckle-Wells syndrome (MWS), and chronic infantile neurologic 
cutaneous and articular syndrome (CINCA). These syndromes are all caused by a mutation 
in the NLRP3 gene encoding cryopyrin, a protein which is responsible for inflammasome 
activation (63). Different stimuli, for example, cold temperature in FCAS, can lead to 
cryopyrin production in these patients, causing a systemic inflammatory response mainly 
caused by IL-1b. FCAS, MWS and CINCA are all characterized by intermittent episodes of 
fever, headache, urticarial rash, and arthralgia (64). Although these symptoms are typically 
present during exacerbations, overall quality of life is also significantly affected and fatigue 
is reported by more than 75% of FCAS patients (65, 66). 
The influence of blocking IL-1 on disease severity and fatigue was assessed in several 
studies. It should be noted that the MWS and CINCA patients tend to have sterile chronic 
meningitis, which probably results in inhibitors having greater entry into the brain (67). 
Koné-Paut et al. assessed the influence of treatment with canakinumab in 35 CAPS 
patients (68). At baseline mean FACIT-F scores for the whole group were 27.4; after 8 weeks 
of treatment the score increased to 40.6, which is a significant decrease in fatigue (p<0.05). 
Symptoms of fatigue, as rated by the physicians, were already absent in more than 
85 percent of patients after eight days of treatment. In the second part of the study, patients 
were randomized to either canakinumab or placebo. In those patients randomized to placebo, 
fatigue recurred. In another study, the influence of canakinumab on fatigue was assessed 
in seven pediatric CAPS patients (69). At several time points physicians scored fatigue 
severity using a 5-point scale. At baseline fatigue was reported to be severe in two patients, 
moderate in three patients and mild in one patient. After one day of treatment, fatigue was 
absent in five patients and minimal in two patients and this effect was maintained until the 
next relapse of fever. 
The effect of rilonacept (Regeneron), a soluble IL-1 decoy-receptor construct, was assessed 
in 47 CAPS patients in two sequential phase III studies (70). In the first double-blind part of 
the trial, patients were randomized between weekly rilonacept or placebo for a duration of 
six weeks. In the subsequent second study, patients were treated with active drug for nine 
weeks, followed by another placebo-controlled period of nine weeks. Fatigue severity was 
measured using a 10-point rating scale by both patients and investigators. In both groups, 
fatigue decreased significantly during the first phase of the trial, with a larger decrease in 
the rilonacept group. In the third phase of the trial patients on placebo had a relapse of 
symptoms, while patients receiving rilonacept remained without fatigue.
The influence of anakinra on the development of symptoms in FCAS, was assessed in 
patients who were exposed to a cold challenge (71). In three patients, anakinra was given 
twenty-four hours and one hour prior to the challenge. None of the patients developed 
by peripherally produced IL-1 that may gain access to the brain is being countered. In case 
of apparent peripheral inflammation, which is the case in RA, this appears to be effective 
as can also be concluded from a study lowering TNF-α using a monoclonal antibody; here a 
rapid effect on central nociceptive brain activity was found (58). 
In the study using anakinra in RA, eight patients were treated daily for eight weeks, although 
there was no placebo-treated control group (2). The decrease of fatigue severity was most 
profound in the first four weeks with visual analog scale (VAS) scores being almost reduced 
by 50 percent. Decrease of fatigue was paralleled by a decrease in disease activity.
Sjögren’s syndrome
Another disease that is often accompanied by joint pain is Sjögren’s syndrome, although 
diminished salivary and lacrimal gland function are the hallmarks. Sjögren’s syndrome 
is characterized by autoantibody production against ribonucleoparticles and mononuclear 
cell accumulations in exocrine glands. Besides sicca complaints, fatigue is one of the most 
frequently noted symptoms in this disease reported by up to 85% of patients (59). Fatigue 
for some part can be explained by an altered sleeping pattern (60), but IL-1 might also be a 
contributor. 
Harboe et al. assessed IL-1 alterations in CSF in 54 adult patients with primary Sjögren 
syndrome (pSS) compared to 53 controls (61). IL-1b concentrations were below the detection 
limit of 1 pg/ml for both patients and controls. IL-1Ra concentrations were significantly 
elevated in patients and correlated to fatigue severity using a visual analog scale (VAS) 
independent of age and depression, although this correlation was very weak (r=0.11, 
p=0.015). 
The effect of IL-1 inhibition on fatigue severity was assessed by the same study group in 26 
pSS patients (3). Patients were treated with either daily anakinra or placebo for a period of 
four weeks, and were randomized on a 1:1 basis. Fatigue scores measured with the fatigue 
severity scale (FSS) after four weeks compared to baseline did not differ between groups. 
However, significantly more patients in the anakinra group had a fatigue reduction of more 
than 50% when using the VAS fatigue scale (p=0.03). This study suggests anakinra could 
be effective for treating fatigue in pSS, although the study was probably underpowered to 
detect significant changes.
Cryopyrin-associated periodic syndrome
In cryopyrin-associated periodic syndrome (CAPS), a group of rare diseases with an 
estimated prevalence of 1 in 360 000 persons (62), increased IL-1b activity plays a crucial 
role. CAPS consists of three auto-inflammatory disorders: familial cold autoinflammatory 
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probably has to be combined with T-cell targeting therapy to reach a maximal effect. The 
effect of anakinra on diabetes regulation was also assessed in type 2 diabetes (78). After 
13 weeks of treatment, patients needed less diabetes lowering drugs to obtain the same 
glycemic control. A similar positive response on glycemic control was established using an 
anti-IL-1β antibody in type 2 diabetes (79).
The interaction between peripheral inflammation and deregulation of central mechanisms 
was demonstrated in type 2 diabetic mice (80). After administration of LPS or IL-1b, diabetic 
mice had prolonged sickness behavior compared to controls. The mechanism for this 
diabetes-induced brain immune alteration is unclear, but it appears that diabetes has an 
effect on the IL-1β counter regulation, as IL-1Ra did not increase after LPS administration 
in diabetic mice. 
Both patients with type 1 and type 2 diabetes experience fatigue, although literature on 
this subject is scarce. In a recent study in 214 patients with type 1 diabetes, severe and 
persistent fatigue was present in 40% of patients (81). Diabetes appeared to be correlated 
with behavioral variables rather than with blood glucose concentrations. These results lead 
to the development of a behavior-based therapy to treat fatigue in type 1 diabetes (82). 
Cavelti-Weder et al. assessed the efficacy of XOMA052, a monoclonal anti-IL1b antibody, 
compared to placebo in 30 type 2 diabetes patients (4). Fatigue was reported by 53% of 
patients and significantly correlated to diabetes duration, but not to age, HbA1c, weight, 
body temperature, and C-reactive protein. After treatment for one month, fatigue decreased 
in the groups treated with moderate and high dosed XOMA052, whereas an increase of 
fatigue was seen in the low-dose and placebo groups. 
Cancer
In cancer, fatigue is one of the most prominent symptoms during all stages of disease, 
leading to substantial impairment and disability. A recent study evaluated the prevalence 
of fatigue in patients with breast, prostate, colorectal, and lung cancer undergoing active 
treatment (n=2177) or who had survived cancer (n=515) (83). Moderate-to-severe fatigue 
was reported by 45% and 29% of patients, respectively. The impact of fatigue on daily 
functioning in these patients is even greater than that of nausea or cancer-related pain (84). 
The exact mechanism causing fatigue during and after cancer treatment is not clear, but it is 
suspected that proinflammatory cytokines, especially TNF-α and IL-1b play an important 
role (85). One of the major reasons for this suspected relationship is that chemotherapeutic 
agents are known to trigger IL-1b release, as mentioned previously (86). In the acute 
situation such cytokine release promotes survival, but during the course of anti-cancer 
treatment it is associated with a variety of manifestations of illness, including fatigue (87). 
A systematic review evaluating the relationship between IL-1 and fatigue in different types 
acute symptoms which they developed without prior anakinra treatment. Although not 
measured objectively, patients reported less fatigue and increased well being, a feeling 
that lasted 48-72 hours after the second anakinra dose. In all of the described studies, the 
decrease in fatigue was accompanied by less inflammatory activity both clinically and 
biologically. These studies demonstrate the effect of IL-1 on clinical symptoms, and the 
fast improvement of these symptoms when IL-1, especially IL-1b, is inhibited.
Sarcoidosis
In sarcoidosis, an inflammatory disease of unknown etiology, patients develop granulomas 
in involved organs. The lungs are affected most often, but extra-pulmonary manifestations 
are present in up to 30% of patients (72). Young patients are most often affected, and 
symptoms usually resolve within 2-4 years. Even when in clinical remission of the disease, 
prevalence of fatigue is rather high. In a Dutch post-sarcoidosis cohort of 75 patients, 49% 
of patients reported severe fatigue, which was associated with psychological distress and 
reduced health status (73). 
To explore the involvement of pro-inflammatory cytokines in post-sarcoidosis patients 
with fatigue, 72 patients were included in a study by Korenromp et al. (74). Patients were 
categorized as being fatigued based on a Checklist Individual Strength subscale fatigue 
(CIS-f) score ≥35 (n=34), or non-fatigued when the score was below 35 (n=38). Whole 
blood IL-1α and IL-1b production was measured after lipopolysacharide (LPS) stimulation. 
In plasma, these cytokines were also determined in addition to IL-1Ra. No differences for 
these proteins could be found between groups. The contribution of IL1b was also assessed 
in 22 patients with active sarcoidosis compared to 22 controls (75). Fatigue was measured 
using the Multidimensional Fatigue Inventory (MFI-20), and IL-1b concentrations were 
determined before and after 11-15 minutes of cardiopulmonary exercise testing. Between 
patients and controls, there were no differences measured in IL-1β concentrations. 
However, pre-exercise circulating IL-1b concentrations in patients significantly correlated 
with fatigue severity in those patients who used immunomodulatory drugs (n=13). Thus, 
fatigue in sarcoidosis patients seems to be a consequence of treatment rather than of the 
disease itself. However the study population is too small to draw firm conclusions. The 
effect of IL-1 inhibition on fatigue severity in sarcoidosis patients has not been assessed. 
Non-inflammatory illnesses
Diabetes Mellitus
During the past 3 decades, a large number of studies have documented a role of IL-1b in 
Type 1 and Type 2 diabetes. IL-1b causes selective pancreatic beta-cell toxicity, resulting 
in decreased insulin production (76). Anakinra might be able to reduce this, disease-
characterizing, islet inflammation in newly diagnosed type 1 diabetes patients (77), but 
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in fatigue scores in the 53 patients evaluated. Interventions directed towards inhibition of 
IL-1 have not been performed in prostate cancer.
Breast cancer
Several studies have been performed in breast cancer patients undergoing radio- or 
chemotherapy. Geinitz and colleagues investigated the association between fatigue and 
cytokine concentrations during adjuvant radiotherapy in breast cancer patients (95). In 
accordance with prostate cancer patients undergoing radiotherapy, fatigue severity reached 
a maximum after four weeks of treatment, IL-1b concentrations in serum did not change 
and did not correlate with fatigue severity. Another study examined potential predictors of 
fatigue before, during and after adjuvant therapy in 44 women after breast cancer surgery 
(96). Blood samples were collected before adjuvant therapy had started. Questionnaires were 
repeated during and after therapy. Before adjuvant therapy, higher IL-1b concentrations 
predicted fatigue severity. During and after adjuvant therapy this association was no longer 
present, but cytokine concentrations were not determined during this period. Liu et al. 
measured fatigue and IL-1Ra in a group of 53 women diagnosed with breast cancer before 
and during chemotherapy (97). At baseline, IL-1Ra did not correlate with higher fatigue 
levels, and had no influence on changes of fatigue severity during treatment. The most 
recent study, performed by Schmidt et al., did find a small but significant influence of 
increased IL-6/IL-1Ra ratio after treatment, which could not be found for IL-1Ra levels 
(r=0.25) (98). 
Besides experiencing fatigue during cancer treatment, breast cancer survivors up to two years 
after completing treatment also report more fatigue than healthy controls (99). This symptom 
may be due to the cytokine response initiated by tissue damage during the acute treatment 
phase and persists after several years. To investigate the contribution of proinflammatory 
cytokines to fatigue after treatment, Bower et al.. compared 20 fatigued women with 
20 women without fatigue between one and five years after breast cancer diagnosis (100). 
Fatigued women had significantly higher concentrations of IL-1Ra in serum (p=0.006), 
there were no differences for IL-1b concentrations, which were below the detection limit 
in almost half of the patients. These observations were not confirmed in a study in 103 
patients 1-3 months after treatment for breast cancer (101). Bower et al. also evaluated ex vivo 
whole blood IL-1b production after LPS stimulation in 10 fatigued and 15 non-fatigued 
breast cancer survivors at baseline, and after completion of the Trier Social Stress Test 
(TSST) (102). At baseline there were no differences with regard to IL-1b production. 
However, after completing the TSST, fatigued patients had significant higher IL-1b 
concentrations. These findings suggest a higher pro-inflammatory response to psychological 
stress in fatigued patients. Circulating IL-1Ra concentrations were determined by the same 
study group in 50 fatigued and non-fatigue breast cancer survivors and were found to 
of cancer during and after treatment, could not prove IL-1b concentrations to be significantly 
correlated to fatigue severity (88). Patients in different stages of disease were analyzed as 
one group, which could have influenced the results. It is known that different biological 
processes take place during treatment and in the post-treatment situation. However, fatigue 
could be associated with an increase in circulating IL-1Ra (r=0.24, p<0.001) in this review, 
thus probably pointing to IL-1 activity. 
In addition to a possible effect of IL-1 during cancer treatment, IL-1 may also influence 
the persistence of symptoms after treatment. This was evaluated in a group of advanced 
cancer patients (n=45) and cancer survivors (n=47) (89). In both patient groups, IL-1Ra 
correlated with physical fatigue (r=0.32, p=0.03 and r=0.24, p=0.10, respectively). In 
cancer survivors, IL-1Ra not only correlated with physical fatigue, but also with mental 
fatigue (r=0.35, p=0.02). When comparing both groups, inflammatory markers were higher 
in patients with advanced cancer than in cancer survivors. Concentrations of circulating 
IL-1b and/or IL-1α were not determined.
Prostate cancer
A possible relationship between IL-1 and fatigue in patients treated for prostate cancer has 
already been addressed more than two decades ago (90). In this study, 15 men undergoing 
external beam radiation therapy for prostate cancer were evaluated for a period of eight 
weeks. Radiation therapy initiates an immunological response to stimulate tissue repair, 
which is accompanied by an increase in pro-inflammatory cytokines (91). Patients reported 
on fatigue daily using a VAS. IL-1b was determined in serum before start of therapy, and 
weekly thereafter. Both concentrations of IL-1b and fatigue increased during treatment, 
with a maximum after four weeks of treatment. A correlation between these measurements 
was not determined. Although performed in a small number of patients, this study was 
the first study on this subject. More recently, other investigators evaluated inflammatory 
markers during radiation therapy in patients with breast (n=28) and prostate (n=20) 
cancer (92). Circulating IL-1b increased significantly during treatment, although there was 
a large variation between patients, and there was no correlation between IL-1b and fatigue 
severity. However, in a subset of 22 patients, IL-1Ra was determined, which did correlate 
with reported fatigue. In another study, a correlation between IL-1b and fatigue was not 
found (93).
A study conducted in patients with prostate cancer evaluated the influence of single 
nucleotide polymorphisms (SNPs), which are associated with the production of pro-
inflammatory cytokines. The study assessed the development of fatigue during androgen-
deprivation therapy (94). Testosterone is suspected to modulate cytokine concentrations, 
especially IL-1b, IL-6 and TNF-α. Variation in IL-1b genotypes did not predict changes 
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Post-stroke fatigue
In patients who experienced a stroke, fatigue is reported by 29-77% of the population. The 
prevalence of fatigue is equally distributed over patients after ischemic stroke and those 
who had an intracerebral hemorrhage (112). With respect to inflammation, high levels of 
circulating IL-6 during the acute phase of stroke have been associated with poor outcome 
(odds ratio 3.1, 95% CI: 1.9-5.0); these data are derived from a large prospective study 
consisting of 844 patients (113). In subarachnoid hemorrhage patients, IL-6 concentrations 
can be lowered using intravenous anakinra infusion (114) and might prove to increase 
survival in future studies.
The relationship between post-stroke fatigue and inflammation was described by Ormstad 
et al., who included 45 patients after a first stroke in a longitudinal study (115). Serum 
samples were collected <24, 24-48, and 48-72 hours after stroke onset in 35, 7, and 3 of the 
45 patients. IL-1b and IL-1Ra were measured in available samples. Fatigue was measured 
using the Fatigue Severity Scale (FSS) up to 18 months after stroke. Directly after stroke, 
IL-1b concentrations correlated with fatigue severity after six months (r=0.37, p=0.015); 
this correlation could no longer be found after 12 and 18 months. At 12 months however, 
a negative correlation between IL-1Ra in the acute phase and fatigue was found (r=-0.38, 
p=0.013), a correlation that was not present at 6 and 18 months. Age, gender, comorbidity 
and use of medication were not confounders for these associations. These results imply that 
the acute inflammatory response during stroke has an impact on the occurrence of fatigue 
in the chronic phase. 
In a study of 39 stroke patients, the presence of a C allele at a SNP located in the promoter 
region of IL1RN, was related to the severity of post-stroke fatigue (116). The presence of a 
C allele in this region has been associated with lower IL-1Ra concentrations and higher 
concentrations of circulating IL-1b (117). In this study patients were included within 72 
hours of stroke onset, fatigue was assed using the Fatigue Assessment Scale (FAS) at one 
or more time points (30-365 days after stroke). In patients with severe fatigue, a C/T or C/C 
genotype was significantly more present (88%) than in patients with moderate (57%) and 
low fatigue (24%, p=0.03). This small study is the only study performed in this field, and 
circulating cytokine concentrations were not determined.
Chronic fatigue syndrome
Chronic fatigue syndrome (CFS) is a condition of unknown origin that is characterized 
by the presence of severe fatigue for a duration of at least six months, next to several 
accompanying symptoms such as headaches, sore throat, muscle and joint pain (118). Over 
the past decades, CFS has been attributed to a range of different causes, but a unifying cause 
has not been found. Even if a distinct abnormality is found repeatedly, for example relative 
be significantly higher in fatigued patients (103). Again, this finding was contradicted by a 
cross-sectional study evaluating IL-1Ra levels in 299 disease-free breast cancer survivors, 
who did not find any positive correlations between this marker and fatigue severity (104). 
The presence of SNPs in promoters of cytokine genes was also studied in breast cancer 
survivors (fatigued n=33, non-fatigued n=14). The presence of at least one cytosine 
nucleotide at the IL-1β gene (rs16944), a common SNP in many diseases, was reported to 
be associated with fatigue (105). However, in a larger cohort (n=302) this association could 
not be confirmed (106). 
Other types of cancer
In two other types of solid tumors, the involvement of IL-1 in the development of fatigue 
has been assessed. Orre et al. evaluated 92 fatigued testicular cancer survivors, compared 
to 191 non-fatigued survivors at a median of 11 years after diagnosis (107). Cases had 
significant higher IL-1Ra concentrations than controls. Increased IL-1Ra concentrations 
significantly correlated with physical fatigue, although they explained only 4% of variance 
in logistic regression analysis. A study investigating IL-1 in 15 patients with uterine cancer 
before, during and after undergoing curative radiation therapy, failed to prove a correlation, 
as IL-1 concentrations remained below the detection limit during the whole study (108). No 
distinction was made between IL-α and IL-1b in this small pilot study.
In hematologic malignancies, a single study has been performed that assessed the correlation 
between fatigue and IL-1 and IL-1Ra in 54 patients with acute myeloid leukemia or 
myelodysplastic syndrome undergoing pretreatment evaluation (109). IL-1Ra concentrations 
correlated with fatigue severity (r=0.52). Concentrations of circulating cytokines were 
higher in patients than in healthy controls.
The effect of IL-1α inhibition, using a neutralizing antibody, on fatigue was determined 
in 16 patients with metastatic, treatment-resistant non-small cell lung cancer (110). Quality 
of life was assessed at baseline and after eight weeks of treatment using the European 
Organization for Research and Treatment of Cancer, Quality of Life Questionnaire 
(EORTC QLQ C-30). After eight weeks fatigue was reported to be less severe, although 
this difference was not significant probably due to the small patient numbers. A significant 
improvement of fatigue after blocking IL-1α was seen in a large group of patients treated 
for metastatic colorectal cancer, in addition to improvement of appetite and a decrease in 
pain severity (personal communications) (111).
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The effect of physical exercise on circulating cytokines was discussed in a separate 
systematic review (126), although some of the studies discussed were also included in the 
review by Blundell (127-131). The conclusion of this review is that also after exercise of 
varying intensity, there are no consistent differences with respect to IL-1β.
Another approach is to compare cytokine production capacity of PBMCs after stimulation 
between CFS patients and controls. An early study reported increased IL-1β production 
after LPS stimulation in a small group of CFS patients (n=9) compared to controls 
(laboratory personal, n=7) (132). Swanink et al. recruited neighborhood controls and found 
the opposite: lower LPS-induced IL-1b concentrations in patients (n=76) than in controls 
(n=69), with a large overlap between concentrations of cytokines (133). Lower IL-1b and 
IL-1α production after PHA stimulation was also reported by Mawle et al. in patients with 
a gradual onset of symptoms, no differences were observed when those with a gradual and 
acute onset analyzed together (134). A fourth study by Cannon et al., published in the same 
period, investigated IL-1b production in women during different phases of the menstrual 
cycle (135). In controls, spontaneous IL-1b production by PBMCs increased during the luteal 
phase, which already has been observed in healthy subjects many years ago (136). However 
this could not be found in CFS patients. One recent study reported no differences between 
CFS patients and controls (137). 
IL-1b production by PBMCs in relation to fatigue has also been studied during the acute 
phase of an infection (138) and in the phase of persisting symptoms (139). During the acute 
phase the IL-1b concentration correlated significantly with fatigue-symptoms, however 
this relationship disappeared in the persistent phase. The perpetuation of fatigue symptoms 
in the absence of peripherally increased cytokine concentrations suggest that other, most 
likely central mechanisms, may be involved in persistent fatigue after an acute infection. 
With the brain as the suspected target organ for immunological dysregulation in CFS, a 
limited number of studies measured cytokine concentrations in cerebrospinal (CSF) fluid 
of patients. The first study, performed in 1991 by Lloyd et al., found no differences in 
IL-1b concentrations between patients and controls (140). Others had similar findings, and 
both IL-1α and IL-1b tended to be below the detection limit (141, 142). A more recent study 
compared 32 CFS patients to 40 patients with multiple sclerosis (MS) and 19 controls (143). 
CFS patients had lower CSF concentrations of both IL-1b and IL-1Ra compared to the MS 
and control group. When CFS patients were compared with MS patients only, IL-1α levels 
were also significantly lower. 
hypocortisolism (119), it is difficult to determine whether this is a causative factor or rather 
an epiphenomenon as a consequence of inactivity, depressive symptoms, sleep problems, 
etc. Perhaps more than any other chronic disease associated with fatigue, cytokines have 
been measured by several investigators. A relationship between IL-1 and fatigue severity 
has often been assessed. The studies reveal a large heterogeneity, not only with respect to 
patient characteristics, but also with respect to selection of controls and sample handling. 
In addition, there is a large variation in questionnaires used to measure fatigue dimensions 
and fatigue related symptoms. These issues make it difficult to draw reliable conclusions.
A systematic review focusing on circulating cytokines in CFS was published recently 
by Blundell et al. (120), who reviewed all studies published on this subject between the 
publication of the first CFS case definition in 1988 (121) to March 2015. All 38 studies 
measuring circulating cytokines in diagnosed CFS patients compared to controls were 
included. As mentioned earlier, there were large differences with respect to recruitment of 
controls, sample handling, and exclusion of concomitant diagnoses. IL-1α was measured in 
11 of the described studies, 27% of studies found increased concentrations, and 73% found 
no significant differences. IL-1b was determined in 28 studies, with only 25% reporting 
increased concentrations, the other studies did not find any significant differences. One 
of the more recent studies included in the review also discriminated patients with a short 
duration of illness (≤3 years, n=52) from patients with a long illness duration (n=246) 
and controls (n=348) (122). It appeared that patients with a short duration of illness had 
significantly higher IL-1α and IL-1Ra concentrations than controls. This was also found 
when comparing IL-1b levels in patients with short versus long illness duration. IL-1b 
appeared to be elevated in patients with a short duration and decreased in patients with 
a long illness duration (when compared to controls). After this extensive review of the 
literature by Blundell, three more studies on circulating cytokines were published (123-125). 
A study by Rusell et al. also tried to discriminate between patients with different illness 
durations (125). Comparing IL-1 concentrations, no differences could be found, although it 
has to be noted that patients with a ‘short’ illness duration had been fatigued for a mean of 
seven years, which is longer than the study mentioned earlier. In the linear classification 
model however, IL-1α appeared to have predictive value in recently ill adolescent patients. 
Hardcastle et al. compared severely ill, house-bound patients (n=19), to moderately ill 
patients (n=22) (123). Although groups are rather small, IL-1b was significantly elevated 
in the moderately ill patients (p=0.002). There were no differences for IL-1Ra. The third 
study could not find any differences between patients and controls for either IL-1b or IL-1α 
in a group of 100 patients and 79 controls (124). We conclude from the literature that there is 
limited evidence for increased circulating IL-1 in CFS patients, although there might be a 
more pro-inflammatory pattern in those with a short illness duration (122).
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Conclusions
In this review, we first described the mechanism by which IL-1 is able the influence 
certain brain regions, thereby leading to the development of fatigue. Next, we reviewed 
the literature describing studies where i) fatigue was correlated to IL-α, IL-1b, or IL-1Ra 
activity, or ii) the effect of lowering IL-1 concentrations on fatigue severity was measured. 
In addition to inflammatory diseases such as CAPS, we also focused on non-inflammatory 
diseases characterized by profound fatigue, such as several malignancies and CFS. There 
might be a distinctive underlying mechanism causing fatigue in inflammatory disorders, 
compared to the other groups of fatigue causing illnesses. In inflammatory diseases fatigue 
often has an acute pattern, however in subgroups of patients fatigue persists even when the 
inflammation phase has subsided. 
It can be concluded that there is no solid evidence that increased concentrations of 
circulating IL-α and IL-1b are associated with fatigue in any of the diseases described. This 
is not surprising, given the fact that circulating concentrations of these cytokines usually 
are very low, as discussed previously (12). However, IL-1Ra seems to be correlated with 
fatigue in some diseases, for example in cancer. However, in each of the studies described 
in this review, but especially in CFS, studies are rather contradicting. For a large part this 
can be caused by the fact that there is a large heterogeneity between studies. Selection 
of controls and sample handling, which is known to be very important when measuring 
cytokines, differed significantly between studies or was not described (145). Furthermore, 
studies differed with respect to questionnaires used to measure fatigue, the presence of 
comorbid diseases, use of medication in the patients studied, sample size, time since onset 
of the disease, duration of the fatigue (acute versus chronic) and the presence or absence 
of inflammatory processes.
For blocking IL-1 activity, most of the currently available inhibitors do not reach effective 
concentrations in the brain when the blood brain barrier is intact. This particularly is the 
case for the large molecular inhibitors (like canakinumab and rilonacept). For anakinra, 
which has a smaller molecular weight of 17kDa, the available pharmacological data show 
that the drug is able to reach the CNS after peripheral administration, although it is not 
clear if the local concentration in the CNS is high enough to have a substantial influence 
on neural processes (146, 147). 
In diseases such as rheumatoid arthritis (2) and Sjögren’s (3) blocking IL-1 using anakinra 
reveals promising effects on fatigue. In addition specific inhibition of either IL-1α (111) or 
IL-1β (4) also has a positive influence on fatigue severity. Unfortunately, the majority of 
the studies were not randomized controlled trials (2, 4), or were most likely underpowered 
Instead of creating more insight into pathological mechanisms in CFS, the described 
studies tend to raise more questions with respect to the role of IL-1 in CFS. It could be that 
disturbances of IL-1 signaling are only present in certain groups, for example only in those 
patients with short illness duration or those who experience fatigue after an infection, instead 
of when all patients are considered together. One possible way to elucidate the role of IL-1 
in CFS, is to investigate the effect of blocking IL-1 on fatigue severity in CFS patients (144).
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Abstract
Introduction: Alzheimer’s disease is a debilitating condition, and the search for an 
effective treatment is ongoing. Inflammation, in reaction to amyloid deposition, is thought 
to accelerate cognitive decline. With tumor necrosis factor alpha being an important pro-
inflammatory cytokine, a recent trial investigated the effect of the tumor necrosis factor 
alpha inhibitor etanercept after peripheral administration in Alzheimer’s patients. Although 
there was no significant effect, others have claimed spectacular effects of etanercept after 
perispinal injection. In the present study, the central delivery of drugs with a large molecular 
weight was evaluated after injection in the cervical perispinal region. When successful, this 
might increase therapeutical options for Alzheimer’s disease.
Methods: Nine male Sprague-Dawley rats were injected with Iodine-125 labeled 
cetuximab (146 kDa), etanercept (51 kDa) and anakinra (17 kDa). Each radioiodinated 
drug was injected in two rats into the perispinal region, and in one rat into the dorsal tail 
vein. Directly after injection, the rat was placed in a head down position for 3 minutes, to 
direct blood flow into the valveless vertebral venous system. A single-positron emission 
computed tomography scan was acquired starting 5 minutes after injection, subsequently 
the rats were euthanized and bio-distribution was determined. 
Results: Intracranial delivery of the radiolabeled drugs could not be visualized in all but 
one of the rats. Injected drugs accumulated locally in the perispinal region.
Conclusions: In this study, no evidence could be found for the delivery of drugs to the 
central nervous system after perispinal injection. Additional research is needed before this 
treatment can be used in patients with Alzheimer’s disease.
Introduction
During the past few years, there has been an increase in the use of targeted therapies for 
different kinds of inflammatory disorders. Most of these drugs, for example, the tumor 
necrosis factor alpha (TNF-α) inhibitor etanercept, have a high molecular weight, which 
prohibits them from passing the blood-brain barrier (BBB). This is no problem when 
treating diseases such as rheumatoid arthritis, but it becomes an obstacle when the brain 
is the primary focus of inflammation. The latter is the case in brain injury in Alzheimer’s 
disease (AD). It is suspected that inflammation, as a consequence of amyloid deposition, 
plays an important role in the cognitive decline in AD (1, 2), and that the intensity of this 
inflammatory reaction influences the speed of cognitive decline in individual patients (3). 
TNF-α is a proinflammatory cytokine known for its activity in several disease conditions (4). 
It plays an important role in immune-to-brain communication (5), and increased TNF-α is 
associated with rapid neurocognitive decline (6) and neuropsychiatric symptoms (7) in AD. 
The effect of peripheral inhibition of TNF-α in AD has been assessed recently in a trial 
evaluating the effect of etanercept and placebo in 41 AD patients (8). Although the drug 
was well tolerated, there were no significant effects on cognitive functioning and behavior. 
However, earlier uncontrolled studies by Tobinick et al., claim benefit from perispinal 
administration of etanercept in AD (9, 10) and post-stroke patients (11). If true, these results, 
which were heavily criticized by Whitlock (12), would open up potential new treatment 
avenues.
The first question to be asked is whether there is a causal relationship between increased 
TNF-α activity and cognitive decline in AD. As mentioned above, the role of inflammation in 
AD has not been fully elucidated at this moment. Therefore, TNF-α inhibition as a strategy 
in this category of patients is questionable. As said, a recent phase II study using peripheral 
etanercept administration in patients with AD was ineffective (8). Still, this lack of an effect 
could have been caused by insufficient inhibition of TNF-α in the central nervous system (CNS) 
after peripheral administration. This leads to the second question, which is: Does perispinal 
administration of drugs with a high molecular weight lead to adequate concentrations in the 
brain? Etanercept does not cross the blood BBB after peripheral administration because of its 
high molecular weight (51 kDa). Tobinick searched for a method to bypass the BBB, without 
having to use more harmful methods of administering drugs, and relies on the vertebral 
venous system (VVS) to accomplish this (9).
In humans, the musculature and the (sub)cutaneous tissues of the back and neck are drained 
by the external vertebral venous plexus (EVVP) (13, 14). The EVVP connects with the internal 
vertebral venous plexus (IVVP), and both plexuses connect with the basivertebral veins. These 
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three venous entities represent the vertebral venous system (VVS), also known as Batson’s 
plexus, which is thought to be valveless and forms a separate and discrete venous network, 
paralleling, joining and at the same time bypassing, the longitudinal veins of the thoraco-
abdominal cavity. The VVS also connects with the intracranial basilar venous plexus and the 
intracranial dural sinuses (15). In nonhuman primates, Batson injected radiopaque material into 
the deep dorsal vein of the penis, and demonstrated the existence of a connection between the 
pelvic venous plexus with the VVS; he also showed that the contrast medium can be redirected 
into the intracranial venous sinuses after compression (and subsequent temporary obstruction 
of the inferior vena cava) of the abdomen (13). With this study, he found an explanation for the 
observation that metastases of retroperitoneal cancers in humans preferably tend to distribute 
to the vertebral skeleton and spinal epidural space, and via the cranial sinuses into the brain. 
Based on these findings and assumptions, Tobinick designed his concept for drug delivery into 
the brain (9). He assumed that, after injection into the perispinal soft tissues, and subsequently 
placing the patient in the Trendelenburg position, the retrograde flow within the VVS would 
result in the delivery of the medication, through the cranial veins, into the brain. Tobinick et al. 
have performed and published only one single experiment in rats, visualizing the intracranial 
distribution of etanercept labeled with the positron emitter Cu-64 (16), and speculate about the 
mechanism without providing further proof (17). Positron emission tomography (PET) studies in 
healthy controls or patients have not been performed. 
In this brief article, the methods published by Tobinick were explored by injecting drugs 
with a large molecular weight to the cervical perispinal region of Sprague-Dawley rats. As 
this technique is claimed to be safe and an effective way to administer drugs to the CNS, it 
could provide a new treatment option for patients with Alzheimer’s disease.
Methods
Preparation of radio-labeled drugs 
Cetuximab 5 mg/mL (Erbitux®, Merck, Darmstadt, Germany), etanercept (Enbrel®, Pfizer, 
New York, United States) and anakinra 149 mg/ml (Kineret®, Swedish Orphan Biovitrum 
AB, Stockholm, Sweden) were dialysed against 50 mM phosphate buffer, pH 7.4 and 
radiolabeled with I-125 (PerkinElmer). For radioiodination the iodogen method was 
applied. Briefly, 100 μg cetuximab, 300 μg etanercept and 300 μg anakinra were incubated 
in an iodogen-coated tube (100 μg) with 50-72 MBq I-125 in phosphate buffer, pH 7.4 
during 10-60 minutes. Labeling efficiency was 68-90% and the radioiodinated products 
were purified by gel filtration on a PD-10 column (GE) that was eluted with PBS, 0.5% 
BSA. The radiochemical purity (RCP) was determined by instant thin layer chromatography 
(ITLC) and exceeded 95% for all preparations.
Animals and procedures
All animal procedures were conducted in accordance with the Radboud Animal Welfare 
guidelines. Nine male Sprague-Dawley rats with an average weight of 250 g were 
anesthetized with 2.5-3% isoflurane inhalation anesthesia, and injected with 150 μL I-125-
labeled cetuximab (146 kDa), etanercept (51 kDa) and anakinra (17 kDa). Drugs with 
different molecular weights were selected to determine the effect of molecular weight on 
central delivery. For each drug, two rats were injected in the area overlying the cervical 
spine at the C6-7 level using a 30 gauge needle at a depth of 6 mm, as described by 
Tobinick et al. (16). One rat was injected in the dorsal tail vein followed by flushing with 1ml 
of saline. Directly after injection, the rats were placed in head down position for 3 minutes. 
Five minutes after the injection, a single-positon emission computed tomography scan 
(SPECT) was performed using a microSPECT/CT scanner (U-SPECT II scanner, MIlabs, 
Utrecht, the Netherlands). After completing the scan, which took 20 minutes, all rats were 
euthanized and bio-distribution was determined. 
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Results
SPECT imaging could not reveal intracranial accumulation of the radioiodinated drugs 
in all but one of the animals (figure 1a). This animal, the first rat that was injected, died 
during acquisition of the SPECT-scan and distribution of the tracer was compatible with 
the anatomical margins of the ventricular system and the intraspinal CSF-space. In the 
other animals, radiolabeled drugs could only be detected in the injection region (figure 1b), 
without any sign of penetration into the central nervous system.
The biodistribution of the radiolabeled drugs is summarized in (table 1), in which the 
uptake in the heart, blood, brain, and perispinal injection region is specified. Except for 
the first rat, deposition of drugs in the brain was ≤0.10 %ID/g. After injection in the dorsal 
tail vein, the average distribution was higher in blood and in the heart. After perispinal 
injection, the drugs accumulated locally, and did not reach the brain.
Figure 1 In vivo distribution of I-125 labeled Cetuximab after perispinal injection using SPECT
Figure 1 Biodistribution of I-125 Cetuximab in the animal in figure 1a suggested injection to 
be intrathecal, instead of perispinal. The animal died during acquisition of the SPECT scan. 
The biodistribution as displayed in figure 1b is in line with images of the other four perispinal 
injected animals. The radiolabeled drug in these animals was only found at the injection site.
Table 1 In vivo distribution of I-125 labeled drugs measured in blood, heart, brain, and the injection 
regions.
AC* (%ID/g) 
Blood
AC (%ID/g) 
Heart
AC (%ID/g) 
Brain
AC (%ID/g) 
Perispinal region
AC (%ID/g) 
Dorsal tail vein
Cetuximab
  perispinal  
    Rat 1
    Rat 2
  dorsal tail vein
    Rat 3
2.06
0.19
5.24
0.39
0.05
1.61
4.05
0.01
0.10
0.06
17.15
-
-
-
0.46
Etanercept
  perispinal  
    Rat 4
    Rat 5
  dorsal tail vein
    Rat 6
0.14
0.10
2.98
0.04
0.03
0.91
0.01
0.01
0.08
1.10
0.93
-
-
-
0.20
Anakinra
  perispinal  
    Rat 7
    Rat 8
  dorsal tail vein
    Rat 9
0.30
0.16
0.37
0.11
0.07
0.19
0.06
0.02
0.04
10.86
7.31
-
-
-
0.15
Table 1 *AC: average concentration
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Discussion
In this study, the previous claim that radiolabeled drugs accumulate in the brain after 
perispinal injection (11, 16, 18), could not be replicated. In only one of the rats, deposition of 
I-125 labeled cetuximab in the brain regions compatible with the intraventricular system 
could be detected. In the other animals, drugs accumulated locally at the injection site.
The first rat that was injected died in the SPECT-scanner (< 20 min after administration). In 
the same rat, accumulation of the tracer in the perispinal region was very low compared to 
the other rats (0.06%ID/g), which supports the suspicion of a “false route” during injection. 
When, according to the protocol, the drug is blindly injected in the perispinal region at a 
depth of 6 mm, there is a high change of injecting intrathecally. In this study, drugs had to 
be administered carefully to prevent this misrouting. In the experiment by Tobinick et al., 
injection might have been directly into the intrathecal space, and not into the perispinal soft 
tissues. As such, the recommendations by Tobinick et al. to use the VVS as a delivery-route 
for drugs into the central nervous system lacks any scientific basis.
Conclusion
In conclusion, we believe that there is a lack of proof that perispinal injection of drugs like 
etanercept would lead to effective concentrations in the brain. Before this technique can 
be recommended for treatment in patients with AD and other neurological diseases, proof 
of concept is needed. However, our present experiments falsified the claim by Tobinick et 
al. about the vertebral venous system being an anatomical route to bypass the blood-brain-
barrier and to deliver high molecular drugs to the central nervous system. Based on the 
literature, and the now available new data, we feel that there is even insufficient basis to 
propose an RCT at this point.
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Abstract
Background: Chronic fatigue syndrome (CFS) is a medically unexplained syndrome for 
which no somatic or pharmacological treatment has been proven effective. Dysfunction of 
the cytokine network has been suspected to play a role in the pathophysiology of CFS. The 
disturbances of the cytokine network detected in CFS patients are highly variable, in part 
due to the lack of adequate controls in many studies. Furthermore, all studies have been 
performed on peripheral venous blood of patients. As cytokines mainly act in the tissues, 
for example, the brain, the information that can be derived from peripheral blood cells is 
limited. The information regarding the possible role of cytokines in the pathophysiology, 
could come from intervention studies in which the activities of relevant cytokines are 
reduced, for example, reducing interleukin-1, interleukin-6 or tumor necrosis factor. In this 
study the clinical usefulness of anakinra, an IL-1 antagonist, will be assessed in patients 
with CFS.
Methods/design: A randomized placebo-controlled, double-blind trial will be conducted. 
Fifty adult female patients meeting Centers for Disease Control (CDC) criteria for CFS, 
and without psychiatric co-morbidity will be included. After inclusion, patients will be 
randomized between treatment with anakinra (recombinant human interleukin-1 receptor 
antagonist) or placebo. Each group will be treated four weeks. Outcome measures will 
be assessed at baseline, after four weeks of intervention, and six months after baseline 
assessment. The primary outcome measure will be fatigue severity measured with the 
validated Checklist Individual Strength (CIS). Secondary outcome measures are functional 
impairment, physical and social functioning, psychological distress, pain severity, presence 
of accompanying symptoms, and cytokine and cortisol concentrations.
Discussion: This is the first randomized placebo-controlled trial that will evaluate the 
effect of interference with IL-1 on the experience of fatigue in patients with CFS. The 
results of this study may expand treatment options for patients with CFS, for whom at this 
moment graded exercise therapy and cognitive behavioral therapy are the only evidence 
based interventions.
Background
Chronic fatigue syndrome (CFS) is a medically unexplained syndrome characterized by 
severe disabling fatigue for a period of at least 6 months, which leads to considerable 
impairment in daily functioning (1). Various accompanying symptoms may be present, 
such as headache, joint and muscle pain, sore throat, impaired memory and concentration, 
and exercise intolerance. In the Netherlands the prevalence of CFS is at least 27.000 
persons (2). So far, the cause for CFS is unclear (3). Cognitive behavioral therapy (CBT) and 
graded exercise therapy (GET) are the only interventions that have shown positive results 
in randomized controlled clinical trials for treating fatigue associated CFS-symptoms and 
disability (4-8).
Cytokines are hormone-like proteins that convey messages between cells. Originally they 
were thought to act only within the host defence system, but soon it became clear that 
they mediate an array of diverse effects in normal physiology and disease. Since pro-
inflammatory cytokines play a key role in inflammation (e.g. by causing fever, inducing 
muscle pain, fatigue, sleep, and other flu like symptoms), they have been hypothesized to 
be responsible for the symptoms in CFS (9, 10). 
Several studies have been performed to investigate whether there is an excess of cytokines 
in CFS, but so far the findings are inconsistent (11, 12). A recent systematic review on 
circulating cytokines in CFS reported that the majority of studies performed during 
the past years did not find significant increased concentrations of proinflammatory 
cytokines (13). A major problem is that many studies did not use adequate controls, and use 
different methods to handle blood samples. Cytokine responses are under genetic control, 
but they are extremely vulnerable to other influences, such as hormonal status, food, 
exercise, stress, behavior, drugs, and vaccines (14). Therefore, it is not easy to compose a 
good control group. An additional problem is that almost all studies have been performed 
on peripheral venous blood. As cytokines mainly act in tissues, with the brain being 
the most important target organ in CFS, information that can be derived from studying 
circulating cytokine concentrations (which are generally in the picogram/ml range) is 
limited. The only information regarding a role of cytokines that is pathophysiologically 
relevant could come from intervention studies in which crucial cytokines in tissue are 
inhibited. A potentially relevant cytokine, which can be blocked in humans without severe 
side effects is interleukin-1 (IL-1) (15).
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Although it is plausible that cytokines play a role in the pathophysiology of CFS, there is 
only indirect evidence for this theory:
1. The complaints of patients with CFS are often described as that of a persistent flu. 
During infections like influenza, symptoms are generally ascribed to the action of 
cytokines (like IL-1, IL-6, tumor necrosis factor alpha (TNF) and interferons) (9). 
2. Many disease states are accompanied by anorexia, loss of interest, somnolence and 
fatigue, a symptom complex coined as sickness behavior. The cytokines IL-1beta, 
TNF and IL-6 are thought to be responsible for it. Administration of either IL-1, 
IL-6, TNF or each of the interferons to humans and animals is accompanied by 
flu-like symptoms (16-18). 
3. Previously, it was reported that IL-8 and IL-10 were significantly elevated in 
cerebrospinal fluid in patients with CFS, compatible with induction of IL-1 (19). 
4. Beta amyloid precursor protein has also been found to be elevated in cerebrospinal 
fluid of CFS patients (20). Production of this protein is under control of IL-1 and 
TNF (21-23).
5. Our group has previously established that patients with CFS have a significant loss of 
grey matter in the brain (24, 25). This loss of grey matter might be caused by enhanced 
cytokine activity. 
Drugs that interfere with the proinflammatory cytokine IL-1 are commonly used nowadays 
for a variety of inflammatory disorders (26). The recombinant IL-1 receptor antagonist 
(anakinra) reduces the activity of both IL-1α and IL-1β by binding to the IL-1 receptor. This 
intervention is highly targeted and hence would allow investigators to draw conclusions 
regarding the pathophysiology of CFS, and the effect of reducing cytokine concentrations 
in CFS patients. Moreover, compared to blocking TNF-α or IL-6, blocking IL-1 with 
anakinra has a long safety record with respect to side-effects, and is not associated with 
increased susceptibility to opportunistic infections such as Mycobacterium tuberculosis. 
The primary aim of this study is to assess the effect of anakinra on fatigue severity in 
patients with CFS. Fatigue is the most central and characterizing symptom of CFS and, in 
contrast to the accompanying symptoms, it is reported by all patients. It is also strongly 
related to the functional impairments reported by patients. As a secondary study aim, we 
will assess the effect of anakinra on level of functional impairment, physical and social 
functioning, pain severity, presence of accompanying symptoms and psychological distress. 
In this paper we describe the protocol to evaluate the effects of anakinra. Other studies with 
anakinra or anti-IL-1β revealed a decrease in fatigue (27-30).
Methods/design
Study design
A randomized placebo-controlled trial (RCT) will be performed to determine whether 
interference with IL-1 is able to reduce fatigue and disabilities in CFS patients. Within each 
study arm, treatment will be double blind. The study will be performed in the Radboud 
University Medical Center, in the Department of Internal Medicine and in the Expert 
Center for Chronic Fatigue (ECCF), located in Nijmegen, the Netherlands. All female CFS 
patients visiting the outpatient clinic of the department of Internal Medicine or visiting the 
ECCF, will be considered for participation. Furthermore, patients connected to the ‘ME/
CVS-stichting’, a Dutch foundation for CFS patients, will be asked to participate in the 
study. To increase homogeneity in our study population, we decided to only include female 
patients, as CFS is a disease that mostly affects women. After inclusion, each patient will 
receive an individual study code. Patients will be asked to bring a healthy, age-matched, 
neighborhood control at their first study visit. If patients decide not to participate in this 
study, an attempt will be made to elucidate the reason for this, but patients are not obligated 
to explain their refusal.
Study population
Fifty subsequent patients will be included and equally randomized between treatment arms. 
Inclusion criteria for participation comprise the CDC diagnosis of CFS (31), fatigue duration 
≤ 10 years or recent progression of fatigue severity, female gender, age between 18 and 59 
years old, a score ≥40 on the subscale fatigue severity of the Checklist Individual Strength 
(CIS), and a score ≥700 on the Sickness Impact Profile (SIP). The exclusion criteria include 
females who are pregnant or nursing, intend to get pregnant during the study, use or have 
used psychotropic medication in the past month, received an alive vaccine during the 
last four weeks, had substance abuse in the past 3 months, have symptoms more than 
10 years, are taking any medication except oral contraceptives and/or paracetamol, have 
evident somatic co-morbidity, have current engagement in CFS research, do not have the 
ability to understand the nature and the extent of the trial and the procedure required, have 
psychiatric co-morbidity (major depression, psychosis, eating disorders, anxiety disorders, 
bipolar disease and post traumatic stress disorder) assessed with ‘The Mini-International 
Neuropsychiatric Interview’ (M.I.N.I.) (32), and are currently engaged in a legal procedure 
with respect to disability claims.
Ethical approval
The study is approved by the Medical Ethical Review Committee of the RadboudUMC 
Nijmegen (registration number 2014/025). The study is registered at the European Union 
Drug Regulating Authorities (EudraCT: 2013-005466-19) and will be conducted according 
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to the Declaration of Helsinki, Good Clinical Practice (GCP) and Good Manufacturing 
Practice (GMP) guidelines. The inclusion of patients started in July 2014. Written informed 
consent will be obtained from all patients before participating in the trial.
Study medication, randomization and follow-up
Eligibility for participation of patients is determined at the pre-study visit. After giving 
informed consent patients will be screened for in- and exclusion criteria by means of 
the examinations listed in figure 1. Laboratory investigations performed earlier will be 
evaluated for all patients and will be repeated if not performed recently, or when essential 
measurements, as recommended by others (31), are missing. Patients who qualify to be 
included will be randomized 1:1 to receive either anakinra (100mg/day) or placebo. 
Randomization will be performed by the study pharmacist (department of Clinical 
Pharmacy, Radboud University Medical Center), the randomization assignment is known 
only by the pharmacist and will only be exposed in case of emergency. If the code is broken, 
it will render the participant not eligible. When the study is completed, the randomization 
list will be made available by the study pharmacist.
Study medication will be provided by the Swedish Orphan Biovitrium (Sobi) and stored at 
the Department of Pharmacy of the RadboudUMC. Preparation and labelling of anakinra 
and placebo will be done according to the current guidelines. This will be performed by the 
Clinical Trials Unit department of Clinical Pharmacy of the RadboudUMC. Anakinra and 
placebo syringes will be identical in appearance, the placebo syringes contain a mixture 
of sodium citrate, sodium chloride, and polysorbate. Medication is used once daily, during 
a period of four weeks. Anakinra and placebo will be provided by the main investigator. 
On the first study day, patients will be instructed how to self-inject the study medication, 
as described by others (27). Administration takes place in the subcutaneous tissue, most 
often the abdomen or the thighs. During the study, patients will be advised to set their 
alarm clock daily at the same time to remind them of using the medication correctly. Drug 
adherence will be evaluated after one week and after completion of treatment. Patients will 
return all used and unused syringes after four weeks.
During the intervention period, use of co-medication is only allowed when used for ≤14 
consecutive days, on the condition that there are no known interactions with anakinra. Oral 
contraceptives and/or paracetamol can be used without a limitation. During the follow-up 
period, there are no limitations regarding the use of medication. All co-medication will be 
registered and reported afterwards.
Since the anakinra arm is difficult to blind because of local reactions at the injection site, 
the research physician and the principal investigator will not be informed of the side effects. 
After the injection instruction by the physician assistant (PA), the patient will be instructed 
to report adverse effects to the PA and not to the research physician. The PA will report all 
side effects to an independent physician. The independent physician will examine patients 
if needed and is mandated to stop treatment. To evaluate blinding of treatment, patients will 
be asked which medication they thought they were using during the trial, after they have 
completed the study.
Study visits are carried out at week zero, week four and, if needed, after six months. After 
one week patients will be contacted by telephone to evaluate the occurrence of any problem 
regarding the use of medication and drug utilization will be recorded. If there are serious 
side effects an additional study visit can be performed by the independent physician at any 
time. Between study visits, subjects will be asked to fill out web-based questionnaires up 
to six months after their first study visit (figure 1). 
 
Outcome measures
The primary outcome measure is the fatigue severity measured with the subscale fatigue 
severity of Checklist Individual Strength (CIS) at four weeks, the primary endpoint of 
the study. Scores on the CIS subscale range from 8-56 (8 items, 7-point Likert Scale).
This questionnaire has been validated extensively in patients with chronic fatigue syndrome 
(33, 34). Patients will fill out this web-based questionnaire weekly during the course of the 
trial, and monthly during the follow-up period (figure 1). 
Secondary outcome measures
Level of functional impairment measured with the Sickness Impact Profile (SIP8) total score. 
The SIP8 is a validated instrument to evaluate sickness-related dysfunction. The total score 
gives an indication of the experienced disabilities in all domains of functioning (35).
Physical and social functioning assessed with the subscale physical functioning and 
subscale social functioning of the Short Form (SF)-36 (36).
Level of psychological distress assessed with the total score on the Symptom Checklist-90 
(SCL-90). A high total score reflects psychological distress (37).
Pain severity assessed with a visual analogue scale (VAS). This score can vary between 0 
(no pain) and 10 (worst pain ever experienced). 
Presence of accompanying symptoms will be evaluated using the CDC-criteria. The number 
of symptoms can vary between 0 and 8.
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Cytokine concentrations in blood (plasma and blood in Pax-gene tubes). Our study can 
provide additional information regarding cytokine levels, because we have the opportunity 
to compare cytokine concentrations with healthy neighborhood controls. Also we will 
compare pre-treatment concentrations with post-treatment concentrations.
Cortisol concentrations in hair and saliva, because of the possible role of the hypothalamus-
pituitary-adrenal axis in CFS. For the baseline assessment, comparison will be made 
with cortisol concentrations in matched neighborhood controls. All patients will collect 
saliva during two consecutive days at four different time points (directly after awakening, 
30 minutes after awakening, 11 a.m., 8 p.m.), using the passive drool method. Saliva will 
be stored at -80ºC until further analysis.
Microbiome determination in stools. This will give more insight into the microbial flora of 
the host, which is a new field of interest in a wide range of diseases. The availability of well-
defined patients with CFS and matched controls is a great opportunity in an unexplored area 
of CFS research, to assess whether the microbiome of CFS patients is peculiar. Patients will 
collect feces at home, all samples will be stored at -80ºC until further analysis.
All secondary outcome measures will be assessed at baseline and directly following the 
intervention (figure 1). Only the VAS pain scale will be filled in weekly (together with the 
CIS) during the trial. 
At 6 months, all questionnaires evaluating primary and secondary outcomes will be 
repeated again to evaluate if the expected effects of the medication are maintained during 
the follow-up period of five months.
Other study parameters collected at baseline will be: demographic data, medical history, 
psychiatric history, serology results collected before inclusion in the study, use of 
medication, smoking and the use of alcohol and drugs.
Withdrawal of individual participants 
Subjects can leave the study at any time for any reason if they wish to do so without any 
consequences. The investigator or independent physician can decide to withdraw a subject 
from the study for urgent medical reasons. In general, non-completers are not to be replaced. 
Subjects withdrawn from the study for a medical reason or adverse events will receive 
adequate follow up. All analysis will be done according to the Intention to Treat principle 
(ITT). In case of discontinuation, efforts will be made to continue all study measurements. 
Withdrawn patients, or patients who are still severely fatigued following the intervention, 
will be offered regular care, which is cognitive behavioral therapy at the ECFF.
Adverse events
Adverse events (AE) are defined as any undesirable experience occurring to a subject 
during the study, whether or not considered related to the investigational product. All 
adverse events reported spontaneously by the subject or observed by the investiga tor or 
his staff will be recorded. Anakinra is known as a very safe drug. Side effects are mainly 
those related to irritation at the injection site, these reactions usually wane with prolonged 
treatment. We have reported from our own experience with long-term use of anakinra in 
patients with Schnitzler syndrome that the risk for infection is not enhanced, even in this 
elderly group (38). Nevertheless, the package insert warns against infectious complications 
in patients with underlying illness. Rarely, neutropenia develops during treatment, which 
is a reason to discontinue therapy. 
Statistical analysis
The primary analysis will be the comparison between the two different treatment groups 
(anakinra or placebo) at 4 weeks. Data will be analysed on an ITT basis. Missing values 
will be replaced using multiple imputation with fully conditional specification with at least 
five imputations. The imputation method that will be used is predictive mean matching for 
missing data in primary and secondary outcome measures. Aside from condition we will 
use the following variables assessed at baseline to generate the imputations: duration of 
symptoms, age, BMI and baseline values of the outcome measures.
The results will be analysed with SPSS for Windows. To determine if there is a significant 
difference between the intervention arm and placebo condition, ANCOVA will be used with 
the outcome measure on the second assessment as dependent measure, the baseline score 
as covariate, and condition as fixed factor (39). We will test if significant differences exist 
between both groups in mean age and BMI at baseline, both known to influence circulating 
cytokine levels. If so, these variables will be entered as covariates in the ANCOVA. When 
a statistical significant difference is found in the primary analysis, a sensitivity analysis will 
be performed on the basis of different assumptions about the values of missing data. For the 
secondary outcome measures, the same analysis will be repeated, but now with the secondary 
outcome measures at second assessment as dependent variable, and the scores at baseline 
as covariate. 
Power calculation
The sample size is based on the fatigue subscale score of the CIS at 4 weeks. In the present 
study the power calculation is based on results from comparable studies with CFS patients 
where fatigue severity was determined with the CIS-fatigue scale (40). If interleukin-1 
plays a central role in CFS symptomatology, we expect a considerable reduction of fatigue 
following treatment. Assuming a large controlled effect size of 0.85, an alpha of 0.05 and a 
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power of 0.80, 23 patients are needed in each arm of the study. The number of patients can 
be further reduced by using ANCOVA, with the outcome measure on the second assessment 
as dependent measure, the baseline score as covariate, and condition as fixed factor. In this 
kind of trials ANCOVA yields greater power than other statistical methods (39). Based on 
the correlation between the pre- and post CIS fatigue scale, the sample size of 23 can be 
multiplied with 0.883 (1-0.3422). Including an assumed dropout rate of 20 percent, we will 
have to include 25 patients in each group to demonstrate a significant difference between 
the medication group and the placebo.
CICFS: Cytokine inhibition in Chronic Fatigue Syndrome
Randomization
Included
• CDC-diagnosed CFS-patients
• female, between 18 and 59 years old
• CIS (Checklist Individual Strength) ≥ 40
• Sickness Impact Prole (SIP) ≥ 700
• fatigue duration ≤ 10 years, or recent progression
   of fatigue severity
T=0: outpatient clinic 
internal medicine
T=4 weeks: outpatient 
clinic internal medicine
Principal investigator:
• temperature, pulse rate;
• blood, saliva, hair and feces 
   samples;
• questionnaires: CIS, SIP, SF-36,
   SCL-90, VAS, CDC-symptoms
Internet questionnaires:
• CIS;
• VAS pain
Self-assessment of pulse rate
Injection of medication
daily
1 week
weekly
monthly
Evaluation of experiences 
by telephone
Internet questionnaires:
• CIS
• VAS pain
Self-assessment of pulse rate
T=6 months: nal evaluation:
• Internet questionnaires: CIS, SIP, SF-36, 
   SCL-90, VAS, CDC-symptoms;
• self-assessment of pulse rate;
• visit outpatient clinic (voluntary)
End of study:
Patient will be informed of study 
outocomes after 24 months.
Principal investigator:
• temperature, pulse rate
• blood, saliva, hair and feces samples
   (+neighborhood controls)
• questionnaires: CIS, SIP, SF-36, SCL-90, VAS, 
   CDC-symptoms (control: CIS, BDI, SCL-90)
Physician Assistant:
• instruction how to take the pulse rate
• injection instruction
Screening for eligibility (outpatient clinic):
• physical examination (if not performed previously)
• medical history
• electrocardiogram (ecg)
Written informed consent will be asked for willingness to:
• undergo screening for eligibility
• be randomized between treatment groups
• permit collection of blood, saliva, hair and feces samples at 0 and 4 weekd after starting treatment
• receive and ll out questionnaires on self-reported symptoms, disabilities, pain and behavioral factors at inclusion up until 
   6 months after starting treatment
Excluded
• pregnant or nursing women
• patients who use or have used psychotropic medication in the past month
• live vaccination during the past 4 weeks
• fatigue duration ≥ 10 years
• substance abuse in the past 3 months
• patients taking any medication except oral contraceptives and/or 
   paracetamol
• patients with evident somatic co-morbidity
• current engagement in CFS research
• inability to understand the nature and the extent of the trial and the 
   procedure required
• current engagement in a legal procedure with respect to disability claims
• psychiatric co-morbidity (major depression, psychosis, eating disorders, 
   anxiety disorders, bipolar disease and post traumatic stress disorder)
• pregnancy test
• psychiatric evaluation (MINI)
• questionnaires (evaluation of fatigue)
Figure 1
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Discussion
This study will be the first randomized placebo-controlled trial to evaluate the effect 
of blocking IL-1 on symptoms in patients with CFS. Earlier studies investigated 
cytokine production to be of relevance in CFS patients, but conflicting results have been 
published (11, 13). A possible explanation is that good controls have not been used in these 
studies, and cytokines were measured in peripheral blood instead of in tissues.
Blinding the study for anakinra is a difficult procedure, because of the occurrence of local 
skin reactions in a significant amount of patients. To maintain the double-blind design 
of this trial, side-effects will be evaluated by an independent Physician Assistant (P.A.). 
In earlier ‘double blind’ trials medication was injected in the presence of the main 
investigator (27). The effect of anakinra will be measured up to six months after the start of 
treatment. In this manner we can evaluate the long-term effect of blocking IL-1 for a short 
period. It will provide more insight into the best treatment for CFS patients, when blocking 
IL-1 appears to be effective. 
In conclusion, this study will provide more insight into the pathophysiology and treatment 
of patients with CFS. If an effective treatment can be found, this will drastically improve 
quality of life in patients with this disabling disease.
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Abstract
Background: Interleukin-1 (IL-1), an important proinflammatory cytokine, has been 
suspected to play a role in the chronic fatigue syndrome (CFS).
Objective: To evaluate in female CFS patients the effect of subcutaneous anakinra versus 
placebo on fatigue severity.
Design: Randomized, placebo-controlled trial from July 2014 until May 2016. Patients, 
providers, and researchers were blinded to treatment assignment.
Setting: University hospital in the Netherlands.
Patients: 50 women, between 18 and 59 years old, with CFS and severe fatigue leading to 
functional impairment.
Interventions: Participants were randomized to daily subcutaneous anakinra (100mg/
day, n=25) or placebo (n=25) for four weeks and followed for an additional 20 weeks off 
treatment (n=50). 
Measurements: Primary outcome: fatigue severity measured by the Checklist Individual 
Strength (CIS-fatigue) subscale at four weeks; Secondary outcomes: level of impairment, 
physical and social functioning, psychological distress and pain severity at four and 24 
weeks. 
Results: At 4 weeks, 8% (2/25) of anakinra participants and 20% (5/25) of placebo 
participants reached a fatigue level within the range reported by healthy individuals. There 
were no clinically important or statistically significant differences between groups in 
fatigue severity at 4 weeks (mean difference CIS-fatigue score: 1.5 points; 95% CI -4.1 to 
7.2) or at the end of follow-up. There was no statistically significant difference between 
groups for any secondary outcome at four weeks or the end of follow-up. One patient in 
the anakinra group discontinued treatment due to an adverse event. Patients in the anakinra 
group had more injection site reactions (68% (17/25) vs. 4% (1/25)). 
Limitations: Small sample size, wide variability in duration of symptoms; inclusion not 
limited to patients with symptoms after an infection.
Conclusions: Peripheral IL-1 inhibition using anakinra for four weeks does not result in a 
clinically significant reduction of fatigue severity in women with CFS and severe fatigue.
Introduction
Chronic fatigue syndrome (CFS) is characterized by severe, persistent and disabling 
fatigue. Although different case definitions for CFS/myalgic encephalomyelitis exist, the 
Center for Disease Control (CDC) criteria are most often used in research. According to 
the CDC definition, patients with fatigue have to report at least four out of the following 
eight accompanying symptoms: post-exertional malaise, unrefreshing sleep, impairment 
of short-term memory or concentration, headache, muscle pain, tender lymph nodes, sore 
throat or arthralgia (1, 2). The pathogenesis of CFS is unknown. The only effective treatments 
are cognitive behavioral therapy and graded exercise therapy (3-5) though a substantial 
proportion of patients do not improve after these therapies (6).
The immune system has been a focus in the search for the pathogenesis of CFS because 
of the resemblance of CFS symptoms with ‘sickness behavior’, in which proinflammatory 
cytokines such as interleukin-1α and β (IL-1α and IL-1β) and tumor necrosis factor play 
a role (7). These findings are derived from studies in mice (8, 9) and humans (10-13). After 
peripheral administration or production, the cytokines can reach the central nervous system 
and influence neurotransmitter systems (14).
Several studies searched for elevated circulating concentrations of cytokines, particularly 
IL-1 and tumor necrosis factor in CFS (15-18). Some studies found CFS patients had increased 
concentrations of IL-1α (19, 20), IL-1β (19, 21), and the IL-1 receptor antagonist (IL-1Ra) 
(15), while others found no such increases (18). Of note, measuring circulating cytokines 
is complex and sample handling is critical (22). Circulating concentrations, especially 
of IL-1β, are often below detection. Most cytokines remain in the intercellular 
environment (23, 24). In CFS increased cytokine activity might be confined to the brain. This 
forces us to explore other methods to investigate the role of proinflammatory cytokines in 
CFS, for example by intervening with cytokine effects.
IL-1 is one of the proinflammatory cytokines associated with fatigue most frequently (25). 
There is extensive experience with blocking IL-1 in different diseases (26). Both IL-1α 
and IL-1β can be inhibited by the IL-1 receptor antagonist anakinra. Anakinra has mild 
side-effects, mainly limited to the injection site (27, 28). Anakinra reaches the CNS, albeit 
in low concentrations (29, 30). Central effects of anakinra are most impressive in patients 
treated for cryopyrin-associated periodic syndromes, a rare autoinflammatory syndrome 
(31, 32). However, these patients have overt inflammation with increased permeability of 
the blood-brain barrier. Several studies in inflammatory (33-35) and non-inflammatory 
(36) illnesses, assessed the effect of IL-1 inhibition on fatigue severity. Most of these 
studies found positive effects of IL-1 blockade on fatigue. Studies using daily 
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anakinra injections (100mg/day), found a decrease of fatigue within four weeks of 
treatment (33, 34). 
To investigate the role of proinflammatory activity in CFS, we conducted a randomized 
placebo-controlled trial in female CFS patients using the IL-1 receptor antagonist anakinra. 
All patients had severe fatigue leading to functional impairment.
Methods
Design overview
The study protocol including a detailed description of the intervention has been published 
(http://www.ncbi.nlm.nih.gov/pubmed/26438161) (37). This randomized parallel-group 
placebo-controlled trial was performed at the Department of Internal Medicine and Expert 
Center for Chronic Fatigue (ECCF) of the RadboudUMC. The local ethics committee 
approved the protocol (2014/025). Patients were randomized 1:1 between daily subcutaneous 
anakinra or placebo for four weeks, followed by a follow-up period of 20 weeks. Participants, 
all study personal (main investigator, physician assistant), and the sponsor were blinded to 
treatment allocation throughout the study. 
Recruitment started in July 2014 and lasted until November 2015. Follow-up was completed 
in May 2016. After approval of the original protocol but before the start of the trial, the 
number of patients was increased to 50 and a decision was made to exclude patients with an 
illness duration of >10 years. During the trial, an amendment was made to allow medication 
use for ≤14 consecutive days for treatment of adverse events if the medication had no 
known interactions with anakinra (use of paracetamol and oral contraceptives already was 
allowed at baseline and during the trial). The published protocol mistakenly mentioned the 
number of accompanying CDC symptoms as a secondary outcome measure whereas the 
original protocol did not specify those symptoms as a secondary outcome.
Setting and participants
All female CFS patients visiting the outpatient clinic of the Department of Internal Medicine 
or the ECCF were considered for participation. Regional hospitals and a CFS-treating center 
could refer patients. Patients connected to a Dutch patient advocacy foundation for CFS were 
also invited to participate. Patients willing to participate were screened for eligibility after 
giving written informed consent. Patients were asked to fill out web-based questionnaires and 
were evaluated by the research physician by means of medical history, physical examination, 
electrocardiogram, pregnancy test, psychiatric evaluation using the Becks Depression 
Inventory-Primary Care version and the Mini International Neuropsychiatric Interview (38).
Patients were included if they met the CDC criteria (1, 2), were aged between 18 and 59 
years old, had a maximal fatigue duration of ten years or recent progression of symptoms, 
had a score of ≥40 on the fatigue severity subscale of the Checklist Individual Strength 
(CIS-fatigue), and had a score of ≥700 on the Sickness Impact Profile. These questionnaire 
scores reflect severe fatigue leading to substantial impairment. The exclusion criteria were 
described previously (37) and are listed in supplementary table 1. 
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Randomization and blinding
The randomization list was computer-generated by the Department of Pharmacy (39). During 
the study, the list was only known by the pharmacist, and could only be exposed in case 
of emergency. The pharmacy provided sequentially numbered boxes, which were given to 
the patient by the research physician on the patients’ starting date. After completion of the 
trial and closing of the data file, the list was made available to the research physician. Both 
anakinra and placebo were provided by the Swedish Orphan Biovitrium (Sobi, Stockholm, 
Sweden). Syringes of both arms were visually inspected by the pharmacy to secure 
identical appearance. Each consecutive patient received a study number corresponding 
with a number on the randomisation list and one of the medication boxes [1-50]. 
Patients were instructed to report side-effects to an independent physician assistant, to 
keep the research physician blinded. After one week of treatment, patients were contacted 
by telephone to evaluate the presence of adverse events. Patients were instructed to call the 
physician assistant or internist on call in case of adverse events. After completion of the 
intervention at four weeks, adverse events were evaluated once more. All adverse events 
were graded by the physician assistant based on their severity (mild, moderate, severe), 
treated if necessary, and followed until they had abated (37). Anakinra frequently causes 
a reaction at the injection site, which could influence blinding if noticed by the research 
physician. The physician assistant was supervised by an independent senior internist. 
After completion of the intervention period, the patients were asked which medication 
they thought they had been using. Data analysis was performed by a researcher blind for 
allocation of patients. 
Interventions
At the first study day, patients received medication boxes providing study drugs for 4 
weeks. Medication was provided by the research physician. The boxes contained either 
anakinra (100mg/day) or placebo, which was administered subcutaneously on a daily basis. 
The placebo contained a mixture of sodiumcitrate, sodiumchloride, and polysorbate. Each 
box contained 28+4 syringes. The physician assistant instructed all participants on the 
subcutaneous injections during the first study visit and handed out written instructions 
to them. After the instruction, the first injection was self-administered in the presence of 
the assistant. Patients were advised to set a daily alarm to remind themselves of using the 
medication. After 1 and 4 weeks, drug adherence was evaluated, and after completion of the 
trial remaining syringes were returned and counted. In case of problems with adherence or 
drug administration during the study, monitoring frequency was intensified. After 4 weeks 
patients were seen at the outpatient clinic by the research physician. After six months, at 
the end of the follow-up period, the research physician phoned the patients (37). 
Outcomes
Primary and secondary outcome measures were assessed using web-based questionnaires, 
which were completed at baseline, after four weeks and 24 weeks post-baseline. 
Questionnaires on fatigue and pain severity were filled out weekly during the intervention, 
and monthly during follow-up. 
The primary study outcome was fatigue severity after completion of the intervention (4 weeks), 
measured with the CIS-fatigue subscale (40, 41). The CIS is a validated questionnaire often used 
in CFS patients. One of the subscales assesses fatigue severity. Scores range between 8 and 56 
with higher scores reflecting more severe fatigue. A previous non-inferiority trial suggested 
that a clinical meaningful change was unlikely if the mean difference between treatment 
groups was less than 5.2 points (42). Secondary outcome measures were level of functional 
impairment assessed with the Sickness Impact Profile (range 0-5799) (43), physical and 
social functioning assessed with the respective subscales of the Short Form (SF)-36 
(range 0-100) (44), level of psychological distress assessed with the Symptom Checklist-90 
(SCL-90, range 90-450) (45), and pain severity assessed with a visual analogue scale (VAS, 
range 0-10) after completion of the intervention period. For all outcome measures, with the 
exception of the SF-36, a higher score means more symptoms. Additional outcome measures 
on body temperature, pulse rate, cytokine and cortisol concentrations, and microbiome were 
collected and will be reported elsewhere. All safety issues were discussed with an independent 
Drug Safety Monitoring Board during the trial.
Statistical analysis
The sample size estimate was based on the effect size reported in previous studies that had 
evaluated CBT in CFS patients (46, 47). In each arm, 23 patients were needed assuming an 
effect size of 0.85, a power of 0.80, and an alpha of 0.05 (two-sided). This would reflect a 
mean between group difference in the CIS-fatigue at post-treatment assessment of 8.5 to 9 
points assuming a within group SD of 12.1 in the anakinra condition and 8.7 in the placebo 
condition (46). The sample size was set assuming analysis of covariance (ANCOVA) and a 
correlation between baseline and post-baseline measurement of 0.342. With an estimated 
dropout of 20 percent, 25 patients had to be included in each study arm. 
All analyses were performed using IBM SPSS Statistics software for Windows 
(version 22.0). Primary and secondary outcome measures were analyzed based upon the 
randomized treatment assignment. Data were complete for all baseline and post-baseline 
measures of primary and secondary outcomes, except for a missing maximum VAS-pain 
score at 8 weeks in an anakinra patient.
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For the analysis of all outcome measures ANCOVA was used in order to determine if 
there were any differences between the study arms. The score on the outcome measure at 
four weeks was entered as dependent variable, with treatment as fixed factor, and score at 
baseline as covariate. For evaluation of the effect of illness duration on outcome, illness 
duration was added as a covariate in a separate analysis. Outcomes were considered as 
significantly different in case of a p-value <0.05.
Role of the funding source
This study was partially supported by the Interleukin Foundation and an independent donor 
that wishes to stay anonymous. Both anakinra and placebo were provided by the Swedish 
Orphan Biovitrium (Sobi, Stockholm, Sweden). Neither the funders nor the manufacturer of 
the medication had a role in study design, data collection, data analysis, data interpretation, 
or writing of the report. 
Results
To reach the required 50 participants, 82 severely fatigued female patients were screened 
for eligibility. After inclusion, 50 patients were randomly assigned to one of the treatment 
arms (figure 1). Reasons for exclusion are displayed in figure 1. During the trial, one patient 
discontinued treatment due to a local skin infection which recovered after antimicrobial 
treatment. No patients were lost to follow-up. Concomitant medication that was used 
during the intervention period is shown in supplementary table 2. None of the patients 
received a co-intervention during the intervention period of the trial.
Figure 1 CDC = Centers for Disease Control and Prevention. 
Figure 1 Inclusion and randomization procedures. 
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Baseline characteristics of groups were similar (table 1). Symptoms started after an infection 
in 24 patients, 14 of these patients were randomized to anakinra. One patient randomized 
to placebo was post-menopausal. 23 patients within the anakinra group and 25 patients 
within the placebo group adhered to ≥90% of the study medication. Only one patient in the 
anakinra group missed >50% of the injections due to medication discontinuation because 
of an adverse event. 
Table 1 Baseline Characteristics of the Study Population
Characteristic Anakinra (n = 25) Placebo (n = 25)
Mean age (SD), y 30 (9) 32 (11)
Median illness duration (range), mo 44 (7–109) 39 (9–108)
Mean body mass index (SD), kg/m2 25 (5) 25 (4)
Mean fatigue severity (CIS-fatigue score) (SD)* 52 (4) 51 (4)
Mean functional impairment (SIP score) (SD)† 1647 (584) 1706 (721)
Mean social functioning (SF-36 score) (SD)‡ 33 (24) 39 (23)
Mean physical functioning (SF-36 score) (SD)‡ 48 (23) 56 (19)
Mean psychological distress (SCL-90 score) (SD)§ 152 (31) 148 (30)
Mean maximum pain score (VAS) (SD)|| 7 (2) 7 (2)
Mean CDC symptoms (SD), n 7 (1) 6 (2)
Table 1 CDC = Centers for Disease Control and Prevention; CIS-fatigue = fatigue severity 
subscale of the Checklist Individual Strength; SCL-90 = Symptom Checklist-90; SF-36 = Short 
Form 36; SIP = Sickness Impact Profile; VAS = visual analogue scale.
* Ranges from 8 to 56; higher scores indicate worse fatigue.
† Ranges from 0 to 5799; higher scores indicate greater impairment.
‡ Ranges from 0 to 100; higher scores indicate better functioning.
§ Ranges from 90 to 450; higher scores indicate greater distress.
|| Ranges from 0 to 10; higher scores indicate worse pain.
Primary outcome
The primary outcome measure was assessed for all patients. After four weeks of treatment 
there was a mean difference of 1.5 on the CIS-f between patients treated with anakinra and 
controls (95% CI -4.1 to 7.2, p=0.59, table 2). Both groups showed an overall decrease 
in fatigue severity over the complete follow-up period, but most participants remained 
severely fatigued with a mean CIS-f score >35 (figure 2). In the anakinra group, 2 patients 
(8%) were no longer severely fatigued after the intervention period, reflected by a CIS-f 
<35 (47), compared to 5 patients (20%) in the placebo group (difference -12.0%, 95% 
CI: -31.8% to 7.8%, p=0.22). In those patients who reported symptoms after an infection, 
there was also no difference in fatigue severity after four weeks between both study arms 
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Figure 2 The mean (95% CI) CIS-fatigue (top), SIP (middle), and maximum VAS pain (bottom) 
scores for both treatment groups during the complete intervention and follow-up periods are 
shown. Summaries are based on questionnaire scores for all 25 anakinra recipients and all 25 
placebo recipients, with the exception of the maximum VAS pain score at 8 wk, for which 1 
anakinra recipient was missing. CIS = Checklist Individual Strength; SIP = Sickness Impact 
Profile; VAS = visual analogue scale.
Figure 2 Fatigue, impairment, and pain scores throughout the study. (p=0.45). In addition, there was no effect of duration of symptoms on fatigue severity after 
treatment (data not shown).
Secondary outcomes
Secondary outcome measures were assessed in all patients. After four weeks and at follow-
up, there were no statistically significant differences in impairment, physical and social 
functioning, psychological distress and pain severity between study arms (table 2). 
Adverse events
The adverse events during the intervention period are listed in table 3. Adverse events 
were more frequent in the anakinra group compared to controls [24/25 (96%) vs. 14/25 
(56%)] due to injection site reactions in the anakinra group [17/25 (68%) vs. 1/25 (4%)]. 
All injection site lesions resolved completely. There were no serious adverse events (SAE). 
Within the anakinra group, 17 patients (68%) correctly guessed which treatment they had 
been using compared to 15 patients (60%) in the placebo group.
Table 3 Adverse Events and Serious Adverse Events Reported During the 4-Week Intervention*
Adverse Event Anakinra (n = 25) Placebo (n = 25)
Death − −
Withdrawal due to adverse event 1 (4) −
≥1 adverse event 24 (96) 14 (56)
Serious adverse event − −
Injection site reaction 17 (68) 1 (4)
Infection 6 (24) 4 (16)
Gastrointestinal symptoms 1 (4) 3 (12)
Central nervous system symptoms 3 (12) 3 (12)
Psychological symptoms 1 (4) 1 (4)
Other 9 (36) 4 (16)
Table 3 * Adverse events were evaluated at 1 and 4 wk. Patients were instructed to contact the 
hospital by telephone if an adverse event occurred. Values are numbers (percentages).
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Discussion
Though 2 anakinra participants and 5 placebo participants reached a fatigue level within 
the range reported by healthy individuals, our study did not find that ankinra led to a 
clinically meaningful decrease of fatigue severity. The CIS-f at four weeks, the primary 
outcome of this study, was 1.5 points higher in the anakinra group and the 95% CI for the 
anakinra-placebo difference was -4.1 to 7.2. The lower bound of the confidence interval of 
this difference is consistent with a maximal potential benefit with anakinra of 4.1 points 
on the CIS-f. A prior non-inferiority study suggested that a clinical meaningful change 
between treatment groups was unlikely if the mean difference was less than 5.2 points 
on the CIS-f (42). We also found no statistically significant differences between groups for 
secondary outcome measures, such as functional impairment and physical impairment. 
Despite many studies reporting circulating cytokines in CFS (18), intervention studies on 
this subject are scarce. We searched for intervention studies (English language search of 
Pubmed to December 2016 and clinicaltrials.gov) and found no published or registered study 
evaluating the effect of directly lowering cytokines on fatigue severity in CFS patients. 
However, a positive effect of IL-1 inhibition on fatigue severity has been found in several 
other illnesses such as rheumatoid arthritis (33), Sjögren’s syndrome (34), and diabetes (36). 
We considered several methodological and study population explanations for our findings. 
Compliance did not differ between treatment groups, although one patient in the anakinra 
group discontinued treatment after two weeks as a consequence of a local skin infection. As 
at least 90% of the injections were administered by 96% of patients, it is unlikely that poor 
adherence explains the findings. As CFS typically affects women, we only included female 
patients to investigate a homogeneous group. Since recent studies suggest an inflammatory 
pattern early in the course of CFS (15), we excluded patients with an illness duration of 
>10 years. Psychiatric illnesses, mainly depression, are known to have an influence on 
inflammation (48). To solely investigate the effect of blocking IL-1 on fatigue, patients with 
active psychiatric comorbidity were excluded. We believe it is unlikely that any of the 
study population selection issues influenced the outcome.
A possible explanation for the results of this study is that peripherally administered anakinra 
does not reach the brain in sufficient concentrations to have a biological effect. Previous 
studies have demonstrated that IL-Ra is able to reach the cerebrospinal fluid (CSF) in low 
concentrations after intravenous (30, 49) and subcutaneous (50) administration. No human data on 
CSF concentrations after s.c. administration exist, but a study in rats found CSF concentration 
of 170(50) ng/mL after a single IL-1Ra injection both in naïve rats and after brain ischaemia (50). 
However, penetration of the brain parenchyma only occurred after brain ischaemia. Thus 
therapeutically active concentrations in the brain might be only reached in case of disruption 
of the blood-brain barrier, which is probably not present in CFS. 
Finally, the lack of an effect in this study could be caused by a limited role of IL-1 in 
CFS. After peripherally produced IL-1 reaches the CNS, an upstream signaling cascade 
is activated, eventually leading to alterations in the production of neurotransmitters, 
especially dopamine (14). Treating fatigue through IL-1 inhibition might only be effective 
in diseases with a more acute inflammatory pattern, whereas in the chronic situation these 
upstream effects should also be addressed. This is supported by the fact that IL-1 inhibition 
especially seems to be effective in diseases with an acute inflammatory pattern (25). It could 
also be that proinflammatory cytokines other than IL-1, for example tumor necrosis factor, 
are responsible for symptoms in CFS. 
Regarding adverse events, there were no large differences in the incidence of infections 
or CNS symptoms. However, skin reactions at the injection sites were more frequent in 
the anakinra group. This is a known side-effect of anakinra, mostly present during the 
first weeks of treatment. It is characterized by macrophage infiltration (51) and causes pain 
and discomfort, which might have impacted pain scores in the anakinra group during 
treatment. The degree of skin reaction has been found to correlate with diminished 
therapeutic effects (51), it is unclear to what extent this contributed to the primary outcome 
of our study, especially because the severity of the injection site reaction varied among 
patients and was not scored in an objective manner. As a consequence of the small sample 
size, uncommon harms of anakinra could have been missed.
Overall, fatigue severity decreased over the total duration of the trial in both study arms, 
comparable to previous studies performed by our group (52). In the placebo group, 20% 
of patients responded positively to the treatment, similar to a pooled placebo response of 
19.6% in previous studies in CFS patients (53). 
Increased concentrations of IL-1β correlate with sickness behavior and fatigue during acute 
infections such as Q-fever and infectious mononucleosis (54). Therefore, interfering with 
IL-1β might be more effective in those patients with persisting fatigue after an infection. 
A limitation of this study is that the inclusion of patients was not limited to these patients. 
However, 48% of patients in the current study reported an infection as the initial trigger for 
their symptoms, and these patients did not respond differently to the treatment. Additional 
limitations of the current study are the small sample size and wide variability in the duration 
of symptoms, although the latter did not influence the main outcome.
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In conclusion, we found no clinically meaningful effect of anakinra on fatigue severity 
in CFS patients. It may be concluded that if IL-1 plays a role in CFS, blockade of the 
IL-1R1 in the peripheral tissues such as the neuromuscular compartment has no effect. 
Future studies should focus on intracerebral processes in CFS patient and on reducing 
inflammation with agents that reduce IL-1 activity in the brain (55, 56).
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Appendix Table 1 Exclusion Criteria
Use of medication (except for oral contraceptives and/or paracetamol)
Use of psychotropic medication in the past month
Psychiatric comorbidity (major depression, psychosis, eating disorders, anxiety disorders, bipolar 
disease, and posttraumatic stress disorder) assessed with the Mini-International Neuropsychiatric 
Interview
Evident somatic comorbidity (as an explanation for fatigue)
Fatigue lasting >10 y (without recent progression)
Substance abuse in the past 3 mo
Pregnancy, nursing, or intended pregnancy during the study
Live vaccine during the past 4 wk
Current engagement in chronic fatigue syndrome research
Inability to understand the nature and extent of the trial and the procedure required
Current engagement in a legal procedure with respect to disability claims
Appendix Table 2 Concomitant Medication Use During the Intervention*
Medication Anakinra (n = 25) Placebo (n = 25)
Oral contraceptives 9 (36) 13 (52)
Paracetamol 16 (64) 16 (64)
Nonsteroidal anti-inflammatory drugs 1 (4) 2 (8)
Codeine 1 (4) −
Antibiotics 3 (12) 1 (4)
Antihistamines 2 (8) −
Other
Alutard (ALK-Abelló) 1 (4) −
Metamucil (Procter & Gamble) 1 (4) −
Melatonin 1 (4) −
Appendix table 2 * Values are numbers (percentages) of patients who used the specific 
medication group. 
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Abstract
Background: Cytokine disturbances have been suggested to be associated with the Chronic 
Fatigue Syndrome (CFS) for decades.
Methods: Fifty female CFS patients were included in a study on the effect of the interleukin-
1-receptor antagonist anakinra or placebo during four weeks. EDTA plasma was collected 
from patients before and directly after treatment. At baseline, plasma samples were 
collected at the same time from 48 healthy, age-matched female neighborhood controls. 
A panel of 92 inflammatory markers was determined in parallel in 1μL samples using a 
‘proximity extension assay’ (PEA) based immunoassay. Since transforming growth factor 
beta (TGFbeta) and interleukin-1receptor antagonist (IL-1Ra) were not included in this 
platform, we measured these cytokines with ELISA.
Results: In CFS patients, the ‘normalized protein expression’ value of IL-12p40 and 
CSF-1 was significantly higher (p-value 0.0042 and 0.049, respectively). Furthermore, 
using LASSO regression, a combination of 47 markers yielded a prediction model with 
a corrected AUC of 0.73. After correction for multiple testing, anakinra had no effect on 
circulating cytokines. TGFbeta did not differ between patients and controls.
Conclusions: In conclusion, this study demonstrated increased IL-12p40 and CSF-1 
concentrations in CFS patients in addition to a set of predictive biomarkers. There was no 
effect of anakinra on circulating cytokines other than IL-1Ra.
Background
Chronic fatigue syndrome (CFS) is a condition of unknown origin that is characterized by 
severe fatigue for more than six months leading to significant disability. To fulfill the CFS 
criteria as recommended by the Centers for Disease control (CDC), patients also have to 
report at least four out of eight of the accompanying symptoms (e.g. muscle pain, post-
exertional fatigue, headache, etc.) (1, 2). With CFS being an exclusionary diagnosis, patients 
often report to have symptoms for several years before being diagnosed (3). Most of the 
current case definitions suggest a collection of mandatory diagnostics to exclude common 
causes for fatigue such as anemia and thyroid illnesses (1, 4), but there is a need for more 
specific tests to diagnose patients. Another advantage of such a test is that it might be easier 
to define CFS subgroups (5), for example those patients that would or would not respond to 
an immune intervention. Last but not least, a distinctive marker or set of markers may point 
to relevant pathogenetic mechanisms that may be further explored.
In the past years, numerous studies have been performed searching for potential biomarkers (6). 
Because of the resemblance of CFS with symptoms that characterize immune activation, 
there has been a particular interest in the immune system with studies measuring lymphocyte 
subsets (7, 8), cytokine production (9-11), and single nucleotide polymorphisms in immune 
related genes (12, 13). However, despite a large number of studies conducted, this has not led 
to a unified conclusion useful for clinical practice. Studies are largely contradicting, and a 
recent systematic review on circulating cytokines did not find evidence for altered cytokine 
concentrations in CFS, with the exception of transforming growth factor-beta (TGF-β) (14). 
TGF-β appeared to be elevated in 63% of the selected studies. This was also found in a 
recent study on cytokine signatures in CFS (15). Other cytokines were only elevated in a 
minority of studies, for example interleukin-1α (IL-1α) in 27% of the studies, interleukin 
12 (IL-12) in 18%, interleukin 23 (IL-23) 25%, and interleukin 8 (IL-8) in 29% of studies. 
Some studies only found differences when differentiating between patients with long and 
short illness duration (9, 16). 
In order to make progress on the role of the immune system in CFS, we have to critically 
review the studies that have been performed, and try to clarify the reasons for these 
discrepancies. When measuring circulating cytokines, several issues have to be taken 
into account. First, patient selection is important. Studies often combine different cohorts 
of patients, recruit employees as controls, or controls who participated in previous 
studies (9, 17), and this may lead to different pre-analytical procedures. The latter is especially 
an important issue in this context. Cytokines may be released ex vivo by different circulating 
cells, and collection tubes, storage time, number of freeze-thaw cycles, and processing 
protocols have been found to be of influence (18, 19). To make a reliable comparison between 
Chapter 6 Cytokine signatures in chronic fatigue syndrome
119118
6
patients and controls, especially in CFS where circulating cytokines are expected to be low, 
it is essential that the pre-analytical process in these groups is identical.
Another important issue is the type of analysis used to determine cytokine concentrations. 
Most studies measuring cytokines use antibody based Enzyme-Linked Immuno Sorbent 
Assays (ELISA) (14). However, limitations of this technique are that multiplex forms of 
the assays often use only one antigen-binding antibody to detect the protein, which limits 
detection specificity as well as sensitivity (20). Sandwich ELISA achieves better performance 
by using pairs of antibodies for each targeted protein, but the assays typically need relatively 
large sample volumes for analyses of single protein species, limiting throughput and spending 
precious samples. By contrast, the proximity extension assay (PEA) uses dual antibody 
recognition with oligonucleotide-conjugated antibodies in multiplex assays with modest 
requirements for sample volumes (20, 21). Upon simultaneous binding of the correct pair of 
antibodies, their attached oligonucleotides anneal to each other and can be enzymatically 
extended, forming specific DNA sequences that can be quantified using quantitative real-time 
polymerase chain reactions (qPCR). 
In this study, cytokine profiles of female CFS patients participating in a randomized controlled 
trial on the effect of IL-1 inhibition on fatigue severity (22) were compared with age- and 
gender-matched healthy neighborhood controls. In addition, TGF-β and the IL-1 receptor 
antagonist (IL1-Ra), which were not included in the PEA, were measured separately using 
an ELISA. Pre-analytical procedures were identical for patients and controls. Furthermore, 
the effect of IL-1 inhibition using the IL-1-receptor antagonist anakinra for one month on 
circulating cytokine concentrations was assessed. As reported in detail elsewhere, the study 
did not demonstrate a beneficial therapeutic effect in these patients (23).
Methods
Patients & design
All patients participated in a double-blind randomized controlled trial (RCT) on the effect 
of IL-1 inhibition on CFS-related symptoms, of which the results were reported elsewhere 
(23). The study was conducted at the Department of Internal Medicine and Expert Center 
for Chronic Fatigue (ECCF) of the RadboudUMC, Nijmegen, the Netherlands. Details of 
the study were described previously (22). In short, fifty female patients between 18 and 59, 
years old were included when they fulfilled the CDC criteria for CFS (1, 2). As recommended 
by the CDC criteria, patients can only be included when the body mass index (BMI) is 
≤40 kg/m2. Main exclusion criteria were the presence of a somatic disease that could 
explain severe fatigue (sleep apnea, anemia, etc.), psychiatric comorbidity (e.g. depression, 
anxiety disorders) or the use of medication (with the exception of oral contraceptives and 
paracetamol). Patients were asked to bring a healthy, female, neighborhood control, without 
complaints of fatigue and within the same age range (±5years), to their first study visit. 
After inclusion, patients were randomized 1:1 to either daily subcutaneous (s.c.) injections 
with anakinra (100 mg/day) or placebo (mixture of sodiumcitrate, sodiumchloride, and 
polysorbate) for a duration of four weeks. Controls did not receive an intervention. Anakinra 
and placebo were provided by the Swedish Orphan Biovitrum (Sobi, Stockholm, Sweden). 
The randomization list was computer-generated by the Department of Pharmacy (24). Patients 
administered the study medication at home on a daily basis. Both the placebo and anakinra 
syringes had an identical appearance, and drug adherence was evaluated as described 
previously (22, 23). 
All participants provided written and oral informed consent before inclusion. The hospitals’ 
ethics committee approved the study protocol (2014/025). The study was performed in 
accordance with the declaration of Helsinki.
Questionnaires
Fatigue was measured in both patients and controls using the fatigue severity subscale of the 
checklist individual strength (CIS), which has been used frequently in CFS patients (25, 26). 
Scores on the CIS-f can vary between 8 and 56, and a score ≥35 reflects severe 
fatigue (27). Psychological distress was measured with the total score on the Symptom 
Checklist-90 (SCL-90) (28). 
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Peripheral blood collection
Morning blood samples were collected from all patients prior to the first s.c. injection, 
and after four weeks of treatment. Samples of controls were collected and processed 
simultaneously with those of patients before treatment. There were no specific instructions 
with respect to food intake prior to blood sampling. Venous blood was collected in EDTA 
tubes, and kept on ice until centrifugation, which was performed within 2-3 hours. Next, 
samples were centrifuged at 2960xg for 10 minutes at 4ºC. Plasma aliquots were then 
frozen at -80ºC for a maximal duration of 2 years. Analyses for all patients and controls 
were run at the same time.
PEA assay
Inflammation biomarker profiles were analyzed by the analysis service of Olink 
Proteomics AB (Uppsala, Sweden), using their PEA based Proseek© Multiplex Inflammation 
panel96*96 (21). This analysis simultaneously measures 92 selected inflammatory proteins, 
listed in S1, using only 1 μL of plasma. For each protein, there are two separate antibodies 
connected to one oligonucleotide each. After binding by the antibody pair to its target, the 3’ 
ends of the oligonucleotides hybridize, priming a DNA polymerization reaction that forms 
a protein-specific reporter DNA-sequence for each detected protein molecule. The reporter 
DNA strands are then quantified using qPCR. Four internal controls and two external controls 
were included in each assay. The raw Cq values were normalized for variation between and 
within runs and converted into Normalized Protein Expression Units (NPX). The NPX values 
are expressed on a Log2 scale where one unit higher NPX values represent a doubling of the 
measured protein concentrations. This arbitrary unit can be used for relative quantification of 
proteins and comparing the fold changes between groups.
Based on the CFS literature, 20 cytokines were selected to be of special interest; CD40L 
(CD40 ligand), CXCL-9 (chemokine ligand 9), CXCL-10 (chemokine ligand 10), CCL-
2 (MCP-1), CCL-11 (eotaxin), IFN-γ (interferon gamma), IL-1α (interleukin-1 alpha), 
IL-2 (interleukin-2), IL-4 (interleukin-4), IL-6 (interleukin-6), IL-7 (interleukin-7), IL-8 
(interleukin-8), IL-10 (interleukin-10), IL-12p40 (interleukin-12 subunit p40), IL-17A 
(interleukin-17A), CSF-1 (macrophage colony-stimulating factor 1), TNF-β (tumor necrosis 
factor-beta), TRAIL (TNF-related apoptosis-inducing ligand), TGF-α (transforming growth 
factor alpha), and TNF (tumor necrosis factor) (9, 14, 29). 
ELISA 
Total TGF-β1 levels were measured by sandwich ELISA as described in detail previously (R&D 
systems) (30). All samples were acid activated to activate latent TGF-β (1 M hydrochloric acid, 
30 min, room temperature). Analysis was performed at the Leiden University Medical Center. 
IL-1Ra ELISA (R&D systems) was performed at the Radboud University Medical Center.
Statistical analysis
Study data were analyzed using IBM SPSS statistic package version 22 and R (31). All 
continuous variables are presented as means and standard deviations (SD) or medians and 
ranges, and categorical variables as percentages. 
Inflammatory markers were excluded if >25% of the measurements were below the detection 
limit. Remaining missing values were imputed with a random value between 0 and the LOD 
for the protein at hand, a method that avoids the artificial reduction of the standard deviation 
that is a consequence of imputing the values LOD/2 or LOD/√2. For the baseline comparison 
of twenty pre-selected cytokines, analysis of covariance (ANCOVA) was performed with age 
and BMI added as covariates. Based on the result of a previous study, the same analysis was 
repeated dividing the patient group into patients with a long illness duration (>3 years) and 
patients with a short illness duration (9). 
In order to establish a predictive model, a logistic regression model was selected using the 
LASSO regression strategy that aims at eliminating predictors with only marginal predictive 
performance. As potential predictors for CFS, the cytokine concentrations supplemented with 
age and BMI were used. To determine the performance of this model, the area under the 
ROC-curve (AUC) was calculated (32). As the model is evaluated in the same population that 
is used for construction, the predictive performance will be overestimated. To correct for 
this optimism, new populations were generated using bootstrap sampling. In each population 
the same modeling strategy was used. Each prediction model was then evaluated in both the 
bootstrap population and the original population. After 500 repetitions of this process, the 
differences between performance in bootstrapped samples and the original population were 
used to estimate the optimism due to internal validation (33).
To determine the influence of IL-1Ra on cytokine concentrations, analysis ANCOVA was 
used with the cytokine concentration after four weeks as dependent variable, treatment as 
fixed factor, and concentration at baseline, age, and BMI as covariates.
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Results
Patient characteristics
A total of 50 CFS patients and 48 age-matched, neighborhood controls were included 
in the study. Two patients were not able to bring a healthy control at baseline. Table 1 
displays demographic and fatigue-related characteristics. Within the CFS group, there 
were 21 patients with a short illness duration (≤3 years, 58%) and 29 patients with a long 
illness duration (>3 years, 42%). As expected, CFS patients had a higher CIS-fatigue 
score than controls (52±4 vs. 20±11, p<0.001). Total score on psychological distress was 
also significantly higher in patients (150±30 vs 119±32, p<0.001). BMI, ethnicity, and 
percentage of patients using oral contraceptives did not significantly differ between groups.
Table 1 Baseline characteristics of chronic fatigue syndrome patients (CFS) and healthy controls 
(HC).
CFS (n=50) HC (n=48) p-value
Age, years 31 (10) 31 (10) 0.98
Ethnicity 
  Caucasian (%)
  Other (%)
49 (98)
1 (2)
47 (98)
1 (2)
0.37
Body mass index, kg/m2 25.1 (4.5) 24.9 (4.4) 0.88
Oral contraceptives (%)
Paracetamol (%)
22 (44)
22 (44)
16 (33)
8 (16)
0.28
0.002
Illness duration, months
  ≤3 years (%)
  >3 years (%)
43 [7-109]
29 (58)
21 (42)
N/A
Fatigue severity (CIS-fatigue) 52 (4) 20 (11) <0.001
Psychological distress (SCL-90) 150 (30) 119 (32) <0.001
Table 1 Data are number (%), mean (SD), or median [range]. CIS= checklist individual strength. 
SCL-90= symptom checklist 90. N/A= not applicable.
CFS patients versus controls
Twenty pre-selected cytokines were compared between patients and controls, based on 
the recent CFS literature (9, 14, 29). For IFN-γ, IL-1α, IL-2, IL-4, IL17A, and TNF, more than 
25% of samples was under the LOD in both patients and controls. Results for the remaining 
14 cytokines are displayed in figure 1. In this exploratory analysis, both IL-12p40 and 
CSF-1 appeared to be elevated in CFS patients (p-value 0.004 and 0.049 respectively). 
Other cytokines did not differ between patients and controls. Dividing the patient group 
into those with short illness duration, and those with longer illness duration did not change 
these results (data not shown). 
Figure 1 Normalized Protein Expression Units (NPX ) values for patients with chronic fatigue 
syndrome (CFS, n=50) compared to healthy controls (HC, n=48)
Figure 1 displays linear NPX values for patients and controls. P-values were derived by 
analysis of covariance.
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There were no differences in TGF-β1 and IL-1Ra between patients and controls, as 
determined by ELISA.
Prediction model
Of the 92 proteins measured, 22 appeared to be below the detection limit for >25% of 
samples for both patients and controls (IFN-γ, IL-1α, IL-2, IL-4, IL17A, TNF, MCP-3, IL-
17c, IL-20Ra, IL-2Rb, TSLP, IL-10Ra, IL-22Ra1, PD-L1, IL-24, IL-13, ARTN, IL-20, IL-
33, LIF, NRTN, and IL-5). Although theoretically there is still information in the recorded 
concentrations for these cytokines, these proteins were excluded from the analysis as they 
were considered not to be candidates with a substantial predictive potential. The remaining 
70 proteins were entered into the LASSO regression analysis in addition to age and BMI. 
Out of this total of 72 variables entered, 47 appeared in the final regression model (table 2). 
22 variables had a positive association with the risk of being a CFS patient, and a negative 
association was present for 23 variables. To determine the performance of this model, an 
AUC was calculated with correction for optimism. Optimism in the current model was 
0.265, which resulted in a corrected AUC value of 0.734.
Influence of IL-1Ra on circulating cytokines
In accordance with the analysis of patients versus controls, in 22 cytokines the NPX value 
was below the detection limit in more than 25% of cases. These cytokines were excluded 
from the analysis. One patient in the anakinra group discontinued treatment after two weeks 
as a consequence of an adverse event and was excluded from the analysis. IL-1α, a cytokine 
of special interest, was not detectable in more than 75% of samples both before and after 
treatment. In figure 2 the influence of anakinra vs placebo is displayed for all detectable 
cytokines with corresponding 95% confidence intervals (95%CI). In the anakinra group 
there appeared to be an inhibiting effect of anakinra on CSF-1, IL-18R1, and ENRAGE. 
In addition there was a stimulating effect on CXCL-9; for the remaining variables there 
was no influence of anakinra. As expected, IL-1Ra was significantly higher in those 
patients treated with anakinra (p<0.001, figure 3). Of the 25 patients treated with anakinra, 
23 patients had a concentration above the detection limit of 2000 pg/ml.
Table 2 LASSO regression analysis: factors associated with the risk of being a CFS patient versus 
healthy controls. 
Table 2 Given associations are all conditional on the other predictors.
Proteins that are positively associated 
with the risk of being a CFS patient:
Protein   Weight
TWEAK    5,077
CCL4   4,182
IL12B   3,898
CDCP1   3,611
VEGFA   3,138
CSF1   2,810
IL10RB   1,737
CCL11   1,354
CD5    1,087
MCP1   1,047
CASP8   0,865
FGF5   0,758
IL6    0,737
CCL23   0,591
CX3CL1   0,568
ST1A1    0,307
TNFSF14   0,303
CD244   0,302
IL10    0,287
CXCL5   0,245
LAPTGFbeta1  0,166
OPG    0,107
Proteins that are negatively associated 
with the risk of being a CFS patient:
Protein   Weight
BetaNGF   -6,683
LIFR   -4,053
HGF    -2,153
CXCL6   -1,849
4EBP1   -1,317
SCF    -1,307
MMP1   -1,256
ADA    -1,237
CXCL10   -1,223
IL18R1   -1,076
CXCL9   -0,697
CCL28   -0,611
CCL25   -0,557
OSM   -0,544
CCL20    -0,514
CCL19   -0,507
TRANCE   -0,498
NT3    -0,489
MCP4   -0,458
TRAIL   -0,406
ENRAGE   -0,356
CD6    -0,109
TNFB   -0,062
MMP10   -0,033
FGF23   -0,017
Optimism: 0.2652
AUC: 0.9996
Corrected AUC: 0.7344
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Discussion
In this study differences in plasma cytokine profiles of 50 CFS patients compared to 
48 healthy age-matched neighborhood controls were evaluated using a PEA protein assay. 
The concentration of IL-12p40 and CSF-1 were significantly higher in CFS patients. For 
the remaining cytokines of interest based on the current CFS literature, no differences 
could be found comparing them individually. However, using the complete inflammatory 
profile, patients and controls could be discriminated using 22 variables with a positive 
association and 24 variables with a negative association.
IL-12p40 was significantly higher in CFS patients compared to healthy controls (p=0.005). 
The IL-12p40 subunit is expressed by activated dendritic cells (DC) and combines with 
either subunit p35 or p19, to form IL-12 or IL-23 (34). IL-12 targets T-cells and NK-cells, in 
which it induces IFN-γ production (35). IL-23 has an important role in Th17 production, has 
an effect on memory T-cells, and appears to be critical in cerebral autoimmune inflammation 
(36). Previous studies in CFS patient also found increased concentration of both IL-12 (17, 37, 
38), IL-12p40 (9) and IL23 (39). A relationship between IL-12 and fatigue has been established 
in studies investigating the effect of administration of human recombinant IL-12 to treat 
ovarian cancer, and head and neck cancer (40, 41). A proportion of treated patients developed 
fatigue, and combined with other side effects such as fever and chills, this toxicity had dose-
limiting consequences. Furthermore, increased concentrations of IL-12 and IL-23 have 
especially been associated with multiple sclerosis, in addition to psoriasis, inflammatory 
bowel disease, cancer and rheumatoid arthritis (34). However, in the light of the explorative 
nature of the current analysis, replication of this finding is important.
CSF-1 or macrophage colony-stimulating factor (M-CSF) is a hematopoietic growth factor 
involved in proliferation and differentiation of monocytes and macrophages. Targeting CSF-
1 has predominantly been described in cancer, where there appears to be an advantage when 
it is used in combination with other immune therapies (42). Interestingly, the role of CSF-1 in 
the development of sickness behavior has recently been assessed by Müller et al. (43). In this 
study, neutralization of the CSF-1 receptor prevented the development of sickness behavior in 
mice treated with an inflammatory stimulus. This behavioral response was mediated through 
increased IL-10 production. Increased IL-10 concentrations were also demonstrated in the 
hypothalamus, where the behavioral effect is most likely to be effected. 
In contrast to the majority of previous studies measuring circulating cytokines, in this 
study there were no differences in TGF-β concentrations (14). TGF-β influences cell 
proliferation, migration, and differentiation, and is known for its dual role in cancer (44). 
TGF-β is released in large quantities by activated platelets (45). Several factors, such as blood 
sampling procedures (46) and use of medication, influence the extent of platelet activation. A 
possible explanation for the increased TGFβ levels previously reported might be caused by 
differences in sample handling and drug use, which has recently been demonstrated (47). For 
example, oral contraceptives induce platelet activation in humans (48), and directly cause 
increased TGF-β concentrations in rats (49).
These differences regarding sample handling might also be the explanation for the fact 
that previous studies found more cytokines to be differentially expressed in CFS patients. 
A substantial proportion of studies included multiple cohorts in their analyses (9, 29), and 
although this gives the opportunity to investigate a larger number of patients, including 
patients coming from geographically different regions results in an inherent danger of 
inaccurate conclusions. This is because sample handling may have been different, for 
example use of different centrifuges, differences in ambient temperature, variations in 
collection time, and storage. Such differences in pre-analytic sample handling and storage, 
were part of the explanation for the spurious reports on the role of murine retroviruses in 
CFS (50). In addition, cytokine concentrations are known to be influenced by drug use. The 
use of non-steroidal anti-inflammatory drugs (NSAIDS), which are frequently used by CFS 
patients, increase the production of various cytokines (51, 52). Differences in use of NSAIDS 
and other medication between patients and controls, might have explained the reported 
increased levels of pro-inflammatory cytokines in previous studies. 
Interestingly, combining all inflammatory markers yields a prediction model containing 
47 markers with a corrected AUC of 0.73. To control for optimism, a bootstrapping 
method was used, which yielded a high correction factor of 0.265. Some of the measured 
proteins have a positive association with CFS (IL-6, CSF-1), whereas for others there was 
a negative association (BetaNGF, CXCL-6). This selection of inflammatory markers could 
be a starting point for further studies investigating potential diagnostic markers in CFS. 
According to the 95% confidence intervals, there was an inhibiting effect of anakinra on 
circulating CSF-1, IL-18R1 and ENRAGE and a stimulating effect on CXCL-9. Given 
the large numbers of cytokines tested, these findings have to be interpreted with caution. 
It is important to mention that IL-1β was not included in the analysis, and IL-α was 
already below the detection limit before treatment in 82% of samples. It was expected that 
there would be a significant decrease of IL-6 in the anakinra group, as IL-1 induces IL-6 
production, and is frequently used as a readout for IL-1 activity (53). In previous studies, 
there was also a significant reduction of IL-6 concentrations after anakinra treatment. 
This was investigated in patients intravenously treated after stroke (54) and patients treated 
with subcutaneous injections for heart failure (55). A possible explanation for the lack of 
a decrease in IL-6 concentrations is that in comparison to the situation in stroke patients 
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where it has an important prognostic role (56), CFS patients exhibit no increase of this 
cytokine at baseline. Since drug adherence was excellent, which is also reflected by the 
significant increase of IL-1Ra in the anakinra treated group, it is unlikely that lack of 
compliance is an explanation for this result.
This study has several strengths. To our knowledge, PEA-based assays have not previously 
been performed in CFS patients. Over the past few years, there has been a search for 
sensitive methods to measure multiple inflammatory markers simultaneously in order 
to find potential biomarkers for CFS. However, this is most commonly performed using 
multiplex bead-based immunoassays, that have limited sensitivity and specificity (20). This 
is not the case for the PEA method, which has a much higher specificity as the signals can 
only be elicited by the cognate antibody pairs, while cross reactions between irrelevant 
antibody pairs are ignored (21). Another asset of this study is the inclusion of neighborhood 
controls. Each patient was asked to bring a healthy, sex- and age-matched control, and 
blood withdrawal of both patient and control took place at the same time. Pre-analytic 
processes were identical, which was not the case in most of the previously published 
biomarker studies in CFS (29, 38). The third advantage of the current study is exclusion of 
patients who use medication, with the exception of oral contraceptives and paracetamol. 
CFS patients frequently use a significant amount of medication, in a recent study 64% of 
patients used complementary and alternative medicine (57). Another study found that >90% 
of CFS patients use at least one drug or supplement, especially antidepressants, sedatives 
and muscle relaxants (58).
A limitation of this study is the relatively small number of patients included measuring 
a large number of variables. However, this has been accounted for using the LASSO 
method for logistic regression, which is an elegant variable reduction method (59). However, 
considering the large factor for optimism, the prediction model has to be interpreted with 
caution. Another limitation of the current study is the fact that IL-1β was not measured 
in plasma samples, although the value of this measurement is limited as IL-1β is usually 
undetectable in peripheral blood, even with the PEA method. 
In conclusion, this study demonstrated increased IL-12p40 and CSF-1 concentrations 
in CFS patients in addition to a set of predictive biomarkers. There was no effect of 
anakinra on circulating cytokines other than IL-1Ra. As emphasized in this study, sample 
handling and diagnostic procedures are very important when measuring cytokines. Future 
studies should take this into account and in order to replicate findings, methods should be 
extensively reported.
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S1 List of proteins included in the PEA analysis.
Full name Abbreviation
Adenosine Deaminase ADA
Artemin ARTN
Axin-1 AXIN1
Beta-nerve growth factor Beta-NGF
Brain-derived neurothropic factor BDNF
C-C motif chemokine 19 CCL19
C-C motif chemokine 20 CCL20
C-C motif chemokine 23 CCL23
C-C motif chemokine 25 CCL25
C-C motif chemokine 28 CCL28
C-C motif chemokine 3 CCL3
C-C motif chemokine 4 CCL4
C-X-C motif chemokine 1 CXCL1
C-X-C motif chemokine 10 CXCL10
C-X-C motif chemokine 11 CXCL11
C-X-C motif chemokine 5 CXCL5
C-X-C motif chemokine 6 CXCL6
C-X-C motif chemokine 9 CXCL9
Caspase-8 CAPS-8
CD40L receptor CD40
CUB domain-containing protein 1 CDCP1
Cystatin D CST5
Delta and Notch-like epidermal growth factor-related receptor DNER
Eotaxin CCL11
Eukaryotic translation initiation factor 4E-binding protein 1 4E-BP1
Fibroblast growth factor 19 FGF-19
Fibroblast growth factor 21 FGF-21
Fibroblast growth factor 23 FGF-23
Fibroblast growth factor 5 FGF-5
Fms-related tyrosine kinase 3 ligand Flt3L
Fractalkine CX3CL1
Glial cell line-derived neurotrophic factor GDNF
Hepatocyte growth factor HGF
Interferon gamma IFN-gamma
Interleukin-1 alpha IL-1 alpha
Interleukin-10 IL10
Interleukin-10 receptor subunit alpha IL-10RA
Interleukin-10 receptor subunit beta IL-10RB
Interleukin-12 subunit beta IL-12B
Interleukin-13 IL-13
Interleukin-15 receptor subunit alpha IL-15RA
Interleukin-17A IL-17A
Interleukin-17C IL-17C
Interleukin-18 IL-18
Interleukin-18 receptor 1 IL-18R1
Interleukin-2 IL-2
Interleukin-2 receptor subunit beta IL-2RB
Interleukin-20 IL-20
Interleukin-20 receptor subunit alpha IL-20RA
Interleukin-22 receptor subunit alpha-1 IL-22 RA1
Interleukin-24 IL-24
Interleukin-33 IL-33
Interleukin-4 IL-4
Interleukin-5 IL-5
Interleukin-6 IL-6
Interleukin-7 IL-7
Interleukin-8 IL-8
Latency-associated peptide transforming growth factor beta-1 LAP TGF-beta-1
Leukemia inhibitory factor LIF
Leukemia inhibitory factor receptor LIF-R
Macrophage colony-stimulating factor 1 CSF-1
Matrix metalloproteinase-1 MMP-1
Matrix metalloproteinase-10 MMP-10
Monocyte chemotactic protein 1 MCP-1
Monocyte chemotactic protein 2 MCP-2
Monocyte chemotactic protein 3 MCP-3
Monocyte chemotactic protein 4 MCP-4
Natural killer cell receptor 2B4 CD244
Neurotrophin-3 NT-3
Neurturin NRTN
Oncostatin-M OSM
S1 Continued
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Osteoprotegerin OPG
Programmed cell death 1 ligand 1 PD-L1
Protein S100-A12 EN-RAGE
Signaling lymphocytic activation molecule SLAMF1
SIR2-like protein 2 SIRT2
STAM-binding protein STAMPB
Stem cell factor SCF
Sulfotransferase 1A1 ST1A1
T cell surface glycoprotein CD6 isoform CD6
T-cell surface glycoprotein CD5 CD5
Thymic stromal lymphopoietin TSLP
TNF-beta TNFB
TNF-related activation-induced cytokine TRANCE
TNF-related apoptosis-inducing ligand TRAIL
Transforming growth factor alpha TGF-alpha
Tumor necrosis factor (Ligand) superfamily, member 12 TWEAK
Tumor necrosis factor TNF
Tumor necrosis factor ligand superfamily member 14 TNFSF14
Tumor necrosis factor receptor superfamily member 9 TNFRSF9
Urokinase-type plasminogen activator uPA
Vascular endothelial growth factor A VEGF-A
S1 Continued
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Abstract
Serum TGF-β1 concentrations are reported to be elevated in chronic fatigue syndrome 
(CFS). However, measurement of circulating cytokines is a complex procedure and control 
of pre-analytical procedures is essential. The objective of the current study was to measure 
circulating TGF-β1 concentrations in CFS patients compared to healthy controls, taking 
into account differences in pre-analytical procedures. Two cohorts of female CFS patients 
were included. In both studies patients were asked to bring a healthy, age-matched control. 
At baseline, TGF-β1 levels were measured in plasma and additionally P-selectin, a marker 
of platelet activity, was determined in a subgroup of participants. 50 patients and 48 
controls were included in cohort I, and 91 patients and 29 controls in cohort II. Within the 
cohorts there were no differences in TGF-β1 concentrations. However, between the cohorts 
there was a large discrepancy, which appeared to be caused by differences in g-force of 
the centrifuges used. The lower g-force used in cohort II (1361g) caused more platelet 
activation, reflected by higher p-selectin concentrations, compared to cohort I (p<0.0001). 
There was a correlation between TGF-β1 and p-selectin concentrations (r 0.79, p<0.0001). 
These results demonstrate that control of pre-analytical procedures is an essential aspect 
when measuring circulating cytokines. 
Introduction
Chronic fatigue syndrome (CFS) is an enigmatic disorder, in which patients suffer from 
incapacitating fatigue, pain and a series of associated symptoms (1). The complaints are not 
due to a known underlying disease, and the pathophysiology has not been elucidated. CFS 
may be provoked by infections (such as infectious mononucleosis), or by any of a series 
of other triggers. Because of the association with preceding infection, and the similarities 
in symptomatology with sickness behaviour that can be induced by proinflammatory 
cytokines (2), many studies aiming to find abnormal cytokine regulation have been performed 
in CFS (3). The picture that emerges from these studies is by no means uniform. The reasons 
for these discrepant findings are often obscure from the publications, but factors like age 
and gender of the patients, composition of the control groups, the robustness of the pre-
analytical procedures (such as sampling, handling, centrifugation and storage) and the kind 
of assays used, probably play an important role. In a recent systematic review on cytokines 
in CFS (3), the most consistent finding was elevation of the anti-inflammatory cytokine 
transforming growth factor β (TGF-β).
Recently we performed a large prospective cytokine study in female CFS patients. This 
study was methodologically robust, as the age- and gender-matched controls from the 
patient’s neighborhood were recruited and bled at the same time and in the same place as 
the patients. In this way the pre-analytical handling of the samples was exactly the same. 
The results of this study, in which 92 inflammatory markers were measured simultaneously 
using the novel Proximity Extension Assay technique, are published elsewhere. In another 
cohort of CFS patients and similarly matched controls, we also sampled blood to measure 
inflammatory markers (4). In the present report we demonstrate the relevance of stringent 
methods to control for variability that may arise during the pre-analytical phase. To this end 
we describe the results of TGF-β1 measurements in these two CFS cohorts.
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Methods
Patients
Two cohorts of patients with CFS were enrolled in this study. The first cohort (cohort I) 
consisted of patients who participated in a double-blind randomized controlled trial (RCT) 
on the effect of IL-1 inhibition on CFS-related symptoms (5). The study was conducted at 
the Department of Internal Medicine and Expert Centre for Chronic Fatigue (ECCF) of the 
RadboudUMC, Nijmegen, the Netherlands. Details of the study were described elsewhere 
(5, 6). In short, 50 female patients between 18 and 59 years old who fulfilled the Center for 
Disease Control (CDC) criteria for CFS were enrolled (1). Use of medication (with the 
exception of oral contraceptives and paracetamol) was not allowed. Each of the patients 
was asked to bring a healthy neighborhood control, without complaints of fatigue and 
within the same age range (±5 years), to their first study visit.
The second cohort (cohort II) consisted of 91 female patients between 18 and 65 years 
fulfilling the CDC criteria for CFS. The inclusion and exclusion criteria have been 
described in detail elsewhere (4). Like for Cohort I, a proportion of patients was asked to 
bring a healthy neighborhood control matched for age and gender at their first study visit.
All participants provided written and oral informed consent before inclusion. The hospitals’ 
ethics committee (Commissie Mensgebonden Onderzoek Regio Arnhem/Nijmegen) 
approved the study protocols (2014/025 and 2013/113). The study was performed in 
accordance with the declaration of Helsinki.
Questionnaires
Fatigue was measured in both patients and controls using the fatigue severity subscale of 
the checklist individual strength (CIS), which has been used frequently in CFS patients (7). 
Scores on the CIS-f can vary between 8 and 56, and a score ≥35 reflects severe fatigue. 
Blood collection
Blood samples were collected at baseline at the outpatient clinic for Internal Medicine at 
the RadboudUMC in Nijmegen, the Netherlands from all patients of Cohort I. Samples of 
controls were collected simultaneously with those of patients. Venous blood was collected 
in EDTA tubes, and kept on ice until centrifugation which was performed within 2-3 hours. 
Plasma aliquots were then frozen at -80ºC for a maximal duration of 2 years. For Cohort 
II, the sampling, handling and storage of the blood of patients and controls were done in 
a similar fashion at the Donders Centre for Neuroimaging in Nijmegen, the Netherlands. 
Measurements of TGF-β and P-selectin
Total TGF-β1 levels were measured by enzyme-linked immunosorbent assay (ELISA), 
as described in detail previously (R&D systems) (8). All samples were acid activated to 
activate latent TGF-β (1 M hydrochloric acid, 30 min, room temperature, neutralization 
with 1M NaOH, followed by direct analysis). All assays were performed on the same day 
using the same reagents.
P-selectin was measured in a proportion of samples by ELISA (R&D systems) according to 
the instructions of the manufacturer.
Statistical analysis
Study data were analyzed using IBM SPSS statistic package version 22. All continuous 
variables are presented as means and standard deviations (SD)/ standard error of the mean 
(SEM). For group comparison a students t test was used. Pearson’s correlation was used for 
the correlation between TGF-β and P-selectin. 
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Results
The results of the TGF-β1 measurements in the patients and controls from Cohort I are 
depicted in figure 1A. No differences in TGF-β1 concentrations were found between 
patients and healthy controls. Likewise, the results of the measurements in Cohort II did 
not reveal differences between CFS patients and controls (figure 1B). However, we were 
greatly puzzled by the large differences in the TGF-β1 concentrations found between Cohort 
I and Cohort II. As it is known that platelets are a rich source of TGF-β (9), we wondered 
whether the higher TGF-β1 levels could be caused by higher number of (activated) 
platelets in Cohort II. To explore whether platelet activation differed between the two 
groups, we measured P-selectin as a platelet marker in a random selection of samples (10). 
The P-selectin concentrations differed greatly between the two cohorts (p<0.001; figure 2). 
There was a strong correlation (r 0.79, p<0.0001) between the concentrations of TGF-β1 
and P-selectin. Differences in platelet activation could be explained by differences in the 
g-force of the centrifuges used at the two study locations. We detected that the g-force of 
these centrifuges differed greatly: 2959g at the University Medical Centre versus 1361g at 
the Donders institute. 
Table 1 Baseline characteristics of chronic fatigue syndrome patients en healthy controls
Cohort I Cohort II
CFS (n=50) HC (n=48) CFS (n=91) HC (n=29)
Age, years 31(10) 31(10) 34(11) 33(11)
Fatigue severity (CIS-f) 52(4) 20(11) 51(4) 17(7)
Figure 1 TGF-β1 concentrations for patients and controls in cohort I and cohort II
Figure 2 P-selectin concentrations for a proportion of patients of cohort I (n=35) and 
cohort II (n=35)
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Discussion
In this report, we demonstrate that even with scrutinized methodology, inaccurate results 
may be obtained. It turned out that the different properties of the centrifuges used at the two 
study locations could be responsible for differences in platelet contamination and platelet 
activation (as assessed by P-selectin measurements).
Although it is well known that platelets contain considerable amounts of TGF-β (9, 11), this 
is often not taken into account when measuring circulating concentrations of this cytokine. 
Many cytokine studies do not mention the pre-analytical procedures of patient samples 
and controls. Our current data show that if for example another cohort of controls would 
have been used for cohort I, which would have had the sample pretreatment of cohort II, 
strong differences could have been observed, not due to actual differences caused by the 
underlying disease but solely by sample handling. The use of different sample collections 
for patients and controls is fairly common. In fact, in the studies that incriminated the 
retroviruses XMRV and XMLV (12, 13), this was the case and led to results that misled both 
the scientific community and more sadly, the patients suffering from CFS (14).
In conclusion, we want to make a plea for better standarisation of pre-analytical sample 
handling for patient studies, not only restricted to CFS research. The use of neighborhood 
controls who are bled at the same time and place, and whose samples undergo the exact 
same procedure as those of the patients is one method to enhance the quality of such 
research. In addition, precise reporting of the nature of the control group and the pre-
analytical procedures of controls and patients is essential in these kinds of studies.
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Abstract
Hypocortisolism has been found in chronic fatigue syndrome (CFS) patients in blood, 
urine, and saliva. It is unclear if hypocortisolism can also be demonstrated using long-
term cortisol measurements, such as cortisol in hair. In addition, the interaction between 
the HPA axis and the immune system, both expected to play an important role in CFS, 
is unclear. The objective of the current study was to compare hair and salivary cortisol 
concentrations in a large cohort of female CFS patients to those in healthy controls, and to 
test the effect of an interleukin-1 receptor antagonist (anakinra) on the HPA axis. Salivary 
cortisol concentrations of 107 CFS patients were compared to 59 healthy controls, with 
CFS patients showing a decreased cortisol awakening response (4.2±5.4 nmol/L vs 6.1±6.3 
nmol/L, p=0.036). Total cortisol output during the day did not differ significantly in saliva, 
there was a trend to lower hair cortisol in a subset of 46 patients compared to 46 controls 
(3.8±2.1 pg/mg vs 4.3±1.8 pg/mg, p=0.062). After four weeks of treatment with either daily 
anakinra (100mg/day) or placebo, there was a slight decrease of hair cortisol concentrations 
in the anakinra group compared to an increase in the placebo group (p=0.022). This study 
confirms the altered dynamics of the HPA axis in a large group of CFS patients, and for the 
first time shows that this might also be present for long-term cortisol measures.
Introduction
Since the first publication by Demitrack and colleagues in 1991 (1), numerous studies have 
been performed investigating alterations of the hypothalamic-pituitary-adrenal (HPA) axis 
in patients with chronic fatigue syndrome (CFS). This interest is predominantly caused 
by the overlap of CFS symptoms with diseases characterized by hypocortisolism such 
as Addison’s disease, where 95% of patients report fatigue at diagnosis (2). Several case 
definitions for CFS exist and, according to most of them, severe and persisting fatigue is 
its central feature (3). The Center for Disease Control (CDC) criteria for CFS are most often 
used in research and require that at least four out of eight accompanying symptoms have 
to be present in addition to fatigue (e.g., joint pain, concentration problems, unrefreshing 
sleep, and post-exertional malaise) (4).
Studies investigating the relationship between levels of cortisol, the end product of the 
stress-responsive HPA axis, and CFS thus far have been summarized in a review by 
Papadopoulos and Cleare (5). Despite the large heterogeneity between studies, it was 
concluded that there is substantial evidence for hypocortisolism in CFS. This was also 
described in a meta-analysis by Tak et al. (6), where a significantly decreased activity of 
the HPA axis was found, which was more frequent in studies predominantly including 
women. A potential mechanism underlying the pathophysiology of hypocortisolism in CFS 
is an heightened negative feedback response (7), although it is unclear whether this is of 
etiological importance or is rather a consequence of for example the use of medication (6), 
widespread pain (8), or illness duration (9). 
Limitations of studies previously performed are the relatively small samples sizes and 
differences in the type of cortisol measurement. HPA axis deregulation can be manifested 
in disturbed short term dynamics of cortisol or alterations of the chronic cortisol secretion. 
Cortisol can be measured in various media, for example blood, saliva, urine, and hair. 
Saliva is usually depicted as the preferred method, as it offers insight into short term 
cortisol fluctuations (diurnal rhythm, response to a stimulus), which makes it a useful 
method to investigate the functional dynamics of the HPA axis. On the other hand, the hair 
cortisol concentration (HCC) offers information on long-term activity of the HPA axis (10). 
An advantage of this measurement is that it is less influenced by situational factors, and 
may thus constitute a more stable measure (10).
Another important issue when investigating the HPA axis is its interaction with other bodily 
systems, for example the immune system, where increased activity of the HPA axis has an 
inhibitory effect on the production of pro-inflammatory cytokines (11). In the context of CFS 
this is of particular interest, as alterations of inflammatory activity have been described 
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in CFS for many years (12). It is suspected that increased activity of pro-inflammatory 
cytokines, for example interleukin-1 (IL-1) and tumor necrosis factor (TNF), lead to the 
experience of typical CFS symptoms often described as sickness behavior (13). The attention 
for this subject is reflected by the large quantity of studies measuring circulating cytokines 
in CFS (14). In a complex illness, like CFS, it is likely that the interaction between the 
neuroendocrine system and the immune system is altered. A decreased inhibitory effect 
of dexamethasone on the immune system has already been established in adolescent CFS 
patients (15), but in adults the opposite has been found (16). A decreased signaling at the level 
of the glucocorticoid receptor (GR) on immune cells can eventually lead to a low-grade 
inflammatory state (17). Understanding the interaction between these systems in CFS, might 
lead to more targeted intervention strategies.
To expand the knowledge on HPA axis alterations in CFS patients, the aim of the current 
study was two-fold: the first aim was to investigate both dynamic (saliva) and long-term 
(hair) cortisol outcome measures in a large group of CFS patients as compared to controls, 
where it was expected to replicate earlier findings on salivary cortisol and for the first time 
investigate if this can be found in HCC as well. The second aim was to investigate the 
interaction between the HPA axis and pro-inflammatory cytokines. Therefore, the effect 
of the interleukin-1 receptor antagonist (IL-1Ra) anakinra on salivary and hair cortisol 
as compared to placebo treatment was assessed. It was hypothesized that decreasing 
inflammation would lead to less fatigue in CFS, improving activity and physical functioning, 
eventually leading to normalization of cortisol. 
Methods
Patients
Patients included in the current study were participating in two separate trials that 
investigated the effect of two distinct interventions on fatigue severity, which were 
described in detail elsewhere (12, 18). Results on the behavioral effects of these therapies will 
be reported separately (19). In the study by van der Schaaf et al. (18), female patients, between 
18 and 59 years old, were included when meeting the CDC consensus criteria for CFS (20). 
In this study, the effect of cognitive behavioral therapy (CBT) on neuronal processes was 
assessed (‘CBT study’). Main exclusion criteria were the presence of a psychiatric disorder 
(e.g. depression, anxiety), presence of a somatic disease that could explain severe fatigue, 
or the use of psychotropic medication. In the second study, inclusion and exclusion criteria 
were largely in accordance with the CBT study. In addition, patients were excluded when 
using any medication (with the exception of oral contraceptives and paracetamol). In both 
studies, patients were asked to be accompanied by a healthy female peer who served as a 
control at baseline. In the study by Roerink et al., patients were treated with either daily 
subcutaneous anakinra (100mg/day) or placebo injection for a duration of four weeks 
(anakinra study) (12). 
For the current analysis, additional exclusion criteria were use of corticosteroids in any 
application form, the presence of fever on the days of saliva collection, and not adhering to 
the saliva collection protocol. For HCC, which was determined in patients participating in 
the anakinra study, samples were excluded when a patient had been sick or used antibiotics 
during the preceding month.
All patients provided written informed consent prior to participation. Both studies were 
approved by the local ethics committee.
Questionnaires
In both studies patients and controls were asked to fill out web-based questionnaires on 
fatigue severity and accompanying symptoms at baseline. Fatigue was measured with 
the fatigue subscale of the Checklist Individual Strength (CIS), which is a validated 
questionnaire used frequently in CFS research (21). The score can range between 0 and 56, 
with a score ≥35 reflecting severe fatigue (22).
Impairment as a consequence of fatigue was measured with the Sickness Impact Profile (SIP8 
total score), a score ≥700 reflects severe disability (23). The presence of depressive symptoms 
was evaluated using the Becks Depression Inventory (BDI) primary care version (24). Scores 
≥ 4 indicate the presence of clinically relevant levels of depressive symptoms. Only patients 
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participating in the anakinra study were asked to complete a visual analog scale (VAS) on 
pain severity, with a range between 0 (no pain) and 10 (worst pain ever). 
In addition to the questionnaires, the following information was collected from all patients: 
age, height, weight, duration of symptoms, use of medication, and menopausal state.
Salivary cortisol
Participants were instructed to collect saliva on two consecutive working days using the 
passive drool method by using Salicap® devices (IBL, Hamburg, Germany) consisting 
of a collection tube and a straw. Thirty minutes before collection, patients were asked to 
refrain from eating, drinking, and taking medication. During the day, four saliva samples 
were collected; at awakening, 30 minutes after awakening (±15 min), at noon (between 11 
a.m. and 1.15 p.m.), and in the evening (between 7 p.m. and 9.30 p.m.). Participants were 
asked to note date and exact time of sampling on the label of the respective Salicap® tube. 
Participants were instructed to store samples in their home freezer before bringing them 
to the hospital (after several days-weeks). At the hospital, all samples were stored at least 
at a temperature of -20ºC until analysis. Salivary cortisol concentrations were determined 
by using commercially available enzyme-linked immunosorbent assays (ELISA; IBL, 
Hamburg, Germany). After completion of therapy in the anakinra study, the collection 
procedure was repeated.
Hair sampling
Participants in the anakinra study provided hair samples for determination of HCC at 
baseline (patients and controls) and after treatment (patients only). Small hair strands 
were taken from the posterior vertex region. As the average hair growth rate is 1cm/
month (25), cortisol was measured in 1cm before and after treatment to evaluate the effect 
of the intervention. All hair samples were kept at room temperature at a dark place until 
analysis. For HCC analysis, washing and extraction procedures were applied according 
to the laboratory protocol originally described by Stalder et al. (26), using 10mg finely cut 
hair for cortisol extraction. HCC concentrations were determined by using a commercially 
available luminescence immunoassay (LIA; IBL, Hamburg, Germany), using 50µL sample 
and standards for analysis (27). 
Statistical analysis
All statistical analyses were conducted using SPSS version 22.0 (IBM Corp., Armonk, NY). 
For baseline variables, continuous variables are displayed as mean ± standard deviation or 
median [range] and categorical variables as number (percentage). 
For each saliva collection day, three cortisol output measures were calculated:
I. Cortisol awakening response (CAR), which reflects the increase in cortisol 
concentrations in the first 30-45 minutes post-awakening (28). The CAR was calculated 
subtracting the awakening sample from the +30 minutes sample.
II. Area under the curve with respect to ground (AUCg), wich was calculated as described 
earlier by Pruessner et al. (29).
III. Area under the curve with respect to increase (AUCi), which reflects cortisol alterations 
during the day. AUCi was also calculated using a formula earlier described (29).
All samples not collected in the predefined time-range were excluded. In case of missing 
values, data from the other collection day of the same time-point were imputated whenever 
possible. The AUCg and AUCi could only be calculated when all four measurements 
were available. The average of the two collection days for each time-point was used for 
comparison between groups (CFS patients vs. healthy controls). 
To compare patients and controls at baseline, a student’s t test was used for continuous 
variables. Since salivary cortisol and HCC showed a skewed distribution, a non-parametric 
Mann-Whitney test was used. For categorical variables, Pearson’s chi-square test was 
applied. The correlation between cortisol outcomes and fatigue severity, illness duration, 
and pain was calculated using Pearson’s correlation. For evaluation of the effect of anakinra 
or placebo on salivary and HCC levels, analysis of covariance was used (ANCOVA) for 
each outcome measure. The outcome measure at four weeks was entered as the dependent 
variable, treatment as fixed factor, and baseline measurement as covariate.
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Results
Subject characteristics
A total of 136 patients and 72 healthy controls collected saliva samples. After exclusion 
of those patients that used corticosteroids (n=15), had fever while collecting saliva (n=2), 
did not adhere to the collection protocol (n=14), did not provide baseline samples (n=6), 
or did not provide enough data to calculate the CAR or AUC (n=5), complete information 
was available for 107 CFS patients and 59 healthy controls. Between trials, there were 
no differences with respect to age, BMI, fatigue severity, disabilities or depressive 
symptoms (data not shown). In the CBT study, participating patients had a significantly 
longer illness duration compared to those participating in the anakinra study (60[12-
276] months vs. 42[7-109] months, p=0.029). Baseline characteristics for patients and 
controls are displayed in table 1. CFS patients had significantly higher CIS-fatigue scores 
(52±4 vs. 20±10, p<0.001) and a higher BDI score (4±3 vs 1±2, p<0.001) than controls. 
There were no differences with respect to age, BMI, and menopausal state. In addition, use 
of oral contraceptives was not different between groups.
Table 1 Baseline characteristics of chronic fatigue syndrome patients (CFS) and healthy controls 
(HC)
CFS (n=107) HC (n=59)
Age, years 33±11 31±10
Body mass index, kg/m2 25±5 25±4
Illness duration, months 47[7-276]* N/A
Use of oral contraceptives, n (%)
 
46 (43) 22 (37)
Postmenopausal, n (%)
  Yes
  No
  Unknown
 
4 (4)
100 (93)
3 (3)
3 (5)
55 (93)
1 (2)
Fatigue severity (CIS-fatigue) 52±4 20±10
Disabilities (SIP) 1741±588 N/A
Depressive symptoms (BDI) 4±3 1±2
Table 1 Data are number (%), mean (SD), or median [range]. BDI= Becks depression inventory.  
CIS= checklist individual strength. N/A= not applicable. SIP= Sickness impact profile. *illness 
duration missing n=2
Baseline hair and salivary cortisol
In CFS patients non-adherence to the protocol, and thus exclusion of that particular sample, 
was present for 10% of the saliva samples. The value from the other day could be imputed 
in 73% of these samples. For controls these numbers were 8% and 72%, respectively. In 
figure 1, baseline cortisol values are displayed for patients and controls. In CFS patients, 
there was a significantly lower CAR (4.2±5.4 nmol/L vs 6.1±6.3 nmol/L, p=0.036). For the 
AUCg and AUCi there were no differences between groups. 
Figure 1 Baseline salivary cortisol outcome measures of CFS patients and healthy controls
Figure 1 The upper panel displays mean concentrations±SEM (nmol/L) of the cortisol 
awakening response for CFS patients and controls. The lower two panels display mean ±SEM 
values for the ‘area under the curve with respect to ground’ (AUCg) and ‘area under the curve 
with respect to increase’ (AUCi) for both groups. 
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In patients participating in the anakinra trial HCC reflecting the past month was analyzed. 
After exclusion of patients who were ill (n=2) or used medication (n=2) in the month 
preceding hair collection and those patients that provided an insufficient amount of hair 
to perform the analysis (n=2), results were available for 46 patients and 46 controls. In 
CFS patients, there was a non-significant trend for lower HCC (3.8±2.1 pg/mg vs 4.3±1.8 
pg/mg, p=0.062, figure 2).
Correlation cortisol with fatigue severity, illness duration, and pain 
severity
A negative correlation was present between basal pain levels and both the CAR (r=-0.30, 
p=0.036) and the AUCg (r=-0.39, p=0.010) in CFS patients. There was no significant 
correlation between the AUCi or HCC and pain (respectively r=0.06, p=0.69 and r=-0.05, 
p=0.73). Fatigue severity and duration of symptoms did not correlate with any of the 
cortisol measures (data not shown).
Influence of anakinra on hair and salivary cortisol
The interaction between the HPA axis and inflammation was assessed in patients participating 
in the anakinra study. Table 2 displays changes in cortisol concentrations in saliva and hair 
after four weeks of treatment with either anakinra or placebo. For salivary cortisol there were 
no differences between groups. In the anakinra group there was a slight decrease in HCC 
(-0.18±0.95 pg/mg) compared to patients treated with placebo where there was an increase 
in HCC (0.49±0.89 pg/mg, p=0.022). Figure 3 displays the change in hair cortisol after 
treatment for both groups. 
Figure 2 Baseline hair cortisol outcome measures of CFS patients and healthy controls
Table 2 Treatment effect of anakinra or placebo on main cortisol outcome measures
Outcome Anakinra Placebo P-value
CAR
N
-2.38±5.56
22
-1.22±6.62
25
0.52
AUCg
N
-430.01±1482.14
17
-483.95±1124.71
17
0.91
AUCi
N
-830.82±3333.07
17
-995.56±1932.37
17
0.86
HCC
N
-0.18±0.95
21
0.49±0.89
21
0.022
Table 2 displays mean (±SD) change for both groups as compared to baseline.
Figure 3 Change of hair cortisol after four weeks of treatment with either anakinra (n=22) or 
placebo (n=21).
Figure 2 displays mean(±SEM) 
hair cortisol concentrations (pg/mg) 
for CFS patients and controls at 
baseline.
Figure 3 displays mean(±SEM) 
decrease of hair cortisol concentration 
(pg/mg) after treatment with either 
anakinra or placebo for a duration of 
four weeks.
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Discussion
In the current study, hair and salivary cortisol in a large cohort of female CFS patients was 
compared to healthy controls. To the best of our knowledge, this is the first study that has 
investigated HCC in CFS. At baseline, CFS patients had a significantly lower CAR and a 
trend to lower HCC compared to healthy controls. There were no baseline differences for 
the AUCg and AUCi. In addition, patients treated with anakinra had a slight decrease of 
HCC after treatment compared to patients treated with placebo where an increase of HCC 
was observed.
An attenuated cortisol awakening response has been found previously in both adolescents (30) and 
adults (31) with CFS. Cortisol response after awakening has been described in several studies 
investigating physical and mental complaints (32) and has been associated with fatigue later 
during the day in healthy adults (33), and in conditions characterized by (chronic) pain (34). 
In the current study, the correlation between cortisol outcome measures and CFS-related 
symptoms was assessed, which confirmed that there was a negative correlation between 
basal pain levels and the CAR. However, CAR was not associated with any CFS-related 
measures such as fatigue severity or duration of symptoms. 
With respect to the AUCg, a measure for total cortisol output during the day, we did not 
find any differences between groups. This is in contrast with previous studies that found 
decreased basal cortisol levels using this measure in CFS patients (6). A possible explanation 
for the absence of a difference could be the strict exclusion criteria used in the current 
study. 
Despite the absence of a difference in total cortisol output in saliva, there was a trend 
to lower HCC in CFS patients. It has been described that salivary cortisol is a reliable 
method to measure free circulating cortisol, but it is subject to day-to-day variation and the 
patients’ compliance to the collection instructions (35). HCC might be a more robust method 
to assess long-term/accumulated cortisol concentrations, and has shown a considerable 
intra-individual stability/reproducibility (36). In CFS, HCC has not been assessed previously 
but lower concentrations have been found in patients with chronic stress conditions such 
as generalized anxiety disorder (GAD) and adults with a history of childhood trauma (37). 
The study in GAD patients also found no differences in total saliva cortisol, but did find 
lower HCC, which stresses the importance of long-term cortisol assessment. A possible 
explanation for this discrepancy is that stress as a consequence of saliva sampling, that 
might have a larger influence on patients, influences acute cortisol levels leading to a false-
high AUCg (38). 
With respect to the interaction of the inflammatory system and the HPA axis there are several 
hypotheses in CFS. One theory within literature focusing on neuro-humoral alterations, is 
that the combination of decreased circulating cortisol (6) and decreased cortisol sensitivity 
of immune cells (15) can lead to a low-grade inflammatory state (17, 39). This is discussed to 
be a consequence of the known inhibitory effect of cortisol on pro-inflammatory cytokines, 
which partially acts through decreased ‘nuclear factor kappa-light-chain-enhancer of 
activated B cells’ (NFκB) activation (11). The anakinra study was aimed at solely intervening 
at the level of the immune alterations (12). It was hypothesized that decreasing inflammation 
with anakinra, an interleukin-1 receptor antagonist (IL-1Ra), would lead to less fatigue, 
and as a consequence normalization of cortisol concentrations. However, against our initial 
expectations, a slight decrease in HCC was found in patients treated with anakinra and an 
increase in placebo treated patients, which makes this theory less likely. This is in line with 
the known stimulating effect of IL-1 on the HPA axis, a response that is reversible by using 
IL-1Ra (40). Thus, the results of this study only provide preliminary insight into the complex 
interaction between these regulatory mechanisms, and additional research is needed. 
This study has several strengths. To our knowledge, this is the largest study measuring 
salivary cortisol in a cohort of CFS patients and matched controls. Previous studies of 
similar magnitude were, for example, performed using urine samples (41), or did not include 
healthy controls (42). In addition, cortisol concentrations were determined in hair in a 
subgroup of patients and controls, a method proven to be of additional value in several 
various conditions such as mental health (e.g., depression (43)), and in pregnancy (44).
A limitation of this study is the inclusion of two separate cohorts of patients. However, 
in both cohorts there were no important differences in main in- and exclusion criteria, as 
both studies included female CFS patients of the same age. The only variable that differed 
between samples, duration of symptoms, did not influence cortisol outcome measures. In 
addition, the protocol used for saliva collection, storage, and cortisol analysis was identical. 
Therefore, we do not believe this could have influenced the outcome. Another limitation 
is incompliance of patients while performing the saliva sampling at home. Although 
collections times were recorded and strict criteria were applied, only slight deviations 
from the protocol can already influence for example the CAR (45). Fortunately, this is no 
problem when measuring HCC. Third, as this was no prospective study, it is still unknown 
if hypocortisolism has a pathophysiological role or is a consequence of CFS. However, a 
previous prospective study in patients presenting with infectious mononucleosis, could not 
find a relation between saliva cortisol and the development of fatigue (46).
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In conclusion, in female CFS patients without comorbid depression, a lower CAR was 
found compared to healthy controls. In addition, there was a trend to lower HCC in patients. 
Especially the latter has important implications for future studies. When lower HCC can be 
confirmed in other studies, it might be used as a more stable and reliable tool for the evaluation 
of the HPA axis in CFS. Earlier studies found that urinary cortisol is able to predict response 
to CBT (47), and that salivary cortisol normalizes with adequate treatment (48). However, in 
the light of the previously mentioned limitations of salivary cortisol, HCC might be an 
interesting alternative to predict the effect of treatment. Although the current study did not 
unravel the exact mechanisms of neuro-humoral and inflammatory interactions in CFS, our 
findings provide preliminary insight into how an interleukin-1 receptor antagonist might 
affect endocrine functioning. 
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Abstract
Background: Postural orthostatic tachycardia syndrome (POTS) is considered a diagnostic 
marker for chronic fatigue syndrome (CFS).
Objectives: The aims of this study were to (i) compare POTS prevalence in a CFS cohort 
with fatigued patients not meeting CFS criteria, and (ii) assess activity, impairment and 
response to cognitive behavioral therapy (CBT) in CFS patients with POTS (POTS-CFS) 
and without POTS (non-POTS-CFS).
Methods: Prospective cohort study at the Radboud University Medical Center in The 
Netherlands. Between June 2013 and December 2014, 863 consecutive patients with 
persistent fatigue were screened. Patients underwent an active standing test, filled out 
questionnaires and wore an activity-sensing device for a period of 12 days.
Results: A total of 419 CFS patients and 341 non-CFS fatigued patients were included in 
the study. POTS prevalence in adult CFS patients was 5.7% versus 6.9% in non-CFS adults 
(P = 0.54). In adolescents, prevalence rates were 18.2% and 17.4%, respectively (P = 0.93). 
Adult POTS-CFS patients were younger (30±12 vs. 40±13 years, P = 0.001) and had a 
higher supine heart rate (71±11 vs. 65±9 beats/min, P= 0.009) compared with non-POTS-
CFS patients. Severity and activity patterns did not differ between groups. In CFS patients, 
criteria for Systemic Exertion Intolerance Disease (SEID) were met in 76% of adults and 
67% of adolescents. In these CFS patients fulfilling the SEID criteria, the prevalence of 
POTS was not different from that in the overall CFS population. POTS-CFS adolescents 
had less clinically significant improvement after CBT than non-POTS-CFS adolescents 
(58% vs. 88%, P = 0.017).
Conclusion: In adults with CFS, the prevalence of POTS was low, was not different from 
the rate in non-CFS fatigued patients, and was not related to disease severity or treatment 
outcome. In POTS-CFS adolescents, CBT was less successful than in non-POTS-CFS 
patients. The evaluation of POTS appears to be of limited value for the diagnosis of CFS. 
Introduction
Chronic fatigue syndrome (CFS) is a debilitating disease with a prevalence ranging 
between 200 and 1400 per 100,000 persons in both Europe and the USA (1-4). With fatigue 
as the most characteristic symptom, CFS patients often report a variety of other symptoms, 
such as unrefreshing sleep, post-exertional malaise and headaches (5). More than 25% 
of patients report having had symptoms more than 5 years before being diagnosed with 
CFS (1), which illustrates the difficulties encountered in the diagnostic process. Trying 
to overcome this problem, several research groups have proposed new CFS criteria (5-7) 
since the first case definition published by the Center for Disease Control and Prevention 
(CDC) in 1988 (8). However, despite the use of different case formulations, none of these 
diagnostic methods has been sufficiently tested (9), and substantial heterogeneity remains in 
addition to difficulties in distinguishing fatigue caused by CFS from other fatigue-causing 
illnesses and idiopathic fatigue. 
In an attempt to improve the diagnostic process, the Institute of Medicine (IOM) recently 
proposed a new case definition (1), with a new name to describe the illness more accurately: 
systemic exertion intolerance disease (SEID). The aim of this new definition is a better 
understanding of CFS, with objective measurements to diagnose patients. In order to fulfill 
the SEID criteria, a patient must have three core symptoms: (i) severe fatigue that is present 
for at least 6 months leading to substantial impairment, (ii) post-exertional malaise and (iii) 
unrefreshing sleep. Additionally, a patient must be diagnosed with cognitive impairment, 
orthostatic intolerance (OI), or both. The advantage of including OI is that most forms can 
be diagnosed in an objective manner, by measuring heart rate and blood pressure during an 
active standing or head-up tilt test.
OI is defined as a syndrome in which patients report symptoms in upright position, with 
(delayed) orthostatic hypotension, reflex syncope and postural orthostatic tachycardia 
syndrome (POTS) as the most common clinical manifestations (10-13); the latter is reported 
most frequently in the CFS population, and several studies have been conducted to evaluate 
the prevalence of POTS in CFS (14-16). Based on the literature search conducted by the IOM, 
the prevalence of POTS is 27% in CFS patients compared to 4% in healthy control subjects. 
The studies included in the review report a wide variety in duration and type of orthostatic 
testing. The recommended duration of testing is at least 10 min (10, 13), although several of the 
reviewed studies took into account only the first few minutes (14, 16). 
POTS is defined as an increase in heart rate of at least 30 beats/min (bpm) or an increase 
to 120 bpm within the first 10 min after attaining an upright position in the absence 
of orthostatic hypotension (12, 13). POTS is predominantly reported in women (17), and 
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hypovolemia, deconditioning and increased sympathetic activity have been described as 
possible pathophysiological mechanisms (17, 18). Some studies have shown that CFS patients 
with POTS (POTS-CFS patients) have shorter symptom duration, are younger (14) and report 
less severe fatigue than CFS patients without POTS (non-POTS-CFS patients) (15), although 
others did not find differences with respect to symptom severity (19). If POTS in CFS could be 
explained by deconditioning, POTS-CFS patients would be expected to be less physically 
active. However, to our knowledge, this has never been investigated. Furthermore it is 
unknown whether POTS-CFS patients respond differently, compared with non-POTS-CFS 
patients, to cognitive behavioral therapy (CBT), which is an evidence-based treatment for 
CFS (20, 21). Before incorporating OI and POTS into a new case definition, the impact of 
POTS on CFS-related symptoms and treatment outcome should be known. 
To overcome these problems, a large CFS population was studied prospectively to evaluate 
whether the prevalence of POTS is in accordance with the IOM report. As recommended, 
testing duration was longer than 10 min in all patients (13). POTS prevalence was also 
determined in patients with persistent fatigue who did not meet the CDC consensus for CFS 
(non-CFS patients), to evaluate the extent to which the presence of POTS discriminates 
between CFS and non-CFS fatigued patients. The prevalence of POTS in CFS patients 
fulfilling the SEID criteria was also evaluated. Furthermore, we examined whether POTS-
CFS patients report more symptoms associated with POTS (e.g. dizziness), are more 
fatigued or impaired, have a lower level of physical activity or respond differently to CBT 
compared with non-POTS-CFS patients.
Materials and methods
Study design and participants
Between June 2013 and December 2014, all patients consecutively referred to the Expert 
Center for Chronic Fatigue (ECCF) at the Radboud University Medical Center underwent a 
standardized blood pressure measurement as part of their clinical assessment. Furthermore, 
patients filled out web-based questionnaires, and during a period of 2 weeks kept a diary 
recording symptoms and wore a motion-sensing device (actometer) (22). CFS patients were 
included following diagnosis with CFS according to the CDC criteria (5). In this patient 
category, the proportion of patients fulfilling the SEID criteria, omitting the criterion of OI, 
was also evaluated. Non-CFS fatigued patients were included if they reported persistent 
fatigue not meeting the CDC consensus criteria for CFS. Patients were excluded if blood 
pressure measurement was not conducted in accordance with the protocol, or if they had 
not filled in the questionnaires.
The local institutional ethics committee approved the present study. Informed consent was 
not required because all measurements were performed as part of routine care.
Blood pressure measurement
Blood pressure measurement and POTS identification were performed using an active 
standing test. First, heart rate and blood pressure were recorded at 2- to 3-min intervals 
while the patient was in the supine position for 15 min using an electronic automated 
device (Mobil-O-Graph, I.E.M., Stolberg, Germany). Next, patients were instructed to 
stand upright without assistance and remain in this position for the next 14–18 min. After 
standing for 5–8 min, blood pressure measurement was resumed for the remaining period. 
POTS was defined as an increase in heart rate of at least 30 bpm compared to the supine 
position, or a standing heart rate of ≥120 bpm for any of the measurements within the first 
10 min after attaining an upright position (13). Supine blood pressure and heart rate were 
calculated using the mean of the last five measurements before standing. The first three 
standing measurements were used to determine the mean blood pressure and heart rate in 
the upright position. Only patients without signs of orthostatic hypotension within the first 
10 min, defined as a decrease in systolic blood pressure of ≥20 mmHg or diastolic blood 
pressure of ≥10 mmHg, could be identified as having POTS. 
Actometer and diary score
The actometer (©Actilog V3.0) is a motion-sensing device, which is worn at the ankle 
during 12 consecutive days and nights as part of the standard diagnostic work-up at our 
center. The small, light (26 g) device contains a sensor that is sensitive in three directions 
(22, 23). When an acceleration passes the predefined threshold, the motion is registered as 
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activity. The acquired information can be used to calculate a mean activity score during 
the time awake; this score is expressed as the average number of accelerations per 5-min 
period. The mean activity score over 12 days for CFS patients has been reported to be 
66±22 (23). When patients scored above 66 on not more than 1 day out of the 12-days, they 
are labeled as low active; a score of >66 on 2–9 days and on 10–12 days is considered 
relatively active and highly active, respectively.
During the same 12-day period, patients kept a diary recording symptoms four times 
daily. Patients recorded the presence of concentration problems, decreased memory, visual 
problems, dizziness, shortness of breath, headache, constipation/diarrhoea, feeling tense, 
irritability and nausea. For each time point, patients reported symptoms to be present or 
absent. A mean symptom prevalence score per time point over 12 days was calculated using 
the formula: number of days the symptom was present divided by the number of days the 
diary was kept, multiplied by 100 (24). The mean of the four different time points was used 
to calculate the total symptom score. 
Questionnaires
Fatigue severity was measured using the subscale fatigue severity of the Checklist Individual 
Strength (CIS-f). Scores range between 8 and 56 (eight items, 7-point Likert scale). The 
CIS is often used to measure fatigue in CFS patients and has excellent psychometric 
characteristics (25). A score of ≥35 reflects the presence of severe fatigue (26). CIS-f scores 
were also collected for patients after completing CBT. The presence of additional CFS 
symptoms as defined by the CDC case definition during the previous 6 months was also 
assessed with a questionnaire. The level of functional impairment was measured using 
the Sickness Impact Profile (SIP8) total score. The SIP evaluates disease-related physical 
and mental disabilities (27). The presence of depressive symptoms was measured using the 
Becks Depression Inventory (BDI) primary care version, the score of which can range 
between 0 and 28 (28). 
Other variables collected using questionnaires were age, gender, body mass index, duration 
of symptoms, use of medication (opioids, sleep medication, and antidepressant, anxiolytic, 
anticonvulsive, antipsychotic, antihypertensive and stimulant drugs) and presence of 
comorbid diseases.
Statistical analysis
Blood pressure data, acquired with Hypertension Management software 3.0 (I.E.M.), were 
exported to an Access database (Microsoft, Redmond, WA, USA) and combined with 
other relevant variables. All statistical analyses were conducted using IBM SPSS statistics 
version 22. All continuous variables are presented as means and standard deviations (SD) 
or medians and ranges, and categorical variables as percentages. For all reported variables, 
POTS-CFS patients were compared to non-POTS-CFS patients. Furthermore, CFS patients 
were compared to non-CFS patients with respect to fatigue severity, disabilities and blood 
pressure-related characteristics. A final comparison was made between CFS patients and 
those CFS patients who fulfilled the SEID criteria with respect to POTS prevalence. All 
categorical variables were compared using Pearson’s chi-squared or Fisher’s exact tests, 
depending on the observed frequency within each category. Continuous variables were 
compared using an independent Student’s t test. Statistical significance was set at 5% 
(P < 0.05). To correct for multiple testing, a Bonferroni correction was used when comparing 
use of medication, presence of comorbid disorders and diary scores between groups. 
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Results
During the study period, 863 fatigued patients underwent blood pressure measurement at 
the ECCF and filled in questionnaires. Overall, 103 patients were excluded because the 
blood pressure measurement was not appropriate to determine the presence of POTS: no 
measurements in the standing position (n = 34), first standing measurement after 10 min 
(n = 35), standing measurement <10 min (n = 33) or no repeated measurement in the supine 
position (n = 1). Of the 760 remaining patients, 419 were diagnosed with CFS (331 adults, 
88 adolescents) and 341 could not be diagnosed with CFS (318 adults, 23 adolescents) due 
to fatigue as a consequence of a psychiatric illness (n = 76) or a chronic somatic illness 
(n = 41), fatigue after cancer treatment (n = 57) or fatigue not fulfilling the CDC consensus 
with respect to severity or accompanying symptoms (n = 167). In those patients who 
fulfilled the CFS criteria, the SEID criteria were met in 75.8% of adults (251/331) and 
67.0% of adolescents (59/88).
POTS prevalence in CFS, SEID and non-CFS patients
The prevalence of POTS was 8.4% (35/419) within the total CFS population, 5.7% for 
adults (19/331) and 18.2% for adolescents (16/88). The POTS prevalence was not different 
between patients with (BDI ≥4) and without a clinically significant level of depressive 
symptoms (5.8% vs. 5.7%, P = 0.96). In CFS patients fulfilling the SEID criteria, POTS 
was present in 5.2% of adults (13/251) and 22.0% of adolescents (13/59), which was not 
significantly different from the POTS prevalence in the overall CFS population (P = 0.77 
and P = 0.57, respectively). In the non-CFS fatigued population, POTS was present in 6.9% 
(22/318) of adults and 17.4% (4/23) of adolescents, which was not statistically different 
from CFS patients (P = 0.54 and P = 0.93, respectively). 
Comparison of CFS and non-CFS patients: fatigue, disability and blood 
pressure
With respect to age, there were no differences between adult CFS and non-CFS patients 
(40 vs. 40 years, P = 0.82), as shown in table 1. This could neither be found for adolescent 
CFS nor for non-CFS patients; mean ages were respectively 16 and 17 years (P = 0.056). 
Although non-CFS patients were severely fatigued with a mean CIS-f of 48, they were 
less fatigued than CFS patients (mean CIS-f 50, P < 0.001). This was also true for 
adolescent non-CFS and CFS patients (mean CIS-f 44 vs. 50, P = 0.001). Furthermore, CFS 
patients were more impaired than non-CFS patients (mean SIP total score 1548 vs. 1198, 
P < 0.001). Mean blood pressure and heart rate in the supine and upright positions did not 
differ between groups. 
Table 1 Comparison of clinical variables between CFS and non-CFS patients
Characteristic Adolescent 
CFS
(n = 88)
Adolescent 
non-CFS
(n = 23)
P-value Adult 
CFS
(n = 331)
Adult
non-CFS
(n = 318)
P-value
Female 79 (90%) 20 (87%) 0.70 224 (68%) 209 (66%) 0.60
Age, years 16 (1) 17 (2) 0.056 40 (13) 40 (13) 0.82
CIS fatigue 50 (4) 44 (8) 0.001 50 (5) 48 (7) <0.001
SIP - - - 1548 (599) 1198 (699) <0.001
Blood pressure, mmHg
  Supine position
   Systolic BP
   Diastolic BP
   Heart rate, bpm
  Standing position
   Systolic BP
   Diastolic BP
   Heart rate, bpm
114 (9)
66 (7)
68 (10)
119 (11)
75 (8)
88 (12)
115 (10)
67 (7)
68 (13)
121 (17)
75 (8)
88 (16)
0.87
0.61
0.91
0.48
0.96
0.96
123 (14)
78 (11)
65 (9)
126 (14)
85 (11)
80 (13)
124 (14)
78 (11)
67 (12)
127 (14)
85 (11)
81 (14)
0.177
0.58
0.054
0.48
0.72
0.46
Table 1 Data were available for all patients, unless stated otherwise, and are shown as number 
(%) or mean (standard deviation).
CFS, chronic fatigue syndrome; non-CFS, fatigue but not meeting the CDC consensus for CFS; 
CIS, Checklist Individual Strength; SIP, Sickness Impact Profile; BP, blood pressure; bpm, 
beats/min.
Comparison of POTS-CFS and non-POTS-CFS patients: demographics 
and blood pressure
Table 2 summarizes the comparison of demographic and blood pressure-related 
characteristics between POTS-CFS and non-POTS-CFS patients. Among adults, female 
patients were equally distributed between the two groups, and POTS-CFS patients were 
significantly younger (30 vs. 40 years, P = 0.001). Furthermore, heart rate in the supine 
position was higher in POTS-CFS patients (71 vs. 65 bpm, P = 0.009), which as expected 
was also found while standing (102 vs. 79 bpm, P < 0.001). Other variables did not differ 
between groups, although POTS-CFS patients tended to have a lower blood pressure in 
the supine position than non-POTS-CFS patients. When comparing adolescents, the only 
variable that differed between groups was heart rate in the standing position, which was 
higher in POTS-CFS patients (99 vs. 86 bpm, P < 0.001).
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Table 2 Comparison of baseline characteristics and blood pressure between POTS-CFS and non-
POTS-CFS patients
Characteristic Adolescent 
POTS-CFS
(n = 16)
Adolescent 
CFS
(n = 72)
P-value Adult 
POTS-CFS
(n = 19)
Adult
CFS
(n = 312)
P-value
Female 15 (94%) 64 (89%) 0.56 17 (89%) 207 (66%) 0.179
Age, years 16 (1) 16 (1) 0.60 30 (12) 40 (13) 0.001
BMI, kg/m2 20.7 (3.2) 20.9 (3.9) 0.88 24.0 (5.6) 25.1 (4.7) 0.31
Fatigue duration*, 
months
30 [19–46] 24 [11–40] 0.23 43 [30–75] 67 [30–121] 0.117
Blood pressure, 
mmHg
  Supine position
   Systolic BP
   Diastolic BP
   Heart rate, bpm
  Standing position
   Systolic BP
   Diastolic BP
   Heart rate, bpm
112 (8)
65 (6)
68 (9)
118 (11)
74 (8)
99 (8)
115 (9)
66 (7)
68 (10)
119 (11)
75 (8)
86 (11)
0.28
0.69
0.88
0.73
0.64
<0.001
117 (10)
73 (9)
71 (11)
125 (15)
81 (12)
102 (12)
123 (14)
78 (11)
65 (9)
126 (14)
85 (11)
79 (12)
0.073
0.072
0.009
0.71
0.169
<0.001
Table 2 Data were available for all patients, unless stated otherwise, and are shown as number 
(%), mean (standard deviation) or median [interquartile range].
POTS-CFS, chronic fatigue syndrome with postural orthostatic tachycardia syndrome; non-
POTS-CFS, chronic fatigue syndrome without postural orthostatic tachycardia syndrome; BMI, 
body mass index; BP, blood pressure; bpm, beats/min.
*Data missing for one patient. 
Comparison of POTS-CFS and non-POTS-CFS patients: symptoms, 
disability, activity patterns, comorbidity and use of medication
There were no significant differences between POTS-CFS and non-POTS-CFS patients 
with respect to fatigue severity, number of CDC symptoms, reported disabilities and 
depressive symptoms (Table 3). Mean activity scores also did not differ between groups. 
The prevalence of all 10 different symptoms assessed with the diary score was not 
significantly different between groups (data not shown). 
A total of 10.5% (n = 2) of POTS-CFS adults used antidepressants, compared with 18.6% 
(n = 58) of non-POTS-CFS patients (P = 0.54); antihypertensive drugs were respectively 
used by 5.3% (n = 1) and 11.2% (n = 35, P = 0.71). These drugs were rarely used by 
adolescents (antidepressants, n = 1 CFS patient; antihypertensive drugs, n = 1 CFS patient). 
The presence of other medical conditions in addition to CFS was distributed equally 
between all groups (data not shown). 
Table 3 Comparison of questionnaires and activity patterns between POTS-CFS and non-POTS-
CFS patients
Adolescent 
POTS-CFS
(n = 16)
Adolescent 
CFS
(n = 72)
P-value Adult 
POTS-CFS
(n = 19)
Adult
CFS
(n = 312)
P-value
CIS fatigue 51 (3) 50 (4) 0.45 50 (6) 50 (6) 0.71
SIP - - - 1462 (602) 1553 (599) 0.52
BDI - - - 3 (2) 3 (3) 0.71
CDC symptoms (n)* 6 (3) 5 (2) 0.21 7 (2) 7 (2) 0.82
Activity score† 64 (15) 66 (19) 0.83 64 (15) 67 (19) 0.51
Activity group
  Low 
  Relatively active
  Highly active
4 (25%)
10 (63%)
2 (12%)
22 (30%)
40 (56%)
10 (14%)
0.77
0.61
0.88
6 (33%)
10 (56%)
2 (11%)
77 (26%)
162 (54%)
62 (20%)
0.47
0.89
0.54
Table 3 Data were available for all patients, unless stated otherwise, and are shown as number 
(%) or mean (standard deviation).
POTS-CFS, chronic fatigue syndrome with postural orthostatic tachycardia syndrome; non-
POTS-CFS, chronic fatigue syndrome without postural orthostatic tachycardia syndrome; CIS, 
Checklist Individual Strength; SIP, Sickness Impact Profile; BDI, Becks Depression Inventory.
*Data missing for three patients;†data missing for 11 patients.
Therapy outcome
In December 2015, 62% of adults and 63% of adolescents had completed CBT; patients 
who did not finish CBT were still following therapy sessions, were referred for treatment 
outside the ECCF or decided not to start therapy after the diagnostic process. Figure 1A 
shows the mean decrease in CIS-f scores after treatment compared to scores before treatment 
for patients who completed CBT. Figure 1B shows the percentage of patients with a CIS-f 
score of ≤35, which can be considered as no longer being severely fatigued (29). Among 
adults, POTS-CFS and non-POTS-CFS patients responded similarly to CBT. However, fewer 
adolescents with POTS-CFS recovered after CBT compared with non-POTS-CFS patients 
(58% vs. 88%, P = 0.017).
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Figure 1 Fatigue severity after completing cognitive behavioral therapy in POTS-CFS and 
non-POTS-CFS patients 
Figure 1 Fatigue severity after completing cognitive behavioral therapy (CBT) in patients with 
chronic fatigue syndrome (CFS) and postural orthostatic tachycardia syndrome (POTS-CFS) 
and in patients with CFS alone. a) Decrease in the subscale fatigue severity of the Checklist 
Individual Strength (CIS-f) scores after completing CBT compared to before treatment are 
presented as means and standard deviation for all patients who completed therapy. b) Shows the 
percentage of patients no longer significantly fatigued after treatment.*P < 0.05.
Discussion
In this study, the prevalence of POTS in a large CFS cohort of adults and adolescents 
was 5.7% and 18.2%, respectively, which is much lower than the 27% reported in the 
review by the IOM. POTS prevalence was not different in CFS patients who fulfilled the 
SEID criteria. To the best of our knowledge our cohort of 419 CFS patients is the largest 
population studied thus far. Although the prevalence of POTS in the healthy population is 
unknown, healthy controls in studies reviewed by the IOM reveal a combined prevalence of 
4%, which seems to be more in accordance with results from the present study. This large 
discrepancy in prevalence could be explained by two methodological issues. First, many 
of the reported studies were performed in healthcare centers specialized in the assessment 
of autonomic symptoms, or included patients who were selected based on their symptoms 
(e.g. dizziness upon standing). This could have led to referral bias and thus an overestimation 
of the true prevalence (16, 30, 31). Secondly, in previous studies the age limit of included 
patients was not reported (14-16), which could mean that adolescents were also included in 
the CFS sample. This could have led to a higher prevalence rate in these cohorts than in 
our sample of adults, although we still found a POTS prevalence of only 18.2% among 
adolescents. As previously reported and found in the present study, orthostatic tachycardia 
is common in adolescents and therefore it has been suggested that different POTS criteria 
should be used for these patients (32, 33). 
This is the first study to report the POTS prevalence in patients presenting with persistent 
fatigue but not meeting CFS criteria according to the CDC. The prevalence of POTS in non-
CFS patients was not significantly different from that in the CFS population. Especially in 
adults, POTS cannot be used to discriminate between CFS and fatigued non-CFS patients. 
To date, nine different CFS definitions have been proposed, none of which has been 
proven to discriminate between different causes of fatigue. Other studies even describe 20 
different case definitions to be present (34). Before a new case definition can be introduced 
and used in daily clinical practice, this has to be validated in order to add value to the 
existing definitions. Furthermore, the aims of the SEID criteria proposed by the IOM were 
a better understanding of CFS and a faster diagnosis, but with the described criteria a large 
proportion of CFS patients might not even fulfill the SEID criteria. This could lead to an 
extension of the diagnostic procedure, and unnecessarily withholding effective treatment. 
In line with previous studies, we found that adult POTS-CFS patients were younger and 
had a higher heart rate in the supine position, compared to non-POTS-CFS patients (14, 15). 
Increased heart rate in the supine position has been reported previously in CFS patients 
by our group and could reflect increased sympatho-adrenomedullary activity (35). These 
differences between POTS-CFS and non-POTS-CFS patients were not found in adolescents. 
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Fatigue severity and CFS-related symptoms were not different between patients with and 
without POTS, in agreement with some (16) but not all previously reported studies (14).
Several pathophysiological mechanisms have previously been described that could be 
responsible for the development of POTS. Such mechanisms include hypovolaemia (17, 36), 
increased sympathetic activity (37) and cardiovascular deconditioning (18), although it is not 
clear whether the latter is the cause of POTS or rather a consequence. However, given 
the fact that CFS patients are usually less active than healthy control subjects (22), we 
assumed deconditioning to be a contributing factor. Although maximum oxygen uptake 
during exercise is the gold standard to measure deconditioning, actometer scores give an 
indication of a patient’s activity pattern, and both of these methods have not been used 
previously in POTS-CFS patients. We did not find differences in the level of physical 
activity between POTS-CFS and non-POTS-CFS patients, which makes it less likely that 
deconditioning is the cause of POTS in these patients.
The influence of POTS on CFS treatment outcome has not been investigated previously. 
For adults, no differences could be found in the response to CBT. However, adolescents 
with POTS did have a higher fatigue score after treatment, although these patients did not 
report more POTS-related symptoms. Despite this significant difference, 58% of POTS-CFS 
adolescents were no longer severely fatigued after treatment, which indicates that treatment 
is still effective in the majority of patients. We propose the use of a stepped-care approach 
in adolescents, with evaluation for the presence of POTS in those who do not respond to 
CBT treatment or those who report vasovagal symptoms. Fortunately, treatment of POTS 
patients is remarkably successful, which means a combined approach could be effective (38). 
Treatment of POTS mainly includes lifestyle interventions, such as preventing dehydration 
and avoiding extreme heat; in addition, regular exercise should be promoted (13). There is 
limited evidence to support pharmacological treatment, for example using aldosterone 
analogues or beta-adrenergic blockers (36). 
This study has several limitations. First, blood pressure measurement was resumed after 
a standing period of 5–8 min. This means that the reported values could be slightly 
underestimating the true prevalence of POTS. Nevertheless, patients with POTS had 
persistent tachycardia at least until 18 min in the standing position, which is consistent 
with the findings of others (39). In previous studies, POTS prevalence was most often based 
on heart rate after 2 min in the upright position, without taking into account the remaining 
8 min. In that situation it should be realized that a transient tachycardia directly after 
standing is normal (40). Thus in daily practice, difficulties are encountered in differentiating 
those patients with a tachycardia upon standing from those with a normal physiological 
response, particularly among adolescents. Another limitation of the present study is the fact 
that POTS-related symptoms were not recorded during the active standing test. However, 
these symptoms were recorded in the diary kept by all participants for 12 days. 
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Conclusion
In conclusion, in adult CFS patients the prevalence of POTS was low and not different from 
that in the non-CFS fatigued population. In addition, POTS in adult CFS patients was not 
related to disease severity, physical activity or treatment outcome. POTS-CFS adolescent 
patients showed a smaller reduction in fatigue after CBT. However, as most patients still 
benefit from CBT, there is no reason to withhold such treatment. Based on the results of 
this study, evaluation for POTS appears to be of limited additional value for the diagnosis 
of CFS; our findings do not support the addition of POTS to a new CFS case definition 
as proposed by the IOM. With the new SEID criteria, we are concerned that a subset of 
patients will not be diagnosed with CFS, although they are not different from other patients 
with respect to fatigue severity or mental and physical disabilities. This eventually could 
lead to a delay in starting effective treatment, which is in contrast to the goal of the IOM to 
accelerate the diagnostic process. 
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In this thesis several biological aspects of the chronic fatigue syndrome (CFS) were 
investigated. Aspects of the immune system, hypothalamic-pituitary-adrenal axis (HPA 
axis), and cardiovascular system in relation to CFS were studied, with an emphasis on the 
role of the pro-inflammatory cytokine interleukin-1 (IL-1). As the studies investigating 
these systems thus far in CFS showed conflicting results, there was a need for strictly 
controlled studies in well-defined patients and controls. 
In chapter 2 we investigated whether there is a relation between circulating interleukin-1 
(α or β), or the interleukin-1 receptor antagonist (IL1-Ra) and fatigue in different 
inflammatory and non-inflammatory diseases. In addition, we reviewed studies that 
inhibited IL-1 and investigated the influence on fatigue severity. It was concluded that based 
on the available literature there is limited evidence for an association between circulating 
IL-1α or IL-1β and fatigue. This for some part can be explained by the use of different 
methods to measure fatigue and different approaches to measure cytokines. In addition, it 
is known that circulating concentrations of IL-1 tend to be low and not very informative. 
IL-1Ra, which is often used as a readout for IL-1 activity, appeared to be correlated with 
fatigue in some diseases, especially in cancer. Evaluation of the effect of inhibiting IL-1 
on fatigue was more informative. This has been done both in inflammatory and non-
inflammatory diseases, where it appeared to have a positive effect. For example, a decrease 
of fatigue after lowering IL-1 was found in patients with rheumatoid arthritis and Sjögren’s 
disease treated with anakinra (IL-1 receptor antagonist) (1, 2), cryopyrin-associated periodic 
syndrome (CAPS) patients treated with canakinumab (monoclonal antibody against IL-1β) 
(3) and diabetes patients treated with gevokizumab (IL-1β antibody) (4). 
It is suspected that cytokine disturbances causing fatigue are predominantly situated in the 
central nervous system (CNS), were pro-inflammatory cytokines such as IL-1 and TNF 
are able to influence neural processes (e.g. dopamine synthesis), leading to behavioral 
alterations (5). Therefore, it would be interesting to interfere with cytokines on a central 
level in addition to inhibition in the periphery. As most cytokine inhibitors are monoclonal 
antibodies with large molecular weights, passage of the blood-brain barrier is minimal. 
Therefore, in chapter 3 a proposed non-invasive method for drug delivery into the CNS 
was investigated. Nine Sprague-Dawley rats were given a single injection of cetuximab 
(146 kDa), etanercept (51 kDa) or anakinra (17 kDa) in the cervical perispinal region or 
dorsal tail vein. After this injection, no intracranial delivery of the drugs could be visualized 
using a single-positron emission computed tomography in all but one of the animals. Based 
on these results it was concluded that a single injection in the perispinal region is not a 
proper method to deliver drugs to the CNS.
In the light of these results, we looked for an alternative method to inhibit IL-1 in CFS 
patients, aiming at both peripheral and central inhibition of both IL-1α and IL-1β. For 
anakinra, central penetration has been described after intravenous and subcutaneous 
administration in rodents and humans (6-8). Thus, we performed a randomized-controlled 
trial to investigate the effect of subcutaneous anakinra for a period of four weeks on fatigue 
severity in fifty female CFS patients. Chapter 4 describes the protocol for this study. It was 
hypothesized that the intervention would lead to a significant decrease of fatigue severity. 
The results of this study were described in chapter 5. In contrast to our hypothesis, there 
was no benefit of treatment with anakinra. There was a decrease of fatigue severity in 
both treatment arms directly after treatment, and up to six months after initiation of the 
treatment. In the anakinra group, 8% of patients no longer had severe fatigue after treatment 
compared to 20% of patients in the placebo group, which was not significantly different. 
Also for the secondary outcomes (functional impairment, physical and social functioning, 
psychological distress, and pain severity) there were no differences between the anakinra 
and placebo condition.
In chapter 6 we asked ourselves the question whether we were able to determine distinct 
cytokine profiles in CFS patients compared to controls, using a new multiplex analysis 
technique (proximity extension assay). Based on recent CFS studies (9-11), 20 pro- and anti-
inflammatory proteins were first compared individually. In this exploratory analysis, there 
was an increased concentration of IL-12p40 and CSF-1 in CFS patients. In addition, we 
aimed at the constitution of a prediction model to discriminate CFS patients from healthy 
controls, using a combination of 92 inflammatory markers. This led to a combination of 
markers that reasonably discriminated between CFS patients and controls. As an explorative 
analysis, the effect of IL-1Ra on circulating cytokines was evaluated. There was a trend 
to a decrease of CSF-1, IL-18R1 and ENRAGE in patients treated with anakinra, and 
an increase in CXCL-9, although this has to be interpreted carefully in the light of the 
number of proteins analyzed. Replication of the prediction model in an independent study 
cohort might help us to develop an inflammatory profile to distinguish CFS patients more 
accurately.
TGF-β1 was the only cytokine that appeared to be elevated in a recent systematic review on 
the role of circulating cytokines in CFS (11). Therefore, we measured TGF-β1 concentrations 
in two different cohorts of female CFS patients and healthy controls of which the results 
are described in chapter 7. We did not find any differences between patients and controls 
within both cohorts. However, there was a large difference in TGF-β1 concentration 
between the two cohorts which could be explained by differences in sample handling. 
There appeared to be a difference in the g-force of the centrifuges used in the two studies, 
where the lower g-force in cohort II (1361g) caused more platelet activation which was 
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reflected by higher p-selectin concentrations. Activated platelets are an important source 
of TGF-β (12), and this finding could explain the differences between the two cohorts. We 
conclude that it is plausible that elevations of TGF-β reported in the literature, reflect a 
methodological problem, rather than real differences. An important lesson from this study 
is that studies like these have to be meticulously controlled, and even then, conclusions 
may be drawn that reflect artifacts rather than real biological phenomena. In the past, the 
use of controls that were not simultaneously sampled with the patients misled the scientific 
community, as well as patients and the general public (13).
Next to investigating the immune system in CFS patients, we also focused on the HPA axis. 
In chapter 8 we compared saliva and hair cortisol of a large group of CFS patients (n=107) 
to healthy controls (n=59). Although measurement of cortisol in saliva has been performed 
repeatedly in CFS, long-term cortisol determinations in hair had not been done before. In 
CFS, there was a decreased cortisol awakening response and a trend towards lower cortisol 
levels in hair. Total salivary cortisol during the day was not different between patients and 
controls. In the subgroup of patients participating in the anakinra trial, the effect of IL-1 
inhibition on the HPA axis was assessed. We found a slight decrease of hair cortisol in 
patients treated with anakinra, compared to an increased concentration in placebo-treated 
patients. Earlier studies demonstrated that cortisol concentrations can be used as measure 
to predict treatment response. However, as there is a substantial variance in day-to-day 
cortisol output, hair cortisol might be a more stable measure to use in this context.
In chapter 9 we investigated the prevalence of postural orthostatic tachycardia (POTS), 
one of the most frequent forms of orthostatic intolerance (OI), in a group of 419 CFS and 
341 fatigued non-CFS patients. This prevalence was compared to the numbers described in 
the report published by the ‘Institute of Medicine’, in which it was claimed that OI should 
become one of the criteria in the new Systemic Exertion Intolerance Disease definition for 
CFS. We found a POTS prevalence of 5.7% in adult CFS patients and 6.9% in non-CFS 
patients; these numbers were not significantly different. In adolescents, this prevalence 
was 18.2 and 17.4%, respectively. This is substantially lower than the reported prevalence 
of 27% by the IOM. Disease severity was not significantly different in POTS patients 
with CFS, compared to those that did not fulfill the POTS criteria. Response to treatment 
with cognitive behavioral therapy was not different between adult CFS patients with and 
without POTS, in adolescent CFS patients clinical improvement after treatment was less 
frequent in those affected with POTS (58% vs. 88%). Based on these results we concluded 
that there is limited value of diagnosing POTS in CFS patients. Routine measurement in 
patients without orthostatic complaints does not seem necessary.
General discussion
The primary aim of this thesis was to investigate the role of IL-1 in fatigue, and evaluate the 
effect of lowering IL-1 on fatigue severity in CFS patients. For the discussion of my thesis, 
I will therefore predominantly focus on the role of cytokines in CFS and the RCT that we 
performed. 
In contrast to our expectations, administration of IL-1Ra during one month had no benefit in 
CFS. Considering these results, we wondered about the main reason for the absence of this 
effect, especially in the light of the positive effect of lowering IL-1 on fatigue severity in 
other conditions, as we described in chapter 2. There are several possible explanations that 
I would like to discuss. 
First of all, patient selection might have played a role. In addition to the selection criteria 
discussed in chapter 5, e.g. not only including patients with post-infectious fatigue, disease 
severity might have played a role as well. As a consequence of the intensity of the study, 
with patients having to visit the hospital frequently and inject themselves on a daily basis, 
only the relatively mobile patients could participate. Some studies report that immunological 
alterations are different in patients that are housebound compared to those that are still 
relatively active (14, 15). However, these studies are too small and inconclusive to draw 
conclusions. Additionally, including these patients as well would have resulted in a more 
heterogeneous study population, an issue that is already a subject of debate in CFS research. 
Second, the method we used to administer IL-1Ra should be discussed. In this thesis, we 
described that IL-1 and other pro-inflammatory cytokines influence the central nervous 
system, altering behavioral decision making and eventually leading to the development of 
fatigue as described in chapter 2 (16). Therefore, we were intrigued by a study describing 
the central delivery of monoclonal antibodies within 30 minutes after administration to 
the brain, after one single injection in the perispinal region (17). Following the exact same 
methods used in this study, we could not replicate these results as described in chapter 3. 
Despite that, we decided to proceed with our approach of repeated peripheral IL-1Ra 
administration in CFS. The main reason to continue with this approach was that, despite a 
large concentration gradient, central delivery of anakinra has been described after repeated or 
continuous administration of anakinra in both animals and humans (6-8). Additionally, it was 
assumed that only peripheral IL-1 inhibition would be effective as well, although this effect 
is probably more pronounced in illnesses with marked peripheral inflammation as described 
in chapter 2. However, considering the results of our trial, peripheral inhibition of IL-1 does 
not have an effect in CFS and the central effect of anakinra might have been too small to 
make a difference. 
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The third important possible explanation is that frequent injection site reactions contributed 
to the absence of an effect. Unfortunately, in hindsight, this local skin reaction was not 
scored in an objective manner, and our records were based on what study participants 
reported. Therefore, we could not control for this adverse event in our analysis. The 
possibility that injection site reactions could have influenced the outcome is demonstrated 
in a study investigating the effect of anakinra on insulin sensitivity in patients with the 
metabolic syndrome (18). In this study, patients with severe injection site reactions had more 
macrophage infiltration of the adipose tissue and were less insulin sensitive. Anakinra-
treated patients with a low macrophage influx did reveal a significant improvement of 
insulin sensitivity. Treating patients for a longer period could also have been a method 
to avoid this possible confounder, as it is known that injection site reactions evade with 
prolonged treatment (19).
Finally, it is possible that in CFS increased inflammation that played a role at the initiation 
of symptoms, no longer play a role in the chronic phase of the disease. This theory is 
strengthened by earlier findings of an increased association of IL-1 and fatigue in the acute 
phase of an infection (20), which was no longer present in the chronic phase (21). In the 
chronic phase it is possible that the upstream effects of IL-1, such as the effect on dopamine 
synthesis, play a role as well (5). This would mean that IL-1 inhibition as a treatment of 
fatigue is more effective in diseases that are accompanied by (low-grade) inflammation, 
such as advanced cancer patients (22). 
Future perspectives
General aspects in (CFS) research
One of the most important lessons from this thesis, especially considering the results of 
chapter 7, is that it is of major importance to conduct studies in a tightly controlled setting. 
Over the years there has been a number of studies performed in CFS patients investigating 
abnormalities of the immune system, HPA axis and the cardiovascular system. However, a 
significant proportion of these studies do not control for pre-analytical procedures which 
can result in wrong conclusions as we have described. It is our hope that future studies in 
CFS will take this into account and will control for pre-analytical procedures in addition to 
inclusion of proper controls. This is an important topic, not only in CFS research, and will 
lead to an increase in reproducibility of findings.
Diagnostic markers
In chapter 6 of this thesis, we focused on possible diagnostic markers for CFS, investigating 
alterations in inflammatory profiles. The set of inflammatory proteins selected in chapter 6 
could be an interesting focus of future studies. The number of markers that was selected 
by LASSO regression, some of which are IL-1 driven (IL-6, TNFβ, IL-10), illustrates the 
complex interaction between different cytokines. Finding a distinct combination of markers 
in CFS, could lead to a new diagnostic test. However, as we performed a small study with 
a large number of markers, the performance of these markers can only be evaluated in a 
second independent cohort of CFS patients. 
Therapeutic options
If our hypothesis on the role of IL-1 in CFS is correct, an interesting subject for future 
studies is to search for drugs that are capable of IL-1 inhibition within the CNS. The 
primary source of IL-1 in the brain is production by activated microglia. Increased 
microglia activation has been demonstrated in CFS patients, although in a small group 
of patients (23). Our group is currently performing a study to see whether we can replicate 
these results and additionally investigate if there are differences between CFS patients and 
patients that have persistent fatigue after acute Q-fever (Q-fever fatigue syndrome, QFS). 
The asset of including QFS patients is that these patients have an overt inflammatory start 
of their symptoms, and hence might be more prone to develop neuroinflammation. If the 
previous findings can be replicated, drugs that can inhibit microglial activity, for example 
the antimicrobial drug minocycline, could also be worth investigating (24). This drug has a 
broader effect compared to selective inhibition of IL-1.
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Research agenda
At the end of this thesis I would like to shortly elaborate on the future research that needs 
to be done, based on our findings.
I. Perform studies in a controlled setting with strict regulation of (pre-)analytical 
procedures and inclusion of proper controls. As demonstrated by the effect of placebo 
on fatigue severity in our anakinra trial, there is no place for uncontrolled intervention 
studies.
II. Investigate the diagnostic performance of the selection of diagnostic markers in 
an independent CFS cohorts, and ideally search for identifiable subgroups (CBT 
responders/non-responders, post-infectious/non-infectious, etc.).
III. Replicate earlier findings of increased microglia activity in CFS to create additional 
therapeutic options.
IV. Search for inhibitors of cytokines like IL-1β that are able to block this cytokine in the 
brain, to see whether such an intervention ameliorates CFS.
These studies are necessary to find out whether (neuro)inflammation and especially 
IL-1, play a role in CFS. It is important for our understanding of the syndrome what 
pathophysiological mechanisms lead to this incapacitating illness. If we can find other 
therapeutic modalities in addition to behavioral interventions that improve the complaints 
of CFS patients, this would mean a major step forward. Well controlled studies with a 
robust methodology (like that applied in our anakinra study) are necessary to achieve this. 
References
1. Omdal R, Gunnarsson R. The effect 
of interleukin-1 blockade on fatigue 
in rheumatoid arthritis--a pilot study. 
Rheumatology international. 2005;25(6): 
481-4.
2. Norheim KB, Harboe E, Goransson LG, 
Omdal R. Interleukin-1 inhibition and fatigue 
in primary Sjogren’s syndrome--a double 
blind, randomised clinical trial. PloS one. 
2012;7(1):e30123.
3. Kone-Paut I, Lachmann HJ, Kuemmerle-
Deschner JB, Hachulla E, Leslie KS, Mouy 
R, et al. Sustained remission of symptoms 
and improved health-related quality of 
life in patients with cryopyrin-associated 
periodic syndrome treated with canakinumab: 
results of a double-blind placebo-controlled 
randomized withdrawal study. Arthritis 
research & therapy. 2011;13(6):R202.
4. Cavelti-Weder C, Furrer R, Keller C, Babians-
Brunner A, Solinger AM, Gast H, et al. 
Inhibition of IL-1beta improves fatigue in type 
2 diabetes. Diabetes care. 2011;34(10):e158.
5. Felger JC, Miller AH. Cytokine effects on 
the basal ganglia and dopamine function: 
the subcortical source of inflammatory 
malaise. Frontiers in neuroendocrinology. 
2012;33:315-27.
6. Gueorguieva I, Clark SR, McMahon CJ, 
Scarth S, Rothwell NJ, Tyrrell PJ, et al. 
Pharmacokinetic modelling of interleukin-1 
receptor antagonist in plasma and 
cerebrospinal fluid of patients following 
subarachnoid haemorrhage. British journal of 
clinical pharmacology. 2008;65(3):317-25.
7. Clark SR, McMahon CJ, Gueorguieva I, 
Rowland M, Scarth S, Georgiou R, et al. 
Interleukin-1 receptor antagonist penetrates 
human brain at experimentally therapeutic 
concentrations. Journal of cerebral blood 
flow and metabolism : official journal of the 
International Society of Cerebral Blood Flow 
and Metabolism. 2008;28(2):387-94.
8. Greenhalgh AD, Galea J, Denes A, Tyrrell 
PJ, Rothwell NJ. Rapid brain penetration 
of interleukin-1 receptor antagonist in rat 
cerebral ischaemia: pharmacokinetics, 
distribution, protection. British journal of 
pharmacology. 2010;160(1):153-9.
9. Hornig M, Montoya JG, Klimas NG, Levine 
S, Felsenstein D, Bateman L, et al. Distinct 
plasma immune signatures in ME/CFS are 
present early in the course of illness. Science 
advances. 2015;1(1).
10. Landi A, Broadhurst D, Vernon SD, Tyrrell 
DL, Houghton M. Reductions in circulating 
levels of IL-16, IL-7 and VEGF-A in myalgic 
encephalomyelitis/chronic fatigue syndrome. 
Cytokine. 2016;78:27-36.
11. Blundell S, Ray KK, Buckland M, White PD. 
Chronic fatigue syndrome and circulating 
cytokines: A systematic review. Brain, 
behavior, and immunity. 2015;50:186-95.
12. Grainger DJ, Mosedale DE, Metcalfe JC. 
TGF-beta in blood: a complex problem. 
Cytokine & growth factor reviews. 
2000;11(1-2):133-45.
13. Lombardi VC, Ruscetti FW, Das Gupta J, 
Pfost MA, Hagen KS, Peterson DL, et al. 
Detection of an infectious retrovirus, XMRV, 
in blood cells of patients with chronic fatigue 
syndrome. Science. 2009;326(5952):585-9.
14. Hardcastle SL, Brenu EW, Johnston 
S, Nguyen T, Huth T, Ramos S, et al. 
Serum Immune Proteins in Moderate 
and Severe Chronic Fatigue Syndrome/
Myalgic Encephalomyelitis Patients. 
International journal of medical sciences. 
2015;12(10):764-72.
15. Stringer EA, Baker KS, Carroll IR, Montoya 
JG, Chu L, Maecker HT, et al. Daily 
cytokine fluctuations, driven by leptin, are 
associated with fatigue severity in chronic 
fatigue syndrome: evidence of inflammatory 
pathology. Journal of translational medicine. 
2013;11:93.
Chapter 10 Summary and future perspectives
199198
10
16. Dantzer R, Heijnen CJ, Kavelaars A, Laye S, 
Capuron L. The neuroimmune basis of fatigue. 
Trends in neurosciences. 2014;37(1):39-46.
17. Tobinick EL, Chen K, Chen X. Rapid 
intracerebroventricular delivery of Cu-DOTA-
etanercept after peripheral administration 
demonstrated by PET imaging. BMC research 
notes. 2009;2:28.
18. van Asseldonk EJ, Stienstra R, Koenen TB, 
Joosten LA, Netea MG, Tack CJ. Treatment 
with Anakinra improves disposition index but 
not insulin sensitivity in nondiabetic subjects 
with the metabolic syndrome: a randomized, 
double-blind, placebo-controlled study. 
The Journal of clinical endocrinology and 
metabolism. 2011;96(7):2119-26.
19. Fleischmann RM. Addressing the safety of 
anakinra in patients with rheumatoid arthritis. 
Rheumatology. 2003;42 Suppl 2:ii29-35.
20. Vollmer-Conna U, Fazou C, Cameron B, Li 
H, Brennan C, Luck L, et al. Production of 
pro-inflammatory cytokines correlates with 
the symptoms of acute sickness behaviour 
in humans. Psychological medicine. 
2004;34(7):1289-97.
21. Vollmer-Conna U, Cameron B, Hadzi-Pavlovic 
D, Singletary K, Davenport T, Vernon S, 
et al. Postinfective fatigue syndrome is not 
associated with altered cytokine production. 
Clinical infectious diseases : an official 
publication of the Infectious Diseases Society 
of America. 2007;45(6):732-5.
22. Hickish T, Andre T, Wyrwicz L, Saunders 
M, Sarosiek T, Kocsis J, et al. MABp1 as 
a novel antibody treatment for advanced 
colorectal cancer: a randomised, double-blind, 
placebo-controlled, phase 3 study. The Lancet 
Oncology. 2017.
23. Nakatomi Y, Mizuno K, Ishii A, Wada Y, 
Tanaka M, Tazawa S, et al. Neuroinflammation 
in Patients with Chronic Fatigue Syndrome/
Myalgic Encephalomyelitis: An (1)(1)
C-(R)-PK11195 PET Study. Journal of nuclear 
medicine : official publication, Society of 
Nuclear Medicine. 2014;55(6):945-50.
24. Zemke D, Majid A. The potential of 
minocycline for neuroprotection in 
human neurologic disease. Clinical 
neuropharmacology. 2004;27(6):293-8.
201200
Chapter 11
Nederlandse samenvatting
Dankwoord
Lijst met publicaties
Curriculum Vitae
203202
Nederlandse Samenvatting
Dit proefschrift is gericht op de biologische aspecten van het chronisch vermoeidheidssyndroom 
(CVS). In dit kader zijn het immuunsysteem, de hypothalamus-hypofyse-bijnier-as (HPA-
as), en het cardiovasculaire systeem bestudeerd in relatie tot CVS, waarbij de nadruk werd 
gelegd op het pro-inflammatoire cytokine interleukine-1 (IL-1). Aangezien de huidige 
literatuur geen uitsluitsel geeft over de rol van de genoemde systemen in CVS, was het 
belangrijk om strikt gecontroleerde studies uit te voeren in zorgvuldig geselecteerde 
patiënten en gezonde controles.
In hoofdstuk 2 onderzochten we literatuur over de relatie tussen circulerend interleukine-1 
(α of β) of de interleukine-1 receptor antagonist (IL1-Ra) en vermoeidheid in verschillende 
inflammatoire en niet-inflammatoire aandoeningen. Daarnaast bestudeerden we studies die het 
effect van het remmen van IL-1 op de ernst van de vermoeidheid hebben onderzocht. Op basis 
van de bestaande literatuur werd geconcludeerd dat er beperkt bewijs is voor een associatie 
tussen circulerend IL-1α of IL-1β en vermoeidheid. Deze bevinding kan deels worden 
verklaard door de grote verschillen in gebruikte methoden voor het meten van cytokinen 
en vermoeidheid, waardoor het moeilijk is om de resultaten te vergelijken. Bovendien zijn 
circulerende concentraties van cytokinen over het algemeen laag, ook in het geval van 
actieve infecties. IL-1Ra wordt frequent gebruikt als graadmeter voor IL-1 activiteit. In een 
deel van de studies, voornamelijk de studies verricht bij patiënten met kanker, werd een 
relatie gevonden tussen IL-1Ra en vermoeidheid. Evaluatie van het effect van het remmen 
van IL-1 op vermoeidheid was meer informatief. Dit is gedaan in zowel inflammatoire als 
niet-inflammatoire aandoeningen, waarbij een positief effect wordt beschreven. Zo werd er 
bijvoorbeeld een afname van vermoeidheid gezien in patiënten met de ziekte van Sjögren 
behandeld met anakinra (recombinant IL-1Ra), in patiënten met cryopyrine-geassocieerd 
periodiek syndroom behandeld met canakinumab (monoklonaal antilichaam tegen IL-1β) en 
diabetespatiënten behandeld met gevokizumab (IL-1β antilichaam).
Er wordt vermoed dat de cytokine verstoringen in CVS-patiënten zich vooral afspelen 
in het centraal zenuwstelsel (CZS). In het CZS kunnen pro-inflammatoire cytokinen 
zoals IL-1 en TNF neurale processen beïnvloeden (o.a. dopamine synthese) waardoor er 
gedragsveranderingen optreden. Daarom is naast het remmen van cytokinen in de periferie, 
ook het centraal remmen van cytokinen belangrijk in het geval van CVS. Echter, het 
merendeel van de beschikbare cytokine remmers zijn monoklonale antilichamen met een 
hoge moleculaire massa, waardoor passage door de bloed-hersen-barrière wordt bemoeilijkt. 
In hoofdstuk 3 onderzochten we een methode waarmee mogelijk op een niet-invasieve 
manier centrale afgifte van medicatie kan worden bewerkstelligd. Er werd een injectie 
met cetuximab molecuul gewicht (146 kDa), etancercept (51 kDa) of anakinra (17 kDa) 
toegediend in het perispinale gebied of de dorsale staartvene van negen Sprague-Dawley 
ratten. Na deze toediening vonden we, op één van de ratten na, geen centrale depositie 
van het medicijn. Voor het meten van centrale depositie werd gebruik gemaakt van een 
‘single-positron emission computed tomography’ (SPECT). Op basis van deze resultaten 
concludeerden we dat het toedienen van medicatie in het paraspinale gebied geen geschikte 
methode is voor de centrale toediening van medicatie.
In het licht van deze resultaten moesten we op zoek naar een andere methode om IL-1 
te remmen in CVS-patiënten, waarbij we zowel perifeer als in het CZS IL-1α en IL-
1β wilden remmen. Centrale depositie van anakinra is beschreven na intraveneuze en 
subcutane toediening. Om de effectiviteit van anakinra te onderzoeken in CVS, voerden we 
een gerandomiseerde dubbelblinde studie uit. Vijftig vrouwelijke CVS-patiënten werden 
gedurende vier weken dagelijks behandeld met subcutane injecties met anakinra of placebo. 
Hoofdstuk 4 beschrijft het onderzoeksprotocol voor de uitvoering van deze studie, waarbij de 
hypothese was dat de interventie tot een afname van vermoeidheid zou leiden. De resultaten 
van deze studie zijn beschreven in hoofdstuk 5. In tegenstelling tot onze verwachting werd 
er geen voordelig effect gevonden van behandeling met anakinra. In beide behandelgroepen 
werd een afname van vermoeidheid gezien direct na behandeling en tot zes maanden na 
het starten van de behandeling. In de anakinra groep was er bij 8% van de patiënten niet 
langer sprake van ernstige vermoeidheid na behandeling en in de placebogroep was dit 20%, 
waarbij er geen significante verschillen waren tussen beide groepen. Ook voor de secundaire 
uitkomstmaten (functionele beperkingen, fysiek en sociaal functioneren, psychische stress 
en pijn) waren er geen verschillen tussen patiënten behandeld met anakinra of placebo.
In hoofdstuk 6 onderzochten we met behulp van een multiplex analyse techniek (proximity 
extension assay) of CVS patiënten een ander cytokine profiel hebben dan gezonde (buurt)
controles. Daarnaast vergeleken we 20 cytokinen, geselecteerd op basis van de recente 
CVS-literatuur, tussen patiënten en controles. In deze exploratieve analyse werd een 
hogere IL-12p40 en CSF-1 concentratie gevonden bij CVS-patiënten. Daarnaast keken 
we of het mogelijk was om een predictiemodel op te stellen om CVS-patiënten te kunnen 
onderscheiden van gezonde controles, gebruik makend van 92 inflammatoire markers. Dit 
heeft geleid tot een combinatie van markers met een redelijk onderscheidend vermogen. Tot 
slot onderzochten we het effect van behandeling met anakinra op circulerende cytokinen. 
Hierbij vonden we een trend tot afname van CSF-1, IL-18R1 en ENRAGE in patiënten 
behandeld met anakinra, en een toename van CXCL-9. Gezien het grote aantal gemeten 
markers moeten deze resultaten echter met enige voorzichtigheid worden geïnterpreteerd. 
Replicatie van het gevonden predictie model in een onafhankelijk studie cohort, kan ons in 
de toekomst mogelijk helpen een inflammatoir profiel op te stellen waarmee CVS-patiënten 
kunnen worden onderscheiden van gezonde controles.
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TGF-β1 was in een recente systematische review het enige circulerende cytokine dat bij 
CVS-patiënten in een hogere concentratie aanwezig was. Derhalve hebben wij TGF-β1 
concentraties gemeten in twee verschillende cohorten van vrouwelijke CVS-patiënten en 
gezonde controles. De resultaten hiervan worden beschreven in hoofdstuk 7. Er werden 
geen verschillen tussen patiënten en controles gevonden in TGF-β1 concentraties binnen 
beide cohorten. We vonden echter grote verschillen tussen de twee cohorten, wat kon 
worden verklaard door verschillen in het preanalytische proces. Er bleek een verschil te 
zijn in de g-kracht van de centrifuges gebruikt in de twee studies. Hierbij zorgde de lage 
g-kracht in cohort II (1361g) voor meer activatie en aanwezigheid van trombocyten, wat 
werd bevestigd door hogere P-selectine concentraties. Geactiveerde trombocyten zijn een 
belangrijke bron van TGF-β waardoor deze bevinding de verschillen tussen beide cohorten 
kan verklaren. Op basis hiervan concludeerden we dat de eerder beschreven verhoogde 
TGF-β concentraties mogelijk worden verklaard door methodologische verschillen, in 
plaats van ware verschillen. Een belangrijke les die uit deze studie kan worden getrokken 
is dat het strikt gecontroleerd uitvoeren van wetenschappelijk onderzoek van groot belang 
is, omdat de kleinste verschillen in methode tot verkeerde conclusies kan leiden.
Naast het immuunsysteem onderzochten we ook de HPA-as in CVS-patiënten. In 
hoofdstuk 8 vergeleken we cortisol concentraties in speeksel en haar tussen CVS-patiënten 
(n=107) en gezonde controles (n=59). Speeksel cortisol is in eerdere studies frequent 
gemeten in CVS-patiënten, echter de lange-termijn cortisol concentraties zoals kunnen 
worden gemeten in haar, werden niet eerder onderzocht. In CVS-patiënten werd een lagere 
cortisol piek na wakker worden gevonden, en een niet significante trend tot lagere cortisol 
concentraties in haar. Totale speeksel cortisol output gedurende de dag was niet verschillend 
tussen patiënten en controles. In een subgroep werd het effect van het remmen van IL-1 
op de HPA-as onderzocht. Hierbij werd een minimale afname van haar cortisol gezien in 
de met anakinra behandelde patiënten, en een stijging in de placebogroep. Eerdere studies 
lieten zien dat cortisol concentraties in CVS-patiënten mogelijk kunnen worden gebruikt 
om effect van behandeling (met cognitieve gedragstherapie) te voorspellen. Echter, gezien 
de grote variatie in speeksel cortisol concentraties is haar-cortisol hier mogelijk een meer 
stabiele en betrouwbare maat voor.
In hoofdstuk 9 onderzochten we de prevalentie van het posturale orthostatische tachycardie 
syndroom (POTS), een van de meest voorkomende vormen van orthostatische intolerantie 
(OI), in een groep van 419 CVS-patiënten en 341 vermoeide patiënten die niet voldeden aan 
de CVS criteria. De gevonden prevalentie werd vergeleken met de aantallen beschreven in 
het in 2015 gepubliceerde rapport van het ‘Institute of Medicine’ (IOM), waarin werd gepleit 
voor het opnemen van OI als een van de diagnostische criteria voor CVS. Hierbij werd 
tevens een nieuwe naam voor CVS voorgesteld, namelijk ‘Systemic Exertion Intolerance 
Disease’. Wij vonden een POTS prevalentie van 5.7% in volwassen CVS-patiënten, en 
een prevalentie van 6.9% in vermoeide patiënten zonder CVS. In adolescenten was de 
prevalentie respectievelijk 18.2% en 17.4%. Deze  prevalentiecijfers zijn substantieel lager 
dan de prevalentie van 27% die wordt genoemd in het IOM rapport. Er was geen verschil 
in ziektelast tussen CVS-patiënten met en zonder POTS. Cognitieve gedragstherapie 
was even effectief in volwassenen met of zonder POTS. Echter, behandeling was minder 
effectief in adolescenten met POTS waarbij POTS patiënten in 58% van de gevallen 
herstelden, in vergelijking met 88% van de adolescenten zonder POTS. Op basis van deze 
resultaten concludeerden we dat het stellen van de diagnose POTS in CVS-patiënten van 
zeer beperkte waarde is. Het routinematig verrichten van onderzoek hiernaar in patiënten 
zonder orthostatische klachten achten wij niet noodzakelijk.
In hoofdstuk 10 worden de belangrijkste resultaten en conclusies van dit proefschrift 
beschreven. Een van de belangrijkste lessen die kan worden geleerd uit dit proefschrift, is 
dat het verrichten van goed gecontroleerd onderzoek van groot belang is. In de huidige CVS 
literatuur is sprake van een groot aantal tegenstrijdige bevindingen, wat deels verklaard kan 
worden door methodologische verschillen. Zeker in het geval van een complexe aandoening 
als CVS, is gestructureerd onderzoek met aandacht voor het preanalytische proces van 
groot belang. Wat betreft vervolgonderzoek is met name het centraal beïnvloeden van 
inflammatoire cytokinen (o.a. IL-1) een interessante therapeutische optie.
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Dit proefschrift is tot stand gekomen met behulp van velen. Hierbij wil ik graag van de 
gelegenheid gebruik maken om een aantal van hen te bedanken.
Allereerst gaat mijn dank uit naar alle patiënten die hebben meegewerkt. Voor jullie 
motivatie en wilskracht om ondanks alles aan deze intensieve studies deel te nemen heb ik 
veel bewondering. Daarnaast wil ik iedereen bedanken die heeft geholpen met de inclusie 
van de studie waarbij in het bijzonder de ME/CVS stichting.
Prof. dr. van der Meer, beste Jos, een betere promotor en mentor had ik me niet kunnen 
wensen. Jij hebt me de afgelopen jaren enorm gemotiveerd voor het doen van onderzoek, 
waarbij je me ook vrij liet om mijn eigen ideeën uit te voeren. Ik heb diep respect voor je 
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